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1. Importance of drug analysis 
‘Health is wealth’. It is vital fact that a healthy body is desire of every human 
being. Good health is first condition to enjoy the life and all other things which mankind 
is having. Nowadays peoples are more concentrating towards health. Even governmental 
bodies of different countries and World health organization (WHO) are also focusing for 
health of human being. Health care is prevention, treatment and management of illness 
and preservation of mental and physical well being. Health care embraces all the goods 
and services designed to promote health including preventive, curative and palliative in 
interventions. The Health care industry is considered an industry or profession which 
includes people’s exercise of skill or judgment or providing of a service related to the 
prevention or improvement of the health of the individuals or the treatment or care of 
individuals who are injured, sick, disabled or infirm. The delivery of modern health care 
depends on an Interdisciplinary Team.  
The medical model of health focuses on the eradication of illness through 
diagnosis and effective treatment. A traditional view is that improvement in health results 
from advancements in medical science. Advancements in medical science bring varieties 
of medicines. Medicines are key part of the health care system. The numerous medicines 
are introducing into the world-market and also, that is increasing every year. These 
medicines are being either new entities or partial structural modification of the existing 
one. So, to evaluate quality and efficacy of these medicines is also important factor. Right 
from the beginning of discovery of any medicine quality and efficacy of the same are 
checked by quantification means. Quality and efficacy are checked by either observing 
effect of drug on various animal models or analytical means. The option of animal models 
is not practically suitable for every batch of medicine as it’s require long time, high cost 
and more man-power. Later option of analytical way is more suitable, highly precise, safe 
and selective. 
The analytical way deals with quality standards which are assigned for products to 
have desirable efficacy of the medicines. Sample representing any batch are analyzed for 
these standards and it is assumed that drug/medicine which is having such standards are 
having desire effect on use. Quality control is a concept, which strives to produce a 
perfect product by series of measures designed to prevent and eliminate errors at different 
stage of production. The decision to release or reject a product is based on one or more 
type of control action.  
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Due to rapid growth of pharmaceutical industry during last several years, number 
of pharmaceutical formulations are enter as a part of health care system and thus, there 
has been rapid progress in the field of pharmaceutical analysis. Developing analytical 
method for newly introduced pharmaceutical formulation is a matter of most importance 
because drug or drug combination may not be official in any pharmacopoeias and thus, no 
analytical method for quantification is available. To check the quality standards of the 
medicine various analytical methods are used. Modern analytical techniques are playing 
key role in assessing chemical quality standards of medicine. Thus analytical techniques 
are required for fixing standards of medicines and its regular checking. Out of all 
analytical techniques, the technique which is widely used to check the quality of drug is 
known as ‘CHROMATOGRAPHY’. 
 
2. History of chromatography and HPLC  
 In 1903 a Russian botanist Mikhail Tswett produced a colorful separation of 
plantpigments through calcium carbonate column. Chromatography word came from 
Greek language chroma = color and graphein = to write i.e. color writing or 
chromatography[1, 2]. 
 Prior to the 1970's, few reliable chromatographic methods were commercially 
available to the laboratory scientist. During 1970's, most chemical separations were 
carried out using a variety of techniques including open-column chromatography, paper 
chromatography, and thin-layer chromatography. However, these chromatographic 
techniques were inadequate for quantification of compounds and resolution between 
similar compounds. During this time, pressure liquid chromatography began to be used to 
decrease flow through time, thus reducing purification times of compounds being isolated 
by column chromatography. However, flow rates were inconsistent, and the question of 
whether it was better to have constant flow rate or constant pressure was debated[3]. High 
pressure liquid chromatography was developed in the mid-1970's and quickly improved 
with the development of column packing materials and the additional convenience of on-
line detectors. In the late 1970's, new methods including reverse phase liquid 
chromatography allowed for improved separation between very similar compounds. 
 By the 1980's HPLC was commonly used for the separation of chemical 
compounds. New techniques improved separation, identification, purification and 
quantification far above the previous techniques. Computers and automation added to the 
convenience of HPLC. Improvements in type of columns and thus reproducibility were 
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made as such terms as micro-column, affinity columns, and Fast HPLC began to 
immerge. 
 By the 2000 very fast development was undertaken in the area of column material 
with small particle size technology and other specialized columns. The dimensions of the 
General Introduction typical HPLC column are 100-300 mm in length with an internal 
diameter between 3-5 mm. The usual diameter of micro-columns, or capillary columns, 
ranges from 3 μm to 200 μm[4]. In this decade sub 2 micron particle size technology 
(column material packed with silica particles of < 2μm size) with modified or improved 
HPLC instrumentation becomes a popular with different instrument brand name like 
UPLC (Ultra Performance Liquid Chromatography) of Waters and RRLC (Rapid 
Resolution Liquid Chromatography) of Agilent. 
 
3. Modern High Performance Liquid Chromatography (HPLC) 
 The highly sophisticated reliable and fast liquid chromatographic (LC) separation 
techniques are become a requirement in many industries like pharmaceuticals, 
agrochemicals, dyes, petrochemicals, natural products and others. Early LC used gravity 
fed open tubular columns with particles 100s of microns in size; the human eye was used 
for a detector and separations often took hours (days?) to develop. 
 
Isocratic and Gradient LC System Operation 
Two basic elution modes are used in HPLC. The first is called isocratic elution. In 
this mode, the mobile phase, either a pure solvent or a mixture, remains the same 
throughout the run. A typical system is outlined in Figure 1. 
A schematic instrumentation of HPLC is given through figure 1-3 as under: 
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Figure 1: Isocratic LC system 
The second type is called gradient elution, wherein, as its name implies, the mobile phase 
composition changes during the separation. This mode is useful for samples that contain 
compounds that span a wide range of chromatographic polarity. As the separation 
proceeds, the elution strength of the mobile phase is increased to elute the more strongly 
retained sample components. 
 
Figure 2: High-Pressure-Gradient System 
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In the simplest case, shown in Figure 2, there are two bottles of solvents and two pumps. 
The speed of each pump is managed by the gradient controller to deliver more or less of 
each solvent over the course of the separation. The two streams are combined in the mixer 
to create the actual mobile phase composition that is delivered to the column over time. 
At the beginning, the mobile phase contains a higher proportion of the weaker solvent 
[Solvent A]. Over time, the proportion of the stronger solvent [Solvent B] is increased, 
according to a predetermined timetable. Note that in Figure 2, the mixer is downstream of 
the pumps; thus the gradient is created under high pressure. Other HPLC systems are 
designed to mix multiple streams of solvents under low pressure, ahead of a single pump. 
A gradient proportioning valve selects from the four solvent bottles, changing the strength 
of the mobile phase over time [Figure 3]. 
 
Figure 3: Low-Pressure-Gradient System 
 Today's HPLC requires very special apparatus which includes the following. 
1. Extremely precise gradient mixers. 
2. HPLC high pressure pumps with very constant flow. 
3. Unique high accuracy, low dispersion, HPLC sample valves. 
4. Very high efficiency HPLC columns with inert packing materials. 
5. High sensitivity low dispersion HPLC detectors. 
6. High speed data acquisition systems. 
7. Low dispersion connecting tubes for valve to column and column to detector. 
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HPLC Gradient mixtures 
 HPLC gradient mixers must provide a very precise control of solvent composition 
to maintain a reproducible gradient profile. This can be complicated in HPLC by the 
small elution volumes required by many systems. It is much more difficult to produce a 
constant gradient when mixing small volumes then when mixing large volumes. For low 
pressure systems this requires great precision in the operation of the miniature mixing 
General Introduction valves used and low dispersion flows throughout the mixer. For 
multi-pump high pressure systems it requires a very precise control of the flow rate while 
making very small changes of the flow rate. 
 
HPLC Pumps 
 Because of the small particles used in modern HPLC, modern LC pumps need to 
operate reliably and precisely at pressures of 10,000 psi or at least 6,000 psi. To operate at 
these pressures and remain sensibly inert to the wide variety of solvents used HPLC 
pumps usually have sapphire pistons, stainless steel cylinders and return valves fitted with 
sapphire balls and stainless steel seats. For analytical purposes HPLC pumps should have 
flow rates that range from 0 to 10 ml/min., but for preparative HPLC, flow rates in excess 
of 100 ml/min may be required. It is extremely difficult to provide a very constant flow 
rate at very low flow rates. If 1% is considered acceptable then for 1ml/min a flow 
variation of less than 10μl/min is required. This level of constancy is required because 
most HPLC detectors are flow sensitive and errors in quantization will result from change 
in flow rate. 
 
HPLC Sample Valves 
 Since sample valves come between the pump and the column it follows that 
HPLC sample valves must also tolerate pressures up to 10,000 psi. For analytical HPLC, 
the sample volume should be selectable from sub micro liter to a few micro liters, 
whereas in preparative HPLC the sample volume may be even greater than 10 ml. To 
maintain system efficiency the sample valve must be designed to have very low 
dispersion characteristics, this is true not only for flow dispersion but also for the less 
obvious problems of dispersion caused by sample adsorption/desorption on valve surfaces 
and diffusion of sample into and out of the mating surfaces between valve moving parts. 
It goes without saying that the valves must deliver a very constant sample size but this is 
usually attained by the use of a constant size sample loop. 
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HPLC Columns 
 HPLC columns are packed with very fine particles (usually a few microns in 
diameter). The very fine particles are required to attain the low dispersion that give the 
high plate counts expected of modern HPLC. Plate counts in excess of 25,000 plates per 
column are possible with modern columns, however, these very high efficiencies are very 
rarely found with real samples because of the dispersion associated with injection valves, 
detectors, data acquisition systems and the dispersion due to the higher molecular weight 
of real samples as opposed to the common test samples. Packing these small particles into 
the column is a difficult technical problem but even with good packing a great amount of 
care must be given to the column end fittings and the inlet and outlet connection to keep 
dispersion to a minimum. The main consideration with HPLC is the much wider variety 
of solvents and packing materials that can be utilized because of the much lower 
quantities of both which are required. In particular very expensive optically pure 
compounds can be used to make Chiral HPLC stationary phases and may even be used as 
(disposable) HPLC solvents. 
 
HPLC Detectors [5-10] 
 UV/Vis spectrophotometers, including diode array detectors, are the most 
commonly employed detectors. Fluorescence spectrophotometers, differential 
refractometers, electrochemical detectors, mass spectrometers, light scattering detectors, 
radioactivity detectors or other special detectors may also be used. 
 Detector consists of a flow-through cell mounted at the end of the column. A 
beam of UV radiation passes through the flow cell and into the detector. As compounds 
elute from the column, they pass through the cell and absorb the radiation, resulting in 
measurable energy level changes. Fixed (mercury lamp), variable (deuterium or high-
pressure xenon lamp), and multi-wavelength detectors are widely available. Modern 
variable wavelength detectors can be programmed to change wavelength while an 
analysis is in progress. Multi-wavelength detectors measure absorbance at two or more 
wavelengths simultaneously. In diode array multi-wavelength detectors, continuous 
radiation is passed through the sample cell, and then resolved into its constituent 
wavelengths, which are individually detected by the photodiode array. These detectors 
acquire absorbance data over the entire UV-visible range, thus providing the analyst with 
chromatograms at multiple, selectable wavelengths, spectra of the eluting peaks and also 
peak purity. 
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 Differential refractometer detectors measure the difference between the refractive 
index of the mobile phase alone and that of the mobile phase containing chromatographic 
compounds as it emerges from the column. Refractive index detectors are used to detect 
non-UV absorbing compounds.  
 Fluorometric detectors are sensitive to compounds that are inherently fluorescent 
or that can be converted to fluorescent derivatives either by chemical transformation of 
the compound or by coupling with fluorescent reagents at specific functional groups. 
 Potentiometric, voltametric, or polarographic electrochemical detectors are useful 
for the quantitation of species that can be oxidized or reduced at a working electrode. 
These detectors are selective, sensitive, and reliable, but require conducting mobile 
phases free of dissolved oxygen and reducible metal ions. Electrochemical detectors with 
carbon-paste electrodes may be used advantageously to measure nanogram quantities of 
easily oxidized compounds, notably phenols and catechols. 
 In order to give an accurate chromatographic profile the detector sampling (cell) 
volume must be a small fraction of the solute elution volume. If the detector volume were 
larger than the elution volume then you would have peaks that appeared with flat tops as 
the whole peak would be resident in the detector at the same time. This means that as 
column volumes decrease and system efficiencies increase the volume of the detector cell 
volume must also decrease. It is odds for the requirement for detector to maintain high 
sensitivity as this is usually dependant on having a larger cell volume. Again, this requires 
the very careful design of modern detectors. Many types of detectors can use with HPLC 
system like UV-Visible or PDA (Photo Diode Array), RI (Refractive Index), 
Fluorescence, ECD (Electro Chemical Detector), ELSD (Evaporative Light Scattering 
detector) and many others hyphenated techniques like MS, MS/MS and NMR as well as 
evaporative IR. 
 
HPLC Data acquisition 
 In HPLC data acquisition system the higher sampling rate needed for the rapidly 
eluting narrow peaks of the HPLC chromatogram. Although the theoretical number of 
samples needed for good quantization are actually quite small, for real systems a hundred 
samples or more per peak is recommended; thus, for a 4 sec wide peak, a rate of 25 
samples per second may be required. The same data analysis and reporting software can 
be used as in ordinary LC. 
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Conclusion 
 HPLC is probably the most universal type of analytical procedure; its application 
areas include quality control, process control, forensic analysis, environmental monitoring 
and clinical testing. In addition HPLC also ranks as one of the most sensitive analytical 
procedures and is unique in that it easily copes with multi-component mixtures. It has 
achieved this position as a result of the constant evolution of the equipment used in LC to 
provide higher and higher efficiencies at faster and faster analysis times with a constant 
incorporation of new highly selective column packings. 
 
3.1 Introduction to HPLC Methods of Analysis for Drugs [11-13] 
Most of the drugs in single/multi component dosage forms can be analyzed by 
HPLC method because of the several advantages like rapidity, specificity, accuracy, 
precision and ease of automation in this method. HPLC method eliminates tedious 
extraction and isolation procedures. Some of the advantages are: 
 Speed (analysis can be accomplished in 20 minutes or less). 
 Greater sensitivity (various detectors can be employed). 
 Improved resolution (wide variety of stationary phases). 
 Reusable columns (expensive columns but can be used for many analysis). 
 Ideal for the substances of low volatility. 
 Easy sample recovery, handling and maintenance. 
 Instrumentation tends itself to automation and quantitation (less time and less 
labour). 
 Precise and reproducible. 
 Calculations are done by integrator itself. 
 Suitable for preparative liquid chromatography on a much larger scale. 
 
 There are different modes of separation in HPLC. They are normal phase mode, 
reversed phase mode, reverse phase ion pair chromatography, affinity chromatography 
and size exclusion chromatography (gel permeation and gel filtration chromatography). 
 In the normal phase mode, the stationary phase is polar and the mobile phase is 
non-polar in nature. In this technique, non-polar compounds travel faster and are eluted 
first. This is because of the lower affinity between the non-polar compounds and the 
stationary phase. Polar compounds are retained for longer times because of their higher 
affinity with the stationary phase. These compounds, therefore take more times to elute. 
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Normal phase mode of separation is therefore, not generally used for pharmaceutical 
applications because most of the drug molecules are polar in nature and hence takes 
longer time to elute.  
 Reversed phase mode is the most popular mode for analytical and preparative 
separations of compound of interest in chemical, biological, pharmaceutical, food and 
biomedical sciences. In this mode, the stationary phase is non-polar hydrophobic packing 
with octyl or octa decyl functional group bonded to silica gel and the mobile phase is 
polar solvent. An aqueous mobile phase allows the use of secondary solute chemical 
equilibrium (such as ionization control, ion suppression, ion pairing and complexation) to 
control retention and selectivity. The polar compound gets eluted first in this mode and 
nonpolar compounds are retained for longer time. As most of the drugs and 
pharmaceuticals are polar in nature, they are not retained for longer times and hence elute 
faster. The different columns used are Octa Decyl Silane (ODS) or C18, C8, C4, etc. (in 
the order of increasing polarity of the stationary phase). 
 In ion exchange chromatography, the stationary phase contains ionic groups like 
NR3+ or SO3-2, which interact with the ionic groups of the sample molecules. This is 
suitable for the separation of charged molecules only. Changing the pH and salt 
concentration can modulate the retention. 
 Ion pair chromatography may be used for the separation of ionic compounds and 
this method can also substitute for ion exchange chromatography. Strong acidic and basic 
compounds may be separated by reversed phase mode by forming ion pairs (coulumbic 
association species formed between two ions of opposite electric charge) with suitable 
counter ions. This technique is referred to as reversed phase ion pair chromatography or 
soap chromatography. 
 Affinity chromatography uses highly specific biochemical interactions for 
separation. The stationary phase contains specific groups of molecules which can absorb 
the sample if certain steric and charge related conditions are satisfied. This technique can 
be used to isolate proteins, enzymes as well as antibodies from complex mixtures. 
 Size exclusion chromatography separates molecules according to their molecular 
mass. Largest molecules are eluted first and the smallest molecules last. This method is 
generally used when a mixture contains compounds with a molecular mass difference of 
at least 10%. This mode can be further subdivided into gel permeation chromatography 
(with organic solvents) and gel filtration chromatography (with aqueous solvents). 
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 3.2 Method Development and Design of Separation Method 
 Methods for analyzing drugs in single or multi component dosage forms can be 
developed, provided one has knowledge about the nature of the sample, namely, its 
molecular weight, polarity, ionic character and the solubility parameter. An exact recipe 
for HPLC, however, cannot be provided because method development involves 
considerable trial and error procedures. The most difficult problem usually is where to 
start, what type of column is worth trying with what kind of mobile phase. In general one 
begins with reversed phase chromatography, when the compounds are hydrophilic in 
nature with many polar groups and are water soluble. 
 The organic phase concentration required for the mobile phase can be estimated 
by gradient elution method. For aqueous sample mixtures, the best way to start is with 
gradient reversed phase chromatography. Gradient can be started with 5-10 % organic 
phase in the mobile phase and the organic phase concentration (methanol or acetonitrile) 
can be increased up to 100 % within 30-45 min. Separation can then be optimized by 
changing the initial mobile phase composition and the slope of the gradient according to 
the chromatogram obtained from the preliminary run. The initial mobile phase 
composition can be estimated on the basis of where the compounds of interest were 
eluted, namely at what mobile phase composition. 
 Changing the polarity of mobile phase can alter elution of drug molecules. The 
elution strength of a mobile phase depends upon its polarity, the stronger the polarity, 
higher is the elution. Ionic samples (acidic or basic) can be separated, if they are present 
in undissociated form. Dissociation of ionic samples may be suppressed by the proper 
selection of pH. 
 The pH of the mobile phase has to be selected in such a way that the compounds 
are not ionized. If the retention times are too short, the decrease of the organic phase 
concentration in the mobile phase can be in steps of 5%. If the retention times are too 
long, an increase of the organic phase concentration is needed.  
 In UV detection, good analytical results are obtained only when the wavelength is 
selected carefully. This requires knowledge of the UV spectra of the individual 
components present in the sample. If analyte standards are available, their UV spectra can 
be measured prior to HPLC method development. 
 The molar absorbance at the detection wavelength is also an important parameter. 
When peaks are not detected in the chromatograms, it is possible that the sample quantity 
is not enough for the detection. An injection of volume of 20 μL from a solution of 1 
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mg/mL concentration normally provides good signals for UV active compounds around 
220 nm. Even if the compounds exhibit higher λmax, they absorb strongly at lower 
wavelength. 
 It is not always necessary to detect compounds at their maximum absorbance. It 
is, however, advantageous to avoid the detection at the sloppy part of the UV spectrum 
for precise quantitation. When acceptable peaks are detected on the chromatogram, the 
investigation of the peak shapes can help further method development. 
 The addition of peak modifiers to the mobile phase can affect the separation of 
ionic samples. For examples, the retention of the basic compounds can be influenced by 
the addition of small amounts of triethylamine (a peak modifier) to the mobile phase. 
Similarly for acidic compounds small amounts of acids such as acetic acid can be used. 
This can lead to useful changes in selectivity. 
 When tailing or fronting is observed, it means that the mobile phase is not totally 
compatible with the solutes. In most case the pH is not properly selected and hence partial 
dissociation or protonation takes place. When the peak shape does not improve by lower 
(1-2) or higher (8-9) pH, then ion-pair chromatography can be used. For acidic 
compounds, cationic ion pair molecules at higher pH and for basic compounds, anionic 
ion-pair molecules at lower pH can be used. For amphoteric solutes or a mixture of acidic 
and basic compounds, ion-pair chromatography is the method of choice. 
 The low solubility of the sample in the mobile phase can also cause bad peak 
shapes. It is always advisable to use the same solvents for the preparation of sample 
solution as the mobile phase to avoid precipitation of the compounds in the column or 
injector. 
 Optimization can be started only after a reasonable chromatogram has been 
obtained. A reasonable chromatogram means that more or less symmetrical peaks on the 
chromatogram detect all the compounds. By sight change of the mobile phase 
composition, the position of the peaks can be predicted within the range of investigated 
changes. An optimized chromatogram is the one in which all the peaks are symmetrical 
and are well separated in less run time. 
 The peak resolution can be increased by using a more efficient column (column 
with higher theoretical plate number, N) which can be achieved by using a column of 
smaller particle size, or a longer column. These factors, however, will increase the 
analysis time. Flow rate does not influence resolution, but it has a strong effect on the 
analysis time.  
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 Unfortunately, theoretical predictions of mobile phase and stationary phase 
interactions with a given set of sample components are not always accurate, but they do 
help to narrow down the choices for method development. The separation scientist must 
usually perform a series of trial and error experiments with different mobile phase 
compositions until a satisfactory separation is achieved. 
 
 
 
The parameters that are affected by the changes in chromatographic conditions are: 
1. Resolution (RS). 
2. Capacity factor (k’). 
3. Selectivity (α). 
4. Plate number (N). 
5. Asymmetry factor (T). 
 
1. Resolution (RS): Resolution is the parameter describing the separation power of the 
complete chromatographic system relative to the particular components of the mixture.  
 
ܴ ൌ 2ሺݐܴ, 2 െ ݐܴ, 1ሻܹܾ, 1 ൅ܹܾ, 2 ൌ
1.177ሺݐܴ, 2 െ ݐܴ, 1ሻ
ܹ0.5,1 ൅ܹ0.5,2  
 
If the peak base widths wb,1 and wb,2 are approximately the same, the resolution R 
signifies the number of times the peak width wb can be fitted into the distance between 
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the peak maxima. At a resolution of R=0.5, two maxima can still be perceived separately. 
For quantitative analysis, a resolution of up to R=1.5 is desirable; greater values of the 
resolution lead only to unnecessarily long analysis times. 
 
The resolution R is dependent on the parameters k2’ (capacity factor of the later eluted 
substance), selectivity α and plate number N of the column: 
ܴ ൌ √ܰ4 ൈ
ߙ െ 1
ߙ ൈ
݇2Ԣ
1 ൅ ݇2Ԣ 
 
2. Capacity factor (k’): The retention time tR is the qualitative information of a 
chromatogram. it is constant for a given component provided the chromatographic 
conditions remain unchanged (column, mobile phase, temperature etc.). for the 
characterization of substance, it is more convenient to quote the capacity factor k’ since, 
in contrast to the retention times, this is dependent neither on the flow of the eluent nor on 
the column length: 
݇ᇱ ൌ ݐܴԢݐ0 ൌ
ݐܴ െ ݐ0
ݐ0 ൌ
ݐܴ
ݐ0 െ 1 
 
3. Selectivity (α): The selectivity (or separation factor) is a measure of relative retention 
of two components in a mixture. Selectivity is the ratio of the capacity factors of both 
peaks, and the ratio of its adjusted retention times. Selectivity represents the separation 
power of particular adsorbent to the mixture of these particular components. This 
parameter is independent of the column efficiency, it only depends on the nature of the 
components, eluent type, eluent composition and adsorbent surface chemistry. In general, 
if the selectivity of two components is equal to 1, then there is no way to separate them by 
improving the column efficiency. 
 
The ideal value of α is 2. It can be calculated by using formula, 
 
ߙ ൌ ݇2Ԣ݇1Ԣ ൌ
ݐܴ, 2 െ ݐ0
ݐܴ, 1 െ ݐ0        ሺ݇2
ᇱ ൐ ݇1ᇱሻ 
 
4. Plate number (N): An additional useful quantity to characterize a separation system is 
the plate number N (number of theoretical plates). A theoretical plate is defined as that 
zone of separation system within which a thermodynamic equilibrium is established 
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between the mean concentration of a component in the stationary phase and its mean 
concentration in the mobile phase. Efficiency is calculated by using the formula, 
  
N = 16 (tR / wb)2  
 
Where, tR is the retention time. 
 wb is the peak width. 
 
5. Asymmetry factor (T): The elution of chromatographic signals as Gaussian peaks is 
often not achieved in practice. An asymmetric peak shape, known as tailing, is often 
found. The peak asymmetry is quantified by the asymmetry factor (tailing factor) T with a 
and b being determined at 10 % peak height: 
ࢀ ൌ ࢈ࢇ 
 
 
For the trouble-free evalution of the area of a peak, T must be < 2.5, above this, the end of 
the peak can be recognized only with difficulty. For a well-packed column, an asymmetry 
factor of 0.9 to 1.1 should be achievable. 
 
3.3 Separation Mode of HPLC 
 Various modes of HPLC utilized to separate compounds are classified as follows: 
 1) Adsorption chromatography 
 2) Normal-phase chromatography 
 3) Reversed-phase chromatography 
 4) Ion-pair chromatography 
 5) Ion-exchange chromatography 
 6) Size exclusion chromatography 
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1. Adsorption chromatography 
Adsorption chromatography uses polar stationary phases with relatively non-polar mobile 
phases. Separations in adsorption chromatography result to a great extent from the 
interaction of sample polar functional groups with discrete adsorption sites on the 
stationary phase. Adsorption chromatography is usually considered appropriate for the 
separation of nonionic molecules that are soluble in organic solvents. 
 
2. Normal-phase chromatography 
In HPLC, if stationary phase is more polar than the mobile phase, it is termed as normal-
phase liquid chromatography. Polar bonded phases that have a diol, cyano, diethylamino, 
amino, or diamino functional groups are used as stationary phase in normal-phase 
chromatography. Due to lower affinity of non-polar compounds to the stationary phases 
used, non-polar compounds are elute first while polar compounds are retained for longer 
time. Normal-phase chromatography is widely applied for chiral separations. 
 
3. Reversed-phase chromatography 
In HPLC, if stationary phase is less polar than the mobile phase, it is termed as reversed-
phase liquid chromatography. In this technique, C18, C8, Phenyl, and cyano-propyl 
functional groups that chemically bonded to micro porous silica particles are used as 
stationary phase. Retention in reversed phase chromatography occurs by nonspecific 
hydrophobic interactions of the solute with stationary phase. The ubiquitous application 
of reversed-phase chromatography arise from the fact that practically all organic 
molecules have hydrophobic regions in their structures and effectively interact with the 
stationary phase. It is estimated that over 65% (possibly as high as 90%) of all HPLC 
separations are executed in the reversed-phase mode. The rationale for this includes the 
simplicity, versatility, and scope of the reversed-phase method[14]. 
 
4. Ion-pair chromatography 
Ionic or partially ionic compounds can be chromatographed on reversed phase columns 
by using ion-pairing reagents. These reagents are typically long chain alkyl anions or 
cations that, when used in dilute concentrations, can increase the retention of analyte ions. 
C-5 to C-10 alkyl sulfonates are commonly used for cationic compounds while C-5 to C-8 
alkyl ammonium salts are generally used in the cases of anionic solutes. 
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5. Ion-exchange chromatography 
Ion-exchange chromatography is an adaptable technique used primarily for the separation 
of ionic or easily ionizable species. The stationary phase is characterized by the presence 
of charged centers having exchangeable counter ions. Both anions and cations can be 
separated by choosing the suitable ion-exchange medium. Ion-exchange chromatography 
employs the dynamic interactions between charged solute ions and stationary phases that 
have oppositely charged groups. 
 
6. Size exclusion chromatography 
Size exclusion chromatography separates molecules according to their molecular mass. In 
Size exclusion chromatography, column is filled with material having precisely controlled 
pore sizes and the sample is simply screened or filtered according to its solvated 
molecular size. Largest molecules are eluted first and the smallest molecules last. This 
method is generally used when a mixture contains compounds with a molecular mass 
difference of at least 10%. This mode can be further subdivided into gel permeation 
chromatography (with organic solvents) and gel filtration chromatography (with aqueous 
solvents). 
 
4. Analytical method validation 
The developed analytical procedure used to measure the quality of pharmaceutical 
products. It is necessary to assure that the performance characteristics of the developed 
analytical procedure meet the requirements for the intended analytical application. The 
procedure which provides assurance for the same by the means of laboratory studies is 
defined as method validation. 
Method validation is the process of demonstrating that analytical procedures are 
suitable for their intended use and that they support the identity, strength and quality, for 
the quantification of the drug substances and drug products. Method validation has 
received considerable attention in the literature and from industrial committees and 
regulatory agencies. The U.S. FDA CGMP[15] states for validation for the test methods 
employed by the firm. The U.S. FDA has also proposed industry guidance for Analytical 
Procedures and Methods Validation[16]. ISO/IEC 17025 includes a chapter on the 
validation of methods[17] with list validation parameters. The ICH[18] has developed a 
consensus text on the validation of analytical procedures. ICH also developed guidance 
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with detailed methodology[19]. The U.S. EPA prepared guidance for method’s 
development and validation for the Resource Conservation and Recovery Act (RCRA)[20].  
The AOAC, the EPA and other scientific organizations provide methods that are 
validated through multi-laboratory studies. The USP has published specific guidelines for 
method validation for compound evaluation[21]. The WHO published validation guidelines 
under the title, ‘Validation of analytical procedures used in the examination of 
pharmaceutical materials’ in the 32nd report of the WHO expert committee on 
‘specifications for pharmaceutical preparations’. Representatives of the pharmaceutical 
and chemical industry have published papers on the validation of analytical methods. 
Hokanson[22, 23] applied the life cycle approach, developed for computerized systems, to 
the validation and revalidation of methods. Green[24] gave a practical guide for analytical 
method validation, with a description of a set of minimum requirements for a method. 
Wegscheider[25] has published procedures for method validation with a special focus on 
calibration, recovery experiments, method comparison and investigation of ruggedness. 
Seno et al.[26] have described how analytical methods are validated in a Japanese QC 
laboratory. The AOAC[27] has developed a Peer-Verified Methods validation program 
with detailed guidelines on exactly which parameters should be validated. Winslow and 
Meyer[28] recommend the definition and application of a master plan for validating 
analytical methods. J. Breaux and colleagues have published a study on analytical 
methods development and validation[29]. 
 
4.1 Strategy for the Validation of Methods 
Method development and validation are an iterative process. The influence of operating 
parameters on the performance of the method can be assessed at the validation stage 
which was not done during development/optimization stage of the method. The most 
significant point raised for validation is that the validity of a method can be demonstrated 
only through laboratory studies. It is not sufficient to simply review historical results; 
instead, laboratory studies must be conducted which are intended to validate the specific 
method, and those studies should be pre-planned and described in a suitable 
documentation. This documentation should clearly indicate the method's intended use and 
principles of operation, as well as the validation parameters to be studied, and a rationale 
for why this method and these parameters were chosen. It also must include pre-defined 
acceptance criteria and a description of the analytical procedure. 
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4.2 Parameters for Method Validation 
The parameters for method validation have been defined in different working groups of 
national and international committees and are described in the literature. An attempt at 
harmonization was made for pharmaceutical applications through the ICH[18, 19]. The 
defined validation parameters by the ICH and other regulatory bodies are summarized as 
under: 
a) Specificity study 
b) Linearity and range study 
c) Limit of detection and Limit of quantitation study 
d) Precision study 
e) Accuracy study 
f) Robustness study 
g) Solution stability study 
h) System suitability 
A brief introduction of above parameters is as below: 
a)  Specificity study 
Specificity of an analytical method is its ability to measure accurately an analyte 
in the presence of interference, such as synthetic precursors, excipients, enantiomers and 
known (or likely) degradation products that may be expected to be present in the sample 
matrix. The term specificity is also referring to selectivity when a number of chemical 
entities that may or may not be distinguished from each other. 
Specificity study should also assess interferences that may be caused by the 
matrix, e.g., urine, blood, soil, water or food. Optimized sample preparation can eliminate 
most of the matrix components, e.g. placebo. The absence of matrix interferences for a 
quantitative method should be demonstrated by the analysis of control matrix in 
specificity. An investigation of specificity should be conducted during the validation of 
identification tests, the determination of impurities and the assay. In order to check the 
interference of degradation products, analyte is forcely subject to chemical (acid, alkali 
and oxidative) and physical (thermal and photolytic) degradation, known as stress 
application. In each stress application, peak purity of the analyte peak is also evaluated[30]. 
 
b)  Linearity and range study 
The linearity of an analytical method is its ability to elicit test results that are 
directly proportional to the concentration (amount) of analyte in samples within a given 
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range. Linearity may be demonstrated directly on the test substance (by dilution of a 
standard stock solution) and/or by using separate weighings of synthetic mixtures of the 
test product components, using the proposed procedure. 
 Linearity is determined by replicate injections of 5 or more concentrations level 
within the range of 40–160 %. The response should be directly proportional to the 
concentrations of the analytes or proportional by means of a well-defined mathematical 
calculation. Linearity is evaluated graphically by plotting a graph of the relative responses 
on the y-axis and the corresponding concentrations on the x-axis. A linear regression 
equation is applied to the results to evaluate correlation coefficient. In addition, y-
intercept, slope of the regression line and residual sum of squares should also calculate. 
 The range of an analytical method is the interval between the upper and lower 
concentrations (amounts) of analyte in the sample (including these concentrations) for 
which it has been demonstrated that the analytical procedure has a suitable level of 
precision, accuracy and linearity. The range is normally expressed in the same units as the 
test results (e.g., percentage, parts per million) obtained by the analytical method. 
 
c)  Limit of detection (LOD) and Limit of quantitation (LOQ) study 
The detection limit of an analytical method is the lowest amount of analyte in a 
sample which can be detected but not necessarily quantitated as an exact value. In 
chromatography, the detection limit is the injected amount that results in a peak with a 
height at least two or three times as high as the baseline noise level. Besides this 
signal/noise method, LOD can be measured by another three different methods; (i) visual 
inspection (ii) standard deviation of the blank response (iii) standard deviation of the 
response based on the slope of the calibration curve. 
The quantitation limit of an analytical method is the lowest amount of analyte in a 
sample which can be quantitated with suitable precision and accuracy. In 
chromatography, the quantitation limit is the minimum injected amount that produces 
quantitative measurements in the target matrix with acceptable precision, typically 
requiring peak heights 10 to 20 times higher than the baseline noise. Beside this 
signal/noise method, LOQ can be measured by another three different methods; (i) visual 
inspection (ii) standard deviation of the response (iii) standard deviation of the response 
based on the slope of the calibration curve. 
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d)  Precision study 
The precision of an analytical method expresses the closeness of agreement 
(degree of scatter) between a series of measurements obtained from multiple sampling of 
the homogeneous sample under the prescribed conditions. 
The measurement of precision of an analytical method is performed on replicate 
standard preparations and replicate sample preparations. The results for the same are 
usually expressed as the variance, standard deviation or confidence level of a series of 
measurements. Precision is performed by means of repeatability, reproducibility and 
intermediate precision (ruggedness). 
Repeatability: Repeatability expresses the precision under the same operating 
conditions over a short interval of time. Repeatability is also termed intra-assay precision.  
Reproducibility: Reproducibility expresses the precision between laboratories. 
The reproducibility of an analytical method is determined by analyzing aliquots from 
same homogeneous lots. 
Intermediate Precision: Intermediate precision expresses within-laboratories 
variations; different days, different analysts, different equipment, etc. The objective of 
intermediate precision validation is to verify that in the same laboratory the method will 
provide the same results once the development phase is over. The objective is also extent 
to verify that the method will provide the same results in different laboratories 
(ruggedness). 
 
e) Accuracy study 
The accuracy of the analytical method is the closeness of agreement between the 
value which is accepted either as a conventional true value or an accepted reference value, 
and the value found. The accuracy of an analytical method is the extent to which test 
results generated by the method and the true value agree. The true value for accuracy 
assessment can be assessed by analyzing a sample with known concentrations (e.g., a 
control sample or certified reference material) and comparing the measured value with the 
true value as supplied with the material. If certified reference materials or control samples 
are not available, a blank sample matrix of interest can be spiked with a known 
concentration by weight or volume. After extraction of the analyte from the matrix and 
injection into the analytical instrument, its recovery can be determined by comparing the 
response of the extract with the response of the reference material dissolved in a pure 
solvent (without matrix). 
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The ICH document on validation methodology recommends accuracy to be 
assessed using a minimum of nine determinations over a minimum of three concentration 
levels covering the specified range (e.g., three concentrations/three replicates each). 
Accuracy should be reported as percent recovery by the assay of known added amount of 
analyte in the sample or as the difference between the mean and the accepted true value. 
 
f)  Robustness study 
The robustness of an analytical method is a measure of its capacity to remain 
unaffected by small, but deliberate, variations in method parameters and provides an 
indication of its reliability during normal usage.  
Robustness tests examine the effect that operational parameters have on the 
analysis results. For the determination of a method’s robustness, method parameters like 
pH, flow rate, column temperature, column lot or mobile phase composition, are varied 
within a realistic range, and the quantitative influence of the variables is determined. If 
the influence of the parameter is within a previously specified tolerance, the parameter is 
said to be within the method’s robustness range. 
 
g)  Solution stability study 
Many solutes readily decompose prior to chromatographic investigations, for 
example, during the preparation of the sample solutions, extraction, cleanup, phase 
transfer or storage of prepared vials (in refrigerators or in an automatic sampler). Under 
these circumstances, method validation should investigate the stability of the analytes and 
standards in solution form (in analytical preparations). The standard and test preparations 
are stored up to specified period at specified temperature and its stability is evaluated by 
comparing solution preparations at different time intervals to that of initial. 
 
h)  System suitability study 
In addition, prior to the start of laboratory studies to demonstrate method validity, 
some type of system suitability must be done to demonstrate that the analytical system is 
performing properly. System suitability should be determined by replicate analysis of the 
standard or reference solution. System suitability is considered appropriate when the 
RSD, theoretical plates, tailing factor and resolution parameters calculated on the results 
obtained at different time intervals, does not exceed more than of specified limit of the 
corresponding value of the system precision. 
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4.3 Prior steps of Validation 
 Prior to start method validation, validation aim should be a well-planned 
according to scientific soundness and completeness with pre-defined acceptance criteria. 
Because the type of analysis and the other information of a sample have so much 
influence on the validation, the objective and scope of the method should always be 
defined as the first step of any method validation. For an efficient validation process, it is 
most importance to specify the right validation parameters.  
 Subsequent to the execution of the validation, results, conclusions and deviations 
should present in report. Provided the pre-defined acceptance criteria are met, and the 
deviations (if any) do not affect the scientific interpretation of the data, then the 
developed analytical method can be considered as valid. 
 
5. Objective of the Work 
 The specific and main objectives of the work are: 
 Development and validation of a stability indicating HPLC assay method for 
determination of lercanidipine hydrochloride in tablet formulation. 
 Development and validation of HPLC assay method for simultaneous 
determination of atenolol and lercanidipine hydrochloride in combined tablet 
dosage form in presence of  degradation product formed under ICH 
recommended stress condition. 
 Development and validation of UPLC assay method for simultaneous 
determination of aspirin, clopidogrel bisulphate and atorvastatin calcium in 
capsule dosage form. 
 UPLC assay method development and validation of six drug used for combined 
hypertension therapy. 
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METHOD DEVELOPMENT AND VALIDATION FOR ASSAY AND CONTENT 
UNIFORMITY DETERMINATION OF LERCANIDIPINE HYDROCHLORIDE 
FROM ITS PHARMACEUTICAL DOSAGE FORM 
 
1. Introduction of drug 
Lercanidipine hydrochloride, a calcium-channel blocker, which is chemically 2-
[(3,3-diphenylpropyl)methylamino]- 1,1-dimethylethylmethyl- 2,6-dimethyl-4-(3-
nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate (Figure 1), is a new drug which 
belongs to the well-known pharmacological active compound series classified as 1,4-
dihydropyridine calcium channel blockers. Its molecular formula is C36H41N3O6 HCl and 
molecular weight 648.19 g/mol. This drug is used for treating angina pectoris and 
hypertension[1-3], based on its selectivity and specificity on the smooth vascular cells[4].  
This molecule corresponds to a new molecular design in which its liposolubility 
has been increased to obtain a long action. It is an amphypatic drug which is transported 
quickly across the cellular barrier, arriving inside to both hydrophilic and hydrophobic 
sites in spite of its highest solubility in the lipophyllic bilayer. This fact explains the 
differences observed in both the clinic and the pharmacokinetic profiles compared with 
other type of drugs. For example, a long action of amlodipine in connection with a long 
plasma halflife, in contrast lercanidipine exhibits a short plasma half-life compared with a 
long pharmacological effect[5].  
The drug is orally administered in dose of 10-/20 mg daily as its hydrochloride 
salt[2, 6] reducing significantly the blood diastolic pressure after a single dose. It is rapidly 
absorbed from gastrointestinal tract, widely distributed and undergoes an extensive first 
pass metabolism[7] generating mainly inactive metabolites. Its half-life of elimination 
ranges from 2 to 5 h, but the therapeutic action is increased about 24 h due to it high 
liposolubility[2, 6]. 
 
 
Figure 1: Structure formula of lercanidipine hydrochloride 
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2. Literature review 
The literature reviews regarding lercanidipne hydrochloride suggest that various 
analytical methods were reported for drug substance as well as in pharmaceutical 
formulation and in various biological fluids. The literature reviews for analysis of 
lercanidipine are as under: 
 
2.1 Mihaljica S, Radulovic D, Trbojevic J have developed reversed phase high 
performance liquid chromatographic method for determination of lercanidipine 
hydrochloride and its synthetic impurities, degradation and oxidative products in Carmen 
tablets. The best separation was performed on Zorbax SB C18 column (250 × 4.6 mm, 
particle size 5µm). Acetonitrile-water-triethylamine (55:44.8:0.2, v/v/v) was used as a 
mobile phase with flow rate 1 ml/min. pH was adjusted to 3.0 with orthophosphoric acid. 
UV detection was performed at 240 nm and total run time was 12 min. The developed 
method can be used for the estimation of lercanidipine hydrochloride and it’s impurities 
in tablet dosage form[8]. 
 
2.2 Shirkhedkar AA, Deore PV and Surana SJ have developed a UV-spectrometric 
method for the determination of lercanidipine hydrochloride in bulk and pharmaceutical 
dosage form. In (50 % v/v) acetonitrile, lercanidipine hydrochloride showed absorbance 
maxima at 237 nm. Linearity was observed the concentration range of 4 – 24 µg/ml (r2 = 
0.9999). The recovery studies were carried out at 3 different levels i.e. at 80, 100 and 120 
%. The mean percentage recovery was found to be in the range of 99.55 – 100.05. The 
method was validated satisfactory and applied directly to analyze bulk and 
pharmaceutical formulations[9]. 
 
2.3 Charde S, Kumar L and Saha R have developed reversed phase liquid 
chromatographic method for lercanidipine hydrochloride in rabbit serum using UV 
detector under isocratic conditions. After subjecting serum to simple and efficient one-
step extn. Procedure, 100 µl of sample was injected onto high-performance liquid 
chromatographic system. The detector response was linear in the range of 25 – 1000 
ng/ml. the developed method was validated as per standard guidelines. The method can 
be considered suitable for application to pharmacokinetic studies of lercanidipine[10]. 
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2.4 Popovic I, Ivanovic D, Medenica M, Malenovic A and Jancic-stojanovic B 
have developed LC method for determination of lercanidipine and its impurities using 
DryLab software and experimental design procedure. Chromatography was performed 
with mobile phase containing a mixture of acetonitrile and 1.5 % TEA (35:65, v/v), pH 
adjusted to 3.0 by addition of orthophosphoric acid, at a flow rate of 1.0 ml/min. 
Separations were performed on a 20 × 4.6 mm, 3.5 µm particle size, C18 column, at 20˚ 
with UV detection at 240 nm. The method was validated according to ICH guideline. All 
the results proved the reliability of the method, so it can be used for the separation and 
identification of lercanidipine and impurities in pharmaceutical dosage form[11]. 
 
2.5 Raju SA, Karadi AB and Manjunath S have developed a high performance 
liquid chromatographic assay method for lercanidipine hydrochloride in pharmaceutical 
dosage forms by using RP-C18 column. The mobile phase consisted of buffer solution 
and acetonitrile (650:350, v/v) and was pumped at 1.0 ml/min at 30˚. The detection was 
carried out at 205 nm and calibration curve was linear in the range of 1-20 µg/ml. the 
intra and inter day variation was < 1 %. The proposed HPLC method may be used for 
determination of lercanidipine hydrochloride in bulk and in pharmaceutical 
formulation[12]. 
 
3. Aim of Present Work 
As per discussion in the literature review, there are few references to the analysis 
of lercanidipine hydrochloride and its impurities in pharmaceutical dosage forms[8] and 
UV spectrophotometric determination of lercanidipine hydrochloride in bulk and tablet 
are reported[9]. The development and validation of high performance liquid 
chromatographic method for estimation of lercanidipine in rabbit serum[10] and 
determination of lercanidipine and its impurities using DryLab software also reported[11]. 
Only one HPLC method reported in the literature for the assay determination of 
lercanidipine hydrochloride in bulk and pharmaceutical dosage form[12]. So far to our 
present knowledge, there are no reports of methods for study of the effect of stress on 
pharmaceutical dosage forms and there is no validated HPLC method, which enable both 
assay and determination of content uniformity of lercanidipine hydrochloride in 
pharmaceuticals dosage forms. Our work deals with the forced degradation of 
lercanidipine under stress condition like acid hydrolysis, base hydrolysis, xidation, 
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thermal and photolytic stress. Hence, the method is recommended for routine quality 
control analysis and also stability sample analysis. 
The objective of this work was to develop a stability-indicating liquid 
chromatographic analytical method for assay of lercanidipine hydrochloride and for 
determination of the content uniformity of a tablet formulation. The validation procedure 
followed the guidelines of ICH[13] and USP 30[14]. 
 
The aim and scope of the proposed work are as under: 
 To developed suitable HPLC method for lercanidipine hydrochloride. 
 Forced degradation study of lercanidipine hydrochloride under stress condition. 
 To resolve all major impurities generated during the force degradation studies of 
lercanidipine hydrochloride. 
 Perform the validation for the developed method. 
 Determination of content uniformity 
 
4. Experimental 
4.1 Materials 
Lercanidipine hydrochloride reference standard was provided by the Glenmark 
Pharmaceuticals, Ankleshwar, India. The pharmaceutical dosage form of lercanidipine 
hydrochloride, Lerka tablets, was procured from local pharmacy with a 10 mg label 
claim, manufactured by Nicholas Pharmaceuticals, India. All chemicals used were of 
analytical grade. Methanol and water both HPLC grade, were from spectrochem 
(Mumbai, India). Nylon syringe filters 0.45 µm were from Millex-HN (Mumbai, India). 
 
4.2 Instrumentation 
Liquid chromatography was performed with Waters equipment with TM 600 
quaternary pump, Waters 2489 UV/Vis Detector, Waters 600 controller, Waters In-line 
Degasser AF and manual injector with 20 µl loop. The equipment was connected to a 
multi-instrument data-acquisition and data-processing system (Empower software). 
 
4.3 Chromatographic conditions 
The chromatographic separation was performed using a Chromasil YMC Pack C8 
column (150 × 4.6 mm, 5µm particle size). Separation was achieved using a mobile phase 
consisted of 0.02 M ammonium dihydrogen phosphate buffer:methanol (35:65, v/v, pH 
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3.5) solution at a flow rate of 1 ml/min. The eluent was monitored using UV detection at 
a wavelength of 240 nm. The column was maintained at 30° temperature and injection 
volume 20 µl was used. The total runtime was 10 min. The mobile phase was filtered 
through 0.45 µm micron filter prior to use. 
 
4.4 Mobile phase preparation 
 The mobile phase consisted of 0.02 M ammonium dihydrogen phosphate buffer: 
methanol (35:65 v/v, pH 3.5). To prepare the buffer solution, 2.3 g ammonium 
dihydrogen phosphate was weighed and dissolved in 1000 ml HPLC grade water and then 
adjusted to pH 3.5 with ortho-phosphoric acid. Mobile phase was filtered through a 0.45 
µm nylon membrane (Millipore Pvt. Ltd. Bangalore, India) and degassed in an ultrasonic 
bath (Spincotech Pvt. Ltd., Mumbai). 
 
4.5 Diluent preparation 
 Water: Methanol (30:70, v/v) used as a diluents. 
 
4.6 Blank preparation 
 Diluent is used as a blank 
 
4.7 Standard preparation 
 To prepare a stock solution (500 µg/ml) for assay, weigh accurately about 50 mg 
lercanidipine hydrochloride reference standard and transfer into 100 ml volumetric flask. 
Add 40 ml of diluent to dissolve the substance by sonication for one minute and then 
dilute to volume with diluent. Pipette out 5 ml of above standard stock solution and 
transfer into 50 ml volumetric flask and dilute up to the mark with diluent. The 
concentration obtained is 50 µg/ml of lercanidipine hydrochloride. 
 
4.8 Test preparation 
 To prepare a stock solution (500 µg/ml) for assay, 20 tablets were weighed and 
mixed. An aliquot of powder equivalent to the weight of 5 tablets was accurately weighed 
and transferred to 100 ml volumetric flask and dissolved in 40 ml of diluent and the 
mixture was sonicated for 30 min. The contents of the flask were then left to return to 
room temperature and volume was adjusted with the same solvent mixture. This solution 
10 ml was filtered through a 0.45 µm nylon syringe filter. Pipette out 5 ml of above test 
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stock solution and transfer into 50 ml volumetric flask and dilute up to the mark with 
diluent. The concentration obtained is 50 µg/ml of lercanidipine hydrochloride. 
 
4.9 Standard preparation (For content uniformity study) 
 As per Std. Preparation 
 
4.10 Test preparation (For content uniformity study) 
 One Tablet was accurately weighed (98.1 mg) and transferred into 200 ml 
volumetric flask. 140 ml of diluent added into the volumetric flask.   The volumetric 
flask was proceeding for sonication of 30 minutes with normal handshaking. Then, 
the flask was cooled to room temperature and diluted to volume with diluent. 10 ml of 
this solution was filtered through 0.45 µm nylon syringe filter. The concentration 
obtained is about 50 µg/ml of lercanidipine.  
Above preparation was repeated for other nine tablets.  
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5. Results and Discussion 
 
5.1 Development and optimization of the HPLC method 
 In the present work, an analytical method based on LC was developed and 
validated for assay and content uniformity determination of lercanidipine hydrochloride 
in tablet formulation. The basic chromatographic conditions used for this method were 
designed to be simple and easy to use and reproduce. The analytical conditions were 
selected after testing the different parameters that influence LC analysis, such as column, 
aqueous and organic phase for mobile phase, mobile phase proportion, wavelength, 
diluent, concentration of analyte and other chromatographic parameters. Chromasil YMC 
Pack C8, 150×4.6 mm column having 5 µm particle size was used because of its 
advantages of high degree of retention, high resolution capacity, better reproducibility, 
ability to produce lower back pressure and low degree of tailing. For mobile phase 
selection, the preliminary trials using different compositions of mobile phases consisting 
of water and methanol (50:50 v/v) gave poor peak shape. The representative 
chromatogram for the same is shown as under (Figure 2): 
 
  
 
 
 
 
 
 
Figure 2: Chromatogram of standard preparation 
[Mobile phase: Water: methanol (50:50 v/v)] 
 
Above chromatogram clearly indicate that the peak is not symmetrical and value of 
theoretical plates is lower side. In focus to develop good symmetrical peak, water was 
replaced by phosphate buffer which is adjusted to acidic pH by ortho-phosphoric acid and 
thus, better peak shape was obtained. The representative chromatogram for the same is 
shown as under (Figure 3):  
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Figure 3: Chromatogram of standard preparation 
[Mobile phase: Phosphate buffer: methanol (50:50 v/v, pH 3.5)] 
 
Further, the mobile phase proportion was optimized to retain analyte properly that 
provide good resolution between lercanidipine and its degradation impurities. Proportion 
of methanol is finalized to 65 % of the mobile phase. Detection at 240 nm wavelength 
offered high response, good linearity, and the best option for detection conditions. As a 
diluent, the mixture of water-methanol (30:70, v/v) was made. Injection volume was fixed 
to 20 µL and the flow rate of the mobile phase is set to 1.0 ml/min. On this finalized 
chromatographic condition, obtained chromatogram was having of good peak symmetry 
and higher theoretical plates. The representative chromatogram for the same is shown as 
under (Figure 4): 
 
 
 
 
 
 
 
 
 
Figure 4: Chromatogram of standard preparation 
 [Mobile phase: Phosphate buffer: methanol (35:65 v/v, pH 3.5)] 
 
The drug substance was easily extracted from pharmaceutical dosage using diluent as 
water-methanol (30:70, v/v). Tablet was easily dispersed using water and the drug 
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substance is freely to very soluble in methanol. Extraction trials are finalized to keep 
sonication time for 30 minutes. Solutions of standard preparation and test preparation 
were found stable in diluent. By keeping same concentration of analyte for assay and 
content uniformity determination, validation study was clubbed in all validation 
parameters except precision study. 
 
5.2 Degradation study 
 To perform the forced degradation study drug was subjected to acidic, alkaline, 
oxidizing, thermal and photolytic conditions[15]. The degraded samples were prepared by 
transferring powdered tablets, equivalent to 50 mg lercanidipine hydrochloride into a 250 
ml round bottom flask. After the degradation treatments were completed, the stress 
content solutions were allowed to equilibrate to room temperature and diluted with the 
diluent to attain 50 µg/ml concentration. Specific conditions and figures were described 
as under. 
 
5.2.1 Acidic condition: In acidic degradation the drug was heated under reflux with 1 N 
HCl at 80° C for 1 h and the mixture was neutralized with 1 N NaOH solutions. 
Lercanidipine hydrochloride was found to be degrading up to 7 % in acidic condition. 
(Figure 5). 
 
 
Figure 5: Chromatogram of acidic forced degradation study 
5.2.2 Alkaline condition: In alkaline degradation the drug was treated with 0.1 N 
NaOH at room temperature for 100 min and the mixture was neutralized with 0.1 N HCl 
solutions. Major degradation was found in alkali condition that product was degraded up 
to 44%. (Figure 6). 
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Figure 6: Chromatogram of alkali forced degradation study 
5.2.3 Oxidative condition: In oxidative degradation the drug was heated under reflux 
with 3 % hydrogen peroxide at 80° C for 1 h. In oxidative degradation, it was found that 
around 15 % of the drug degraded (Figure 7).  
 
Figure 7: Chromatogram of oxidative forced degradation study 
5.2.4 Thermal condition: Thermal degradation was performed by exposing solid drug 
at 70° C for 72 h. Lercanidipine was found to be degrading up to 6 % in thermal condition 
(Figure 8). 
 
Figure 8: Chromatogram of thermal forced degradation study 
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5.2.5 Photolytic condition: Photolytic degradation was performed by exposing the drug 
content in sunlight for 72 h. Lercanidipine was found to be degrading up to 10 % in 
photolytic condition (Figure 9). 
 
Figure 9: Chromatogram of photolytic forced degradation study 
 
 
5.3 Method Validation 
 
5.3.1 Specificity 
The specificity of the method was determined by checking for interference with drug 
from placebo components. Further the specificity of the method toward the drug was 
established by means of the interference of the degradation products against drug during 
the forced degradation study. There was no interference of any peak of degradation 
product with drug peak. 
 
5.3.2 Linearity 
The linearity plot was prepared with seven concentration levels (20, 30, 40, 50, 60, 70, 
and 80 µg/ml of lercanidipine hydrochloride). These concentration levels were 
respectively corresponding to 40, 60, 80, 100, 120, 140, and 160% of test solution 
concentration. The response of the drug was found to be linear in the investigation 
concentration range and the linear regression equation was y = 48,443x + 20,928 where x 
is the concentration in µg/ml and y is the peak area in absorbance units; the correlation 
coefficient was 0.9992 (Figure 8). Chromatogram obtain during linearity study were 
shown in Figure 9-15. 
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Figure 8: Linearity curve for lercanidipine hydrochloride 
 
 
Figure 9: Chromatogram of 40% linearity level 
 
Figure 10: Chromatogram of 60% linearity level 
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 Figure 11: Chromatogram of 80% linearity level 
 
 
Figure 12: Chromatogram of 100% linearity level 
 
 Figure 13: Chromatogram of 120% linearity level  
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Figure 14: Chromatogram of 140% linearity level 
 
 
Figure 15: Chromatogram of 160% linearity level 
 
5.3.3 Limit of detection and Limit of quantitation 
The limit of detection (LOD) and limit of quantitation (LOQ) were determined by 
calculating the signal to noise (S/N) ratio of the LOD preparation and LOQ preparation. 
LOQ value is precised by six replicate injections and checked for linear response with 
respect to other linearity levels by extended linearity curve (Figure 16). 
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5.3.4 Precision study 
Precision study was established by evaluating method precision and intermediate 
precision study. 
Method precision of the analytical method was determined by analyzing six sets 
of sample preparation. Assay of all six replicate sample preparations was determined and 
mean % assay value, standard deviation, % relative standard deviation and 95% 
confidence interval for the same was calculated. 
Intermediate precision of the analytical method was determined by performing 
method precision on another day by another analyst using different make of raw materials 
under same experimental condition. Assay of all six replicate sample preparations was 
determined and mean % assay value, standard deviation, % relative standard deviation 
and 95% confidence interval for the same was calculated. Overall assay value of method 
precision and intermediate precision was compared and % difference and overall % 
relative standard deviation was calculated.  
 
Table 1: Summary of precision study 
 
Study Set No. Assay (%) 
Mean 
assay 
(%) 
Stdev RSD % 
95 % 
Confidence 
Interval 
Method 
precision 
1 101.4 
101.5 0.28 0.28 0.30 
2 101.7 
3 101.4 
4 101.6 
5 100.9 
6 101.7 
Intermediate 
precision 
1 101.5 
101.4 0.47 0.46 0.49 
2 101.7 
3 101.6 
4 100.4 
5 101.4 
6 101.3 
Overall 
Mean 101.4 Absolute difference between mean % 
assay values of Method precision and 
Intermediate precision= 0.1 
Stdev 0.38 
RSD % 0.38 
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Figure 19: Chromatogram of standard preparation of method precision study 
 
 
Figure 20: Chromatogram of standard preparation of intermediate precision study 
 
5.3.5 Accuracy study 
The accuracy of the method was assessed by determination of recovery for three 
concentrations (corresponding to 50, 100 and 150 % of test solution concentration) 
covering the range of the method.  For each concentration three sets were prepared and 
injected in duplicate. The mean recovery of lercanidipine hydrochloride was between 
99.3 -101.9% and RSD of recoveries between 0.4-1.44 %, which indicates accuracy of the 
method (Table 2). Chromatogram obtain during accuracy study were shown in Figure 21-
23. 
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Table 2: Evaluation data of accuracy study 
Accuracy 
level 
Set 
No. 
Amount 
added 
Amount 
found 
Recovery 
(%) 
Mean 
recovery 
(%) 
Stdev RSD (%) 
50% 
1 25.17 25.18 100.06 
101.76 1.47 1.44 2 25.41 26.07 102.64 
3 25.52 26.17 102.57 
100% 
1 50.51 50.25 99.48 
99.32 0.14 0.15 2 50.83 50.46 99.28 
3 50.92 50.51 99.20 
150% 
1 74.97 76.02 101.40 
101.87 0.41 0.40 2 75.02 76.55 102.04 
3 75.21 76.84 102.16 
 
 
Figure 21: Chromatogram of accuracy level-I (50 %) 
 
 
Figure 22: Chromatogram of accuracy level-II (100 %) 
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Figure 23: Chromatogram of accuracy level-III (150 %) 
 
5.3.6 Solution stability study 
Stability in solution was evaluated for the standard solution and the test preparation. The 
solutions were stored at 5° and at ambient temperature. Without protection of light and 
tested after 12, 24, 36 and 48 h. the responses for the aged solution were evaluated by 
comparison with freshly prepared solutions. During study of the stability of stored 
solutions of standards and test preparations for assay determination the solutions were 
found to be stable for up to 36 h[16]. Assay values obtained after 36 h were statistically 
identical with the initial value without measurable loss. Table 3 shows the summary of 
solution stability study. 
 
Table 3: Evaluation data of solution stability study 
Time intervals Absolute difference in assay for standard solution, % 
Absolute difference in assay for 
test solution, % 
  At 5°C At room temperature At 5° C At room temperature
           
After 12 hrs 1.63 1.66 0.01 0.21 
After 24 hrs 1.51 1.71 0.26 0.36 
After 36 hrs 1.69 1.92 1.50 1.70 
After 48 hrs 2.02 2.45 2.06 2.26 
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5.3.7 Robustness study 
The robustness of the method was evaluated by assaying test solutions after slight 
but deliberate changes in the analytical conditions flow rate (± 0.1 ml/min), the 
proportions of buffer: methanol (33:67 and 37:63, v/v) and changing the column 
temperature 35°C. For each different analytical condition the standard solution and test 
solution were prepared separately. The result obtained from assay of the test solution was 
not affected by varying the conditions and was in accordance with the true value. System 
suitability data were also found to be satisfactory during variation of the analytical 
conditions.  The analytical method therefore remained unaffected by slight but deliberate 
changes in the analytical conditions. Table 4 shows the results obtained from robustness 
study. Chromatogram obtain during robustness study were shown in Figure 24-28. 
 
Table 4: Evaluation data of robustness study 
 
Robust conditions Assay % 
% Assay 
difference
RT, 
minute
System-suitability 
parameters 
Theoretical 
plates Asymmetry
0.9 ml/min flow rate 101.5 0.1 4.28 4271 1.01 
1.1 ml/min flow rate 101.9 0.5 4.03 7655 1.02 
Methanol-Buffer (67:33, v/v) 99.8 1.6 3.69 4541 1.02 
Methanol-Buffer (63:37, v/v) 99.9 1.5 4.28 4467 1.02 
Column temperature change 99.6 1.8 4.02 4146 1.02 
 
 
 
Figure 24: Chromatogram of standard preparation (0.9 ml/min flow rate) 
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Figure 25: Chromatogram of standard preparation (1.1 ml/min flow rate) 
  
 
Figure 26: Chromatogram of standard preparation [Methanol: Buffer (67:33, v/v)] 
 
 
Figure 27: Chromatogram of standard preparation [Methanol: Buffer (63:37, v/v)] 
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Figure 28: Chromatogram of standard preparation (Column temperature change) 
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5.3.8 Content uniformity study 
 Analytical method validation of the developed chromatographic method for 
content uniformity determination of lercanidipine from lercanidipine tablets. 
 
Validation Approach 
 
 Validation of analytical method will be done by using Lercanidipine tablets 10 mg 
formulation to establish by laboratory studies, that the performance characteristic of the 
method meets the requirement for the intended analytical application. 
 
This whole experiment of validation is applicable to above mentioned Standard 
Testing Procedure for determination of content uniformity. As chromatographic 
parameters and concentration of content uniformity test are same as that of assay method, 
only precision study is performed for analytical method validation of content uniformity 
determination. 
 
Validation procedure for content uniformity determination of lercanidipine  
 
Precision study 
 
 Precision study was established by evaluating method precision and intermediate 
precision study. Method precision of the analytical method was determined by analyzing 
test preparations. Content of all test preparations was determined and mean % content 
uniformity value, standard deviation, % relative standard deviation and 95% confidence 
interval for the same was calculated. 
 
 Intermediate precision of the analytical method was determined by performing 
method precision on another day by another analyst using different make of raw materials 
under same experimental condition. Content of all test preparations was determined and 
mean % content uniformity value, standard deviation, % relative standard deviation and 
95% confidence interval for the same was calculated. Overall content value of method 
precision and intermediate precision was compared and % difference and overall % 
relative standard deviation was calculated. 
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Table 5: Summary of precision study 
 
Study Set No. Assay (%) 
Mean assay 
(%) Stdev % RSD  
95 % 
Confidence 
Interval 
Method 
precision 
1 99.73 
100.62 0.61 0.61 0.64 
2 100.02 
3 100.25 
4 100.50 
5 101.35 
6 100.55 
7 100.22 
8 100.67 
9 101.49 
10 101.42 
Intermediate 
precision 
1 100.77 
100.87 0.83 0.82 0.86 
2 100.59 
3 101.94 
4 100.55 
5 101.65 
6 101.11 
7 99.82 
8 102.15 
9 100.1 
10 99.98 
Overall 
Mean 100.7 Absolute difference between mean % assay 
values of Method precision and Intermediate 
precision= 0.25 
Stdev 0.72 
% RSD  0.71 
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5.3.9 System suitability study 
Before each measurement of validation data a system suitability test was 
performed by measurement of general characteristics such as peak asymmetry, number of 
theoretical plates and % RSD of peak area observed for a standard solution. The values 
obtained were satisfactory and in accordance with in-house limits (Table 5). 
 
Table 5: System suitability data 
 
System suitability data % RSDa Theoretical plates Asymmetry 
In-house limit NMTb 2.0 NLTc 3000 NMTb 2.0 
Validation data    
Specificity 0.52 4221 1.02 
Linearity 0.43 4324 1.00 
Limit of detection 0.34 4421 1.03 
Limit of quantitation 0.41 4213 1.01 
Method precision   
For assay 0.43 4532 1.00 
For content uniformity 0.37 4357 0.98 
Intermediate precision   
For assay 0.40 4231 1.01 
For content uniformity 0.55 4436 0.99 
Accuracy 0.34 4315 1.00 
Solution stability 0.27 4231 1.01 
Robustness 0.46 4328 1.02 
aRelative standard deviation                                                                                          
bNot more than                                                                                                                   
cNot less than 
 
System suitability was found satisfactory during each validation parameter. Hence, 
system is suitable for the same. 
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6. Calculations and Data 
 Calculation formula used 
 
1. Calculation formula for % assay of lercanidipine hydrochloride 
 
% ܣݏݏܽݕ ൌ ܣܶܣܵ ൈ
ܹ1
100 ൈ
5
50 ൈ
100
ܹ2 ൈ
50
5 ൈ
ܣܹ
ܮܥ ൈ ܲ 
  
Whereas, 
AT = Average area of lercanidipine obtained in test preparation 
AS = Average area of lercanidipine obtained in standard preparation 
W1 = Weight taken of lercanidipine reference standard (mg) 
W2 = Weight taken of test sample (mg) 
AW = Average weight of tablets (mg) 
LC = Label claim (mg) 
P = Potency of lercanidipine reference standard (%) 
 
2. Relative standard deviation 
 
% ܴܵܦ ൌ  ܵݐܽ݊݀ܽݎ݀ ݀݁ݒ݅ܽݐ݅݋݊ܯ݁ܽ݊ ݒ݈ܽݑ݁ ൈ 100 
 
3. Amount added 
 
ܣ݉݋ݑ݊ݐ ܽ݀݀݁݀ ሺߤ݃ ݈݉ሻ⁄ ൌ ܹݐ. ݐܸܽ݇݁݊݋݈ݑ݉݁ 1 ൈ
ܸ݋݈ݑ݉݁ 2
ܸ݋݈ݑ݉݁ 3 ൈ 1000 
 
4. Amount found  
 
ܣ݉݋ݑ݊ݐ ݂݋ݑ݊݀ ሺߤ݃ ݈݉ሻ⁄ ൌ ܯ݁ܽ݊ ܽݎ݁ܽ ݋݂ ݐ݁ݏݐܯ݁ܽ݊ ܽݎ݁ܽ ݋݂ ܵݐ݀ ൈ ݏݐܽ݊݀ܽݎ݀ ܿ݋݊ܿ. 
 
5. Recovery 
% ܴ݁ܿ݋ݒ݁ݎݕ ൌ ܣ݉݋ݑ݊ݐ ݂݋ݑ݊݀ܣ݉݋ݑ݊ݐ ܽ݀݀݁݀ ൈ 100 
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6. Absolute difference 
ܣܾݏ݋݈ݑݐ݁ ܦ݂݂݅݁ݎ݁݊ܿ݁ ሺ%ሻ ൌ   ൤100 െ ൬ܣܴܣܫ ൈ 100൰൨ 
Whereas, 
 AR = Standard mean area of respective time interval stage 
 AI = Standard mean area of initial stage 
 
6. Content uniformity 
 
% ܥ݋݊ݐ݁݊ݐ ൌ  ܣܶܣܵ ൈ
ܹ
100 ൈ
5
50 ൈ
200
ܮܥ ൈ ݌ 
 
Whereas, 
 AT = Area of lercanidipine obtained in test preparation 
 AS = Average area of lercanidipine obtained in standard preparation 
 W = Weight taken of lercanidipine reference standard (mg) 
 LC = Label claim (mg) 
 P = Potency of lercanidipine reference standard (%) 
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 Specificity study for analytical method validation of lercanidipine 
hydrochloride tablets 
 
Observation 
  
Data for standard preparation 
 
Data for test preparation 
    
Replicate Area Replicate Area 
1 2401872 1 2415789 
2 2445828 2 2398915 
3 2436968 Average 2407352 
4 2438184     
5 2426135     
Average 2429797     
Stdev 17117.05     
% RSD 0.52     
    
Standard weight 50.8 mg Test weight 505.4 mg 
Standard potency 99.80% Label claim 10 mg 
 
Calculation: 
% ܣݏݏܽݕ ൌ ܣܶܣܵ ൈ
ܹ1
50 ൈ
5
50 ൈ
100
ܹ2 ൈ
50
5 ൈ
ܣܹ
ܮܥ ൈ ܲ 
 
                                          ൌ 24073522429797 ൈ
50.8
100 ൈ
5
50 ൈ
100
505.4 ൈ
50
5 ൈ
101
10 ൈ 99.8 
 
                                                     ൌ 100.38 
 
Whereas, 
AT = Average area of lercanidipine obtained in test preparation 
AS = Average area of lercanidipine obtained in standard preparation 
W1 = Weight taken of lercanidipine reference standard (mg) 
W2 = Weight taken of test sample (mg) 
AW = Average weight of tablets (mg) 
LC = Label claim (mg) 
P = Potency of lercanidipine reference standard (%) 
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 Linearity study for analytical method validation of lercanidipine tablets 
 
 Summary of linearity and range study: 
Observation 
  
Data for standard preparation 
    
 
    
Replicate Area Standard weight 49.6 mg 
1 2397778 Standard potency 99.80% 
2 2408902     
3 2412184     
4 2416076     
5 2409946     
Average 2408977     
Stdev 6838.18     
% RSD 0.43     
Data for linearity level preparations 
  
Linearity Level Replicate Area Mean area 
Level 1 (40%) 1 977076 980626 
2 984176 
Level 2 (60%) 1 1464523 1473381 
2 1482239 
Level 3 (80%) 1 1955312 1967190 
2 1979069 
Level 4 (100%) 1 2464212 2462382 
2 2460552 
Level 5 (120%) 1 2856134 2832868 
2 2809602 
Level 6 (140%) 1 3404160 3418748 
2 3433337 
Level 7 (160%) 1 3877980 3898376 
2 3918772 
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 Summary of concentration and linearity evaluation: 
Linearity level % Level Concentration (µg/ml) Mean area 
1 40 19.92 980626 
2 60 29.88 1473381 
3 80 39.84 1967191 
4 100 49.80 2462382 
5 120 59.76 2832868 
6 140 69.72 3418749 
7 160 79.68 3898376 
     
Correlation co-efficient 0.9992 
Slope 48443 
Intercept 20928 
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 LOD and LOQ study for analytical method validation of lercanidipine tablets 
 
 Summary of LOQ study: 
Observation 
    
Data for standard preparation 
 
Data for LOQ preparation 
      
Replicate Area Replicate Area 
1 2410351 1 14700 
2 2405593 2 14621 
3 2415702 3 14240 
4 2423619 4 14366 
5 2423607 5 14630 
Average 2415774 6 14543 
Stdev 7999.48 Average 14517 
% RSD 0.33 Stdev 177.36 
    % RSD 1.22 
 
 
 Summary of LOQ study by evaluating linearity up to LOQ concentration: 
 
Linearity level % Level Concentration (µg/ml) Mean area 
1 LOQ 0.3 14517 
2 40 19.92 980626 
3 60 29.88 1473381 
4 80 39.84 1967191 
5 100 49.80 2462382 
6 120 59.76 2832868 
7 140 69.72 3418749 
8 160 79.68 3898376 
    
Correlation co-efficient 0.9987 
Slope 48627 
Intercept 10271 
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 Precision study for analytical method validation of lercanidipine tablets 
 
 Summary of method precision study: 
Observation 
    
Data for standard preparation 
      
 
    
Replicate Area Standard weight 49.6 mg 
1 2394079 Standard potency 99.80% 
2 2410856       
3 2414501       
4 2422410       
5 2413260       
Average 2411021       
Stdev 10415.03       
% RSD 0.43     
Data for test preparation 
  
Set No. Replicate Area Mean area Weight of sample 
1 1 2459562 2470450 505.0 mg 
2 2481337 
2 1 2466304 2473159 504.0 mg 
2 2480013 
3 1 2470200 2471263 505.2 mg 
2 2472325 
4 1 2469175 2472557 504.5 mg 
2 2475938 
5 1 2390360 2428221 498.6 mg 
2 2466082 
6 1 2465457 2470704 503.6 mg 
2 2475951 
 
 % Assay Calculation for one set is as under: 
  
For Set 1:- 
                                % ܣݏݏܽݕ ൌ ܣܶܣܵ ൈ
ܹ1
50 ൈ
5
50 ൈ
100
ܹ2 ൈ
50
5 ൈ
ܣܹ
ܮܥ ൈ ܲ 
                                                  ൌ 24704502411021 ൈ
49.6
100 ൈ
5
50 ൈ
100
505 ൈ
50
5 ൈ
101
10 ൈ 99.8 
                                                  ൌ 101.4 
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 Summary of Intermediate precision study: 
Observation 
    
Data for standard preparation 
      
  
    
Replicate Area Standard weight 49.8 mg 
1 2402081 Standard potency 99.80% 
2 2420084       
3 2427600       
4 2423482       
5 2419979       
Average 2418645       
Stdev 9769.92       
% RSD 0.40     
Data for test Preparation 
  
Set No. Replicate Area Mean area Weight of sample 
1 1 2390183 2433668 497.5 mg 
2 2477152 
2 1 2480432 2477799 505.3 mg 
2 2475165 
3 1 2484846 2483003 507.1 mg 
2 2481159 
4 1 2490325 2430581 500.1 mg 
2 2370837 
5 1 2470283 2475428.5 506.2 mg 
2 2480574 
6 1 2483442 2476969.5 507.5 mg 
2 2470497 
 
 % Assay Calculation for one set is as under: 
  
For Set 1:- 
                                 % ܣݏݏܽݕ ൌ ܣܶܣܵ ൈ
ܹ1
50 ൈ
5
50 ൈ
100
ܹ2 ൈ
50
5 ൈ
ܣܹ
ܮܥ ൈ ܲ 
                                                   ൌ 24336682418645 ൈ
49.8
100 ൈ
5
50 ൈ
100
497.5 ൈ
50
5 ൈ
101
10 ൈ 99.8 
                                                   ൌ 101.5 
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 Accuracy study for analytical method validation of lercanidipine tablets 
 Summary of accuracy study: 
 
Observation 
    
Data for standard preparation 
    
Replicate Area 
 
Standard weight 50.16 mg 
1 2391386 Standard potency 99.80% 
2 2392900 Standard conc. 50.16 
3 2406312       
4 2407632       
5 2406447       
Average 2400935       
Stdev 8060.53       
% RSD 0.34     
Data for test preparations 
Accuracy level Set No. Replicate Area Mean area 
50% 
1 
1 1159923
1205526 
2 1251129
2 
1 1241330
1247939 
2 1254547
3 
1 1250717
1252868 
2 1255019
100% 
1 
1 2405281
2405112 
2 2404943
2 
1 2414359
2415369 
2 2416378
3 
1 2410527
2417714 
2 2424901
150% 
1 
1 3632991
3638811 
2 3644630
2 
1 3673138
3664031 
2 3654924
3 
1 3685447
3677855 
2 3670262
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 Summary for added amount: 
Accuracy 
level 
Set 
No. 
Weight 
taken (mg) 
Vol-1 
(ml) 
Vol-2 
(ml) 
Vol-3 
(ml) 
Amount 
added 
(µg/ml) 
50% 
1 25.17 100 5 50 25.17 
2 25.41 100 5 50 25.41 
3 25.52 100 5 50 25.52 
100% 
1 50.51 100 5 50 50.51 
2 50.83 100 5 50 50.83 
3 50.92 100 5 50 50.92 
150% 
1 74.97 100 5 50 74.97 
2 75.02 100 5 50 75.02 
3 75.21 100 5 50 75.21 
 
Prototype calculation for Set-1of accuracy level-1 is as under: 
 
 
ܣ݉݋ݑ݊ݐ ܽ݀݀݁݀ ሺߤ݃ ݈݉ሻ⁄ ൌ ܹݐ. ݐܸܽ݇݁݊݋݈ݑ݉݁ 1 ൈ
ܸ݋݈ݑ݉݁ 2
ܸ݋݈ݑ݉݁ 3 ൈ 1000 
 
ൌ 25.17 100 ൈ
 5
50 ൈ 1000 
ൌ 25.17 
 
 Summary of % recovery: 
Accuracy 
level 
Set 
No. 
Amount 
added 
Amount 
found 
Recovery 
(%) 
Mean 
recovery 
(%) 
Stdev RSD (%) 
50% 
1 25.17 25.18 100.06 
101.76 1.47 1.44 2 25.41 26.07 102.64 
3 25.52 26.17 102.57 
100% 
1 50.51 50.25 99.48 
99.32 0.14 0.15 2 50.83 50.46 99.28 
3 50.92 50.51 99.20 
150% 
1 74.97 76.02 101.40 
101.87 0.41 0.40 2 75.02 76.55 102.04 
3 75.21 76.84 102.16 
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Prototype calculation for set-1of accuracy level-1 is as under: 
ܣ݉݋ݑ݊ݐ ݂݋ݑ݊݀ ሺߤ݃ ݈݉ሻ⁄ ൌ ܯ݁ܽ݊ ܽݎ݁ܽ ݋݂ ݐ݁ݏݐܯ݁ܽ݊ ܽݎ݁ܽ ݋݂ ܵݐ݀ ൈ ݏݐܽ݊݀ܽݎ݀ ܿ݋݊ܿ. 
 
ൌ 1205526 2400935 ൈ 50.16 
ൌ 25.18 
 
                        % ܴ݁ܿ݋ݒ݁ݎݕ ൌ ܣ݉݋ݑ݊ݐ ݂݋ݑ݊݀ܣ݉݋ݑ݊ݐ ܽ݀݀݁݀ ൈ 100 
 
ൌ 25.18 25.17 ൈ 100 
ൌ 100.06 
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 Solution stability study for analytical method validation of lercanidipine 
tablets 
 
System suitability of standard preparation for solution stability 
Replicate Initial After 12 hrs After 24 hrs After 36 hrs After 48 hrs 
1 2407500 2423554 2402756 2477276 2494527 
2 2414142 2418172 2415781 2493433 2485145 
3 2417902 2416318 2420042 2498658 2498128 
4 2418327 2426496 2418798 2497090 2498927 
5 2425681 2426422 2428557 2495564 2493451 
Mean 2416710 2422192 2417187 2492404 2494036 
Stdev 6631.99 4715.31 9357.53 8674.27 5484.06 
% RSD 0.27 0.19 0.39 0.35 0.22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Solution stability for test preparation at room temperature 
Solution stability of test sample at room temperature 
Duration Mean area of test 
Mean area of 
standard 
Standard 
weight (mg) 
Test weight 
(mg) 
Average test 
weight (mg) 
Label 
claim (mg) Potency
% 
Assay 
Initial stage 2472679 2416710 49.8 506.4 101.00 10 99.8 101.42 
after 12 hrs 2476183 2422192 49.6 505.0 101.00 10 99.8 101.21 
after 24 hrs 2481414 2417187 50.0 508.3 101.00 10 99.8 101.79 
after 36 hrs 2478966 2492404 50.2 504.7 101.00 10 99.8 99.72 
after 48 hrs 2483285 2494036 50.2 507.4 101.00 10 99.8 99.30 
 
Calculation: 
Prototype calculation for one set: 
 
                                    % ܣݏݏܽݕ ൌ ܣܶܣܵ ൈ
ܹ1
100 ൈ
5
50 ൈ
100
ܹ2 ൈ
50
5 ൈ
ܣܹ
ܮܥ ൈ ܲ 
                                                      ൌ 24726972416710 ൈ
49.8
100 ൈ
5
50 ൈ
100
506.4 ൈ
50
5 ൈ
101
10 ൈ 99.8 
                                                      ൌ 101.42 
  Solution stability for test preparation at 5° C 
Solution stability of test sample at 5° C 
Duration Mean area of test 
Mean area of 
standard 
Standard 
weight (mg) 
Test weight 
(mg) 
Average test 
weight (mg) 
Label 
claim (mg) Potency
% 
Assay 
Initial stage 2472679 2416710 49.8 506.4 101.0 10 99.8 101.42 
after 12 hrs 2481197 2422192 49.6 505.0 101.0 10 99.8 101.41 
after 24 hrs 2478782 2417187 50.0 508.3 101.0 10 99.8 101.68 
after 36 hrs 2483940 2492404 50.2 504.7 101.0 10 99.8 99.92 
after 48 hrs 2484884 2494036 50.2 507.4 101.0 10 99.8 99.36 
 
Calculation: 
Prototype calculation for one set: 
 
                                    % ܣݏݏܽݕ ൌ ܣܶܣܵ ൈ
ܹ1
100 ൈ
5
50 ൈ
100
ܹ2 ൈ
50
5 ൈ
ܣܹ
ܮܥ ൈ ܲ 
                                                      ൌ 24726972416710 ൈ
49.8
100 ൈ
5
50 ൈ
100
506.4 ൈ
50
5 ൈ
101
10 ൈ 99.8 
                                                      ൌ 101.42 
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 Solution stability for standard preparation at room temperature 
Solution stability of standard at room temperature 
Duration Mean area of standard 
Mean area of standard 
(Initial) 
Absolute 
difference (%) 
after 12 hrs 2456926 2416710 1.66 
after 24 hrs 2458049 2416710 1.71 
after 36 hrs 2463193 2416710 1.92 
after 48 hrs 2475892 2416710 2.45 
 
 Solution stability for standard preparation at 5° C 
Solution stability of standard at 5° C 
Duration Mean area of standard 
Mean area of standard 
(Initial) 
Absolute 
difference (%) 
after 12 hrs 2456210 2416710 1.63 
after 24 hrs 2453303 2416710 1.51 
after 36 hrs 2457622 2416710 1.69 
after 48 hrs 2465760 2416710 2.02 
 
Calculation: 
Prototype calculation for one set: 
 For standard preparation (at room temperature): 
ܣܾݏ݋݈ݑݐ݁ ܦ݂݂݅݁ݎ݁݊ܿ݁ ሺ%ሻ ൌ   ൤100 െ ൬ܣܴܣܫ ൈ 100൰൨ 
            ൌ    ൤100 െ ൬24569262416710 ൈ 100൰൨ 
                      ൌ   1.66 
 For standard preparation (at 5° C temperature): 
ܣܾݏ݋݈ݑݐ݁ ܦ݂݂݅݁ݎ݁݊ܿ݁ ሺ%ሻ ൌ   ൤100 െ ൬ܣܴܣܫ ൈ 100൰൨ 
            ൌ    ൤100 െ ൬24562102416710 ൈ 100൰൨ 
                      ൌ   1.63
 Robustness study for analytical method validation of lercanidipine tablets 
Robustness study of Lercanidipine 
Robustness Parameters Mean area of Test 
Mean area 
of Standard 
Standard 
weight  
(mg) 
Test 
weight  
(mg) 
Average 
test weight 
(mg) 
Label 
claim 
(mg) 
Potency % Assay 
Flow rate 0.9 ml/min 2752312 2690130 49.8 506.0 101.0 10 99.8 101.50 
Flow rate 1.1ml/min 2223689 2164035 49.8 506.0 101.0 10 99.8 101.94 
Methanol: Buffer (67:33, v/v) 2477019 2492386 50.0 502.0 101.0 10 99.8 99.78 
Methanol: Buffer (63:37, v/v) 2475109 2486997 50.0 502.0 101.0 10 99.8 99.92 
Column temp. change 2473538 2491837 50.4 506.2 101.0 10 99.8 99.62 
 
Calculation: 
Prototype calculation for one set: 
 
                                    % ܣݏݏܽݕ ൌ ܣܶܣܵ ൈ
ܹ1
100 ൈ
5
50 ൈ
100
ܹ2 ൈ
50
5 ൈ
ܣܹ
ܮܥ ൈ ܲ 
                                                      ൌ 27523122690130 ൈ
49.8
100 ൈ
5
50 ൈ
100
506.0 ൈ
50
5 ൈ
101
10 ൈ 99.8 
                                                      ൌ 101.50 
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 Content uniformity study for analytical method validation of lercanidipine 
tablets 
 
 Summary of method precision study 
Observation 
    
Data for standard preparation 
      
 
    
Replicate Area Standard weight 49.4 mg 
1 2476782 Standard potency 99.80% 
2 2451466       
3 2464680       
4 2466495       
5 2464072       
Average 2464699       
Stdev 9010.14       
% RSD 0.37     
  
Data for test preparations 
  
Unit No. Area Assay % Weight of tablet (mg) 
1 2492974 99.73 98.1 
2 2500224 100.02 100.5 
3 2505930 100.25 101.2 
4 2512181 100.50 101.8 
5 2527154 101.35 101.3 
6 2513360 100.55 101.6 
7 2505120 100.22 101.0 
8 2516277 100.67 101.8 
9 2534370 101.49 101.5 
10 2529659 101.42 101.4 
  
Mean 100.62 
  
Sdev 0.61 
% RSD 0.61 
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 Summary of intermediate precision study 
Observation 
    
Data for standard preparation 
      
 
    
Replicate Area Standard weight 49.6 mg 
1 2471839 Standard potency 99.80% 
2 2440006       
3 2466724       
4 2470093       
5 2471305       
Average 2463993       
Stdev 13556.08       
% RSD 0.55     
  
Data for test preparations 
  
Unit No. Area Assay % Weight of tablet (mg) 
1 2508012 100.77 101.8 
2 2503582 100.59 99.85 
3 2537108 101.94 101.0 
4 2502442 100.55 100.8 
5 2529964 101.65 100.7 
6 2516490 101.11 101.5 
7 2531347 99.82 100.9 
8 2542261 102.15 101.6 
9 2533090 100.1 102.0 
10 2505927 99.98 101.7 
  
Mean 100.87 
  
Sdev 0.83 
% RSD 0.82 
  
 
Calculation: 
Prototype calculation for unit-1: (Method precision) 
                                 % ܥ݋݊ݐ݁݊ݐ ൌ  ܣܶܣܵ ൈ
ܹ
50 ൈ
5
50 ൈ
200
ܮܥ ൈ ݌ 
                                   ൌ   24929742464699 ൈ
49.4
100 ൈ
5
50 ൈ
200
10 ൈ 99.8 
                                                       ൌ 99.73 
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Prototype calculation for unit-1: (Intermediate precision) 
                                    % ܥ݋݊ݐ݁݊ݐ ൌ  ܣܶܣܵ ൈ
ܹ
50 ൈ
5
50 ൈ
200
ܮܥ ൈ ݌ 
                                 ൌ   25080122463993 ൈ
49.6
100 ൈ
5
50 ൈ
200
10 ൈ 99.8 
                                    ൌ 100.77 
Whereas, 
 AT = Area of lercanidipine obtained in test preparation 
 AS = Average area of lercanidipine obtained in standard preparation 
 W = Weight taken of lercanidipine reference standard (mg) 
 LC = Label claim (mg) 
 P = Potency of lercanidipine reference standard (%) 
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HPLC METHOD DEVELOPMENT AND VALIDATION OF COMBINE DOSAGE 
FORM OF ATENOLOL AND LERCANIDIPINE HYDROCHLORIDE 
 
1. Introduction of drugs  
1.1 Atenolol 
 Atenolol (ATE), 4-[2-hydroxy-3-[(1-methylethyl) amino] propoxy] 
benzeneacetamide (Figure 1)[1] is a selective ß1-adrenoceptor antagonist applied in the 
treatment of numerous cardiovascular disorders such as hypertension and angina 
pectoris[2]. It is reported to lack intrinsic sympathomimetic activity and membrane- 
stabilizing properties. Atenolol is official in USP, IP and BP[3-5]. 
NH2
O
O
H
N
OH  
  
Figure 1: Chemical structure of atenolol 
 
1.2 Lercanidipine hydrochloride 
 As per part-A section-1 
 
2. Literature review 
 There are many reported method for the determination of either atenolol or 
lercanidipine alone or in combination with other drug in pharmaceutical dosage forms or 
individually in biological fluids are as under: 
 
2.1 Literature review for atenolol 
2.1.1 Lamprecht G, Kraushofer T, Stoschitzky K, Lindner W have developed an 
HPLC column-switching method for the enantioselective determination of (R,S)- atenolol 
in human urine was developed and validated.  Diluted urine samples were  injected onto a 
LiChrospher ADS restricted access column and atenolol was separated from most of the 
matrix components using 0.01 M Tris buffer. The atenolol peak was sharpened by a step 
gradient of 30% acetonitrile and the atenolol-containing fraction was switched onto an 
enantioselective column. Separation of the atenolol enantiomers was carried out on a 
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Chirobiotic T (Teicoplanin) column using acetonitrile-methanol-acetic acid-triethylamine 
(55:45:0.3:0.2, v/v) as eluent. Detection of the effluent was performed by fluorescence 
measurement. Several experiments were carried out to suppress the high blank reading, 
which was efficiently achieved using Tris buffer in the first dimension. For the 
enantioselective analysis of (R) and (S) atenolol in plasma under the same conditions the 
sample capacity of the ADS column is considerably lower[6].  
 
2.1.2 Sivakumar T, Venkatesan P, Manavalan R, Valliappan K have developed of a 
HPLC method for the simultaneous determination of losartan potassium and atenolol in 
tablets. The separation was achieved on Supelcosil ODS analytical  column (250 × 4.6 
mm i.d., 5 µm) using acetonitril and 25 mM potassium dihydrogen phosphate buffer (45: 
55 v/v, pH 3.00 ± 0.05) as mobile phase at a  flow rate of 1.2 ml/min. Detection was 
carried out using a UV detector at 227 nm. The total run time per sample was about 6 min 
with atenolol, chlorzoxazone  (internal std.) and losartan eluting at retention time of about 
2.72, 4.89 and 5.61 min, respectively. The std. curves were linear over the concentration 
ranges, 1 – 10 µg/ml for losartan potassium and atenolol. The values obtained of LODs 
were 0.029 and 0.062 µg/ml and LOQs were 0.078 and 0.187 µg/ml for losartan and 
atenolol respectively. The proposed method is fast, accurate and precise for the 
determination of losartan potassium and atenolol for routine quality control of tablets 
containing these two drugs[7]. 
 
2.1.3  Barman R, Islam MA, Ahmed M, Wahed M, Islam R, Khan A, Hossain BM, 
Rahman BM have developed high performance liquid chromatographic method  for the 
simultaneous determination of atenolol and amlodipine in  pharmaceutical dosage form. 
The chromatographic separation was achieved on shim-pack CLC,  ODS C18column (250 
× 4.6 mm i.d., 5 µm) using a mobile phase of ammonium acetate buffer, acetonitrile and 
methanol (35: 30: 35 v/v, pH 4.5 ± 0.05). The chromatographic conditions are flow rate 
of 1.5 ml/min, column temperature at 40° C and detector wavelength of 237 nm. Both the 
drugs were well resolved on the stationary phase and the retention times were around 1.5 
min for atenolol and 3.4 min for amlodipine. The method was validated for precision and 
accuracy. The proposed method was successfully applied to the pharmaceutical dosage 
forms containing the above mentioned drug combination without interference by the 
excipients[8].  
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2.1.4  Chheta N, Gandhi SP, Rajput SJ have developed a stability indicating high 
performance liquid chromatographic method for atenolol and hydrochlorthiazide  in bulk 
and tablet formulation. The analytes were separated by RP-HPLC on a Hypersil-BDS 
column (250 × 4.6 mm i.d., 5 µm). The mobile phase was 25 mM phosphate buffer and 
acetonitrile (85: 15 v/v, pH 3.00 ± 0.05) at a 0.7 ml/min flow rate. The detector was 
operated at 227 nm for the determination of both the drugs. The optimized methods 
proved to be specific, robust and accurate for the quality control of atenolol and 
hydrochlorothiazide in bulk and pharmaceutical formulations[9]. 
 
2.2. Literature review for lercanidipine  
(Other references given in part-A section-1) 
 
2.2.1 Alvarez-Lueje A, Pujol S, Squella JA, Nunez-Vergara LJ have developed a 
selective HPLC method for determination of lercanidipine in tablets. An HPLC reversed 
phase method using both UV (356 nm) and electrochem. (1000 mV) detection was 
developed an order to determination of lercanidipine in commercial tablets. Repeatability 
and reproducibility were adequate. For quantification they  have used the calibration plot 
method for lercanidipine concentration ranging between 1 × 10-5 and 1 × 10-4 M. The 
typical exipients included in the drug formulation (talk, lactose, cornstarch, cellulose, 
CM-cellulose and magnesium stearate) do not interfere with the selectivity of the method. 
Finally, the proposed chromatographic method was successfully applied to the 
quantification of lercanidipine in commercial tablets[10]. 
  
2.3  Literature review for atenolol and lercanidipine hydrochloride 
 
2.3.1  Deore PV, Shirkhedkar AA, Surana SJ, Patel RC have developed a method for 
the simultaneous quantification of atenolol and lercanidipine hydrochloride in combined 
pharmaceutical dosage form using spectrophotometer. In methanol (50 % v/v), atenolol 
showed maximum absorbance at 224 nm and lercanidipine hydrochloride at 238 nm. Both 
the drugs follow linearity in the concentration range 4 – 28 µg/ml at their respective 
wavelengths. The method was validated statistically and by recovery studies[11]. 
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3. Aim of Present Work 
 In recent times, there is increased tendency towards the development of stability-
indicating assays[12-14], using the approach of stress testing as enshrined in the 
International Conference on Harmonization (ICH) guideline Q1A (R2)[15]. Even this 
approach is being extended to drug combinations[16, 17] to allow accurate and precise 
quantitation of multiple drugs in presence of their degradation products and interaction 
product if any. 
 
 Various publications are available regarding determination method of atenolol and 
lercanidipine but most of the methods are applicable for the analysis of atenolol or 
lercanidipine either alone or in combination with other drugs in pharmaceutical dosage 
form or in biological fluids. Only one method is reported for the simultaneous 
spectrometric estimation of atenolol and lercanidipine hydrochloride in tablet dosage 
form. To our present knowledge, no stability-indicating analytical method for the 
determination of atenolol and lercanidipine hydrochloride in combine dosage forms has 
been published. The previous published methods are not directly applicable for this issue 
and need more investigation for method development and validation. 
 
 Consequently, the focus in the present study was to develop a validated stability-
indicating HPLC method for the combination, by degrading the drugs together under 
various stress conditions like acid hydrolysis, base hydrolysis, oxidation, thermal and 
photolytic stress which is recommended by ICH guideline. 
 
The aim and scope of the proposed work are as under 
 To developed suitable HPLC method for simultaneous determination atenolol
 and lercanidipine in tablet formulation. 
 Forced degradation study of atenolol and lercanidipine under stress condition. 
 To resolve all major impurities generated during the force degradation studies of
 atenolol and lercanidipine. 
 Perform the validation for the developed method. 
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4. Experimental 
4.1 Materials 
 Active pharmaceutical ingredient (API) working standards of atenolol and 
lercanidipine were provided by Emcure pharmaceuticals, Pune, India. A tablet containing 
50 mg atenolol and 10 mg lercanidipine (Lotensyl AT; Sun Pharmaceuticals, Baroda, 
India) was obtained commercially. 
 HPLC grade acetonitrile and ortho-phosphoric acid were obtained from Merck, 
Mumbai, India Limited. Analytical grade hydrochloric acid, sodium hydroxide pellets and 
hydrogen peroxide solution (30%, v/v) were obtained from Ranbaxy Fine Chemical (New 
Delhi, India) and 0.45 µm membrane filter was obtained from pall life sciences (Mumbai, 
India). High purity deionised water was obtained from Millipore, Milli-Q (Bedford, MA, 
USA) purification system. 
4.2 Instrumentation 
 HPLC system (waters 2489, Milford, USA) consisting of quaternary gradient 
pump (TM 600), rheodyne manual injector with 20 µl loop, column oven and UV 
detector was employed for analysis. Chromatographic data was acquired using Empower 
software.  
4.3 Mobile phase preparation 
 The mobile phase was consisted of acetonitrile and 20 mM potassium dihydrogen 
phosphate (55:45, v/v). Mobile phase was filtered through a 0.45 µm membrane filter 
before use and degassed in an ultrasonic bath (Spincotech Pvt. Ltd., Mumbai). 
 
4.4 Diluent preparation 
 Acetonitrile and water (50:50, v/v) used as a diluent. 
 
4.5 Standard preparation 
 Standard stock solution containing atenolol (500 µg/ml) and lercanidipine (100 
µg/ml) was prepared by transferring 50 mg atenolol and 10 mg lercanidipine working 
standard into a 100 ml volumetric flask. A 40 ml portion of diluent (acetonitrile-water 
50:50, v/v) was added, sonicated and cooled to room temperature. The solution was 
diluted to the mark with diluent. Standard solution containing atenolol (100 µg/ml) and 
lercanidipine (20 µg/ml) was prepared by pipetting 10 ml stock solution into a 50 ml 
volumetric flask and diluted up to the mark with diluent. 
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4.6 Test preparation 
 Twenty tablets were weighed and the average weight was calculated. The tablets 
were crushed with a mortar and pestle for 10 min. A portion of powder equivalent to the 
weight of one tablet was accurately weighed and transferred to a 100 ml volumetric flask. 
Approximately 50 ml diluent was added and the mixture was sonicated for 15 min with 
intermittent shaking. The contents were restored to room temperature and diluted to 
volume with diluent to furnish stock test solution. The stock solution was filtered through 
0.45 µm membrane filters and 10 ml of the filtered solution was transferred to a 50 ml 
volumetric flask and diluted to volume with diluents to give test solution containing 100 
µg/ml atenolol and 20 µg/ml lercanidipine. 
 
4.7 Chromatographic conditions 
 The chromatographic separation was achieved on a Phenomenex Gemini C18 
column (250 × 4.6 mm, 5µm particle size). The isocratic mobile phase consisting of 
acetonitrile and buffer (0.02 M potassium dihydrogen phosphate, pH 3.5 adjusted with 
ortho-phosphoric acid) in the ratio of (55:45, v/v) was used throughout the analysis. The 
flow rate of the mobile phase was 1.0 ml/min. Detector signal was monitored at 
wavelength of 235 nm. The column temperature was kept ambient and injection volume 
was 20 µl. 
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5. Results and Discussion 
5.1 Development and Optimization of the HPLC Method 
 In the presence work, an analytical method based on LC using UV detection was 
developed and validated for assay determination of atenolol and lercanidipine in tablet 
formulation. The analytical conditions were selected, keeping in mind the different 
chemical nature of atenolol and lercanidipine. The development trials were taken by using 
the degraded sample of each component was done, by keeping them in various extreme 
conditions. The column selection has been done on the basis of backpressure, resolution, 
peak shape, theoretical plates and day-to-day reproducibility of the retention time and 
resolution between atenolol and lercanidipine peak. After evaluating all these factors, 
Phenomenex Gemini C18 (250 × 4.6 mm i.d., 5 μm particle size) column was found to be 
giving satisfactory results. The selection of buffer based on chemical structure of both the 
drugs. The acidic pH range was found suitable for solubility, resolution, stability, 
theoretical plates and peak shape of both components. Initial trial was taken using 
methanol and potassium dihydrogen phosphate buffer (pH 3.5) as a mobile phase but we 
didn’t get good peak shape of lercanidipine (Figure 2). When methanol was replaced by 
acetonitrile improved the peak shape of atenolol and lercanidipine. Finally, the mobile 
phase composition consisted of a mixture of acetonitrile and 0.02 M potassium 
dihydrogen phosphate buffer (55:45, v/v, pH 3.5). Optimized mobile phase proportion 
was providing good resolution between atenolol and lercanidipine and also for 
degradation product which is generated during force degradation study. For the selection 
of organic constituent of mobile phase, acetonitrile was chosen to reduce the longer 
retention time and to attain good peak shape. Figure 3 and Figure 4 represent the 
chromatograms of standard and test preparation respectively. 
 
Figure 2: Chromatogram of standard preparation  
(Mobile phase: methanol: buffer (60:40, v/v, pH 3.5) 
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Figure 3: Chromatogram of standard preparation 
 
 
Figure 4: Chromatogram of test preparation 
 
5.2 Degradation study 
 In order to determine whether the analytical method or assay were stability 
indicating, atenolol and lercanidipine combine tablets were stressed under various 
conditions to conduct forced degradation studies. Regulatory guidance in ICH Q2A, Q2B, 
Q3B and FDA 21 CFR section 211 all require the development and validation of stability-
indicating potency assays. Unfortunately, the current guidance documents do not indicate 
detailed degradation conditions in stress testing. However, the used forced degradation 
conditions, stress agent concentration and time of stress, were found to effect degradation 
and not complete degradation of active materials. The discovery of such conditions was 
based on development trial.  
 The degradation samples were prepared by transferring tablets powder equivalent 
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under acidic, alkaline, oxidizing, thermal and photolytic stress conditions. When 
degradation was complete, the solution were left to equilibrate to room temperature and 
diluted with diluents to furnish solutions of concentration equivalent to 100 µg/ml 
atenolol and 20 µg/ml lercanidipine. The specific degradation conditions were described 
as below.  
5.2.1 Acidic condition: In acidic degradation study, drug content was heated under 
reflux  with 1 N hydrochloric acid for 30 min at 80°C on oil bath and mixture was 
neutralized with 1 N NaOH solution. The drug content was found to be degrading up to 
36 % in acidic condition (Figure 5).  
 
Figure 5: Chromatogram of acidic forced degradation study 
 
5.2.2 Alkaline condition: Alkaline degradation study was performed by the drug 
content in 0.1 N NaOH at room temperature for 2 h and mixture was neutralized with 1 N 
HCl solutions. In alkali degradation, it was found that around 8.3 % of the drug degraded 
(Figure 6).        
 
Figure 6: Chromatogram of alkali forced degradation study 
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5.2.3 Oxidative condition: Oxidation degradation study was performed by heating the 
drug content in 2% v/v H2O2 at room temperature for 2 h. In oxidative degradation, it was 
found that around 50 % of the drug degraded (Figure 7). 
 
 
Figure 7: Chromatogram of oxidative forced degradation study 
 
 
5.2.4 Thermal condition: Thermal degradation was performed by exposing solid drugat 
70° C for 72 h. Resultant chromatogram of thermal degradation study (Figure 8) indicate 
that drug is found to be slightly stable under thermal degradation condition. Only 3.4 % 
drug content were degraded. 
 
 
Figure 8: Chromatogram of thermal degradation study 
 
 
5.2.5 Photolytic condition: Photolytic degradation study was performed by exposing 
the drug content in sun-light for 72 h. There is 16.8 % degradation observed in above 
specific photolytic condition (Figure 9). 
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Figure 9: Chromatogram of UV-light degradation study 
 
 
5.3  Method Validation 
 
5.3.1 Specificity: The specificity of the method was evaluated by assessing interference 
from excipients in the pharmaceutical dosage form prepared as a placebo solution. The 
specificity of the method for the drug was also established by checking for interference 
with drug quantification from degradation products formed during the forced degradation 
study. The peak purity of the atenolol and lercanidipine were found satisfactory under 
different stress condition. There was no interference of any peak of degradation product 
with drug peak. 
 
5.3.2 Linearity: For linearity seven points calibration curve were obtained in a 
concentration range from 40-160 µg/ml for atenolol and 8-32 µg/ml for lercanidipine. The 
response of the drug was found to be linear in the investigation concentration range and 
the linear regression equation for atenolol was y = 16456x + 117767 with correlation 
coefficient 0.9995 (Figure 10) and for lercanidipine was y = 47672x+7888.1 with 
correlation coefficient 0.9993 (Figure 11). Where x is the concentration in µg/ml and y is 
the peak area in absorbance unit. Chromatogram obtain during linearity study were shown 
in Figure 12-18. 
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Figure 10: Linearity curve for atenolol 
 
 
 
 
 
Figure 11: Linearity curve for lercanidipine 
 
 
 
Figure 12: Linearity study chromatogram of level-1 (40%) 
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Figure13: Linearity study chromatogram of level-2 (60%) 
 
 
 
Figure14: Linearity study chromatogram of level-3 (80%) 
 
 
 
Figure 15: Linearity study chromatogram of level-4 (100%) 
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Figure 16: Linearity study chromatogram of level-5 (120%) 
 
 
 
Figure 17: Linearity study chromatogram of level-6 (140%) 
 
 
 
Figure 18: Linearity study chromatogram of level-7 (160%) 
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5.3.3 LOD and LOQ: The limit of detection and limit of quantification were evaluated 
by serial dilutions of atenolol and lercanidipine stock solution in order to obtain signal to 
noise ratio of 3:1 for LOD and 10:1 for LOQ. The LOD value for atenolol and 
lercanidipine were found to be 0.02 ppm and 0.05 ppm, respectively and the LOQ value 
0.05 ppm and 0.1 ppm, respectively. Chromatogram of LOD and LOQ study were shown 
in Figure 19-22. 
 
Figure 19: Chromatogram of LOD study of atenolol 
 
 
Figure 20: Chromatogram of LOD study of lercanidipine 
 
 
Figure 21: Chromatogram of LOQ study of atenolol 
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Figure 22: Chromatogram of LOQ study of lercanidipine 
 
 
5.3.4 Precision: The precision of the method, as intra-day repeatability was evaluated 
by performing six independent assays of the test sample preparation and calculating the % 
RSD. The intermediate (interday) precision of the method was checked by performing 
same procedure on different days by another person under the same experimental 
conditions. Data obtain from precision experiments are given in Table 1 for intraday and 
interday precision study for both atenolol and lercanidipine. The RSD values for intraday 
precision study and interday precision study was < 2.0% for atenolol and lercanidipine. 
Which confirm that the method was precise. 
 
Table 1: Results of precision study 
 
  
Set 
Atenolol (% assay) Lercanidipine (% assay) 
Intraday 
(n=6) 
Interday 
(n=6) 
Intraday 
(n=6) 
Interday 
(n=6) 
  
1 99.15 99.86 98.76 98.26 
2 99.56 100.45 98.93 98.82 
3 99.18 100.26 98.60 98.56 
4 99.89 100.02 99.22 98.10 
5 100.30 100.04 98.96 98.07 
6 100.01 100.20 98.47 98.45 
Mean 99.68 100.14 98.82 98.38 
Standard deviation 0.465 0.208 0.271 0.290 
% RSD 0.47 0.21 0.27 0.29 
  
 
 
LE
R
A
U
-0.0002
0.0000
0.0002
0.0004
0.0006
0.0008
0.0010
Minutes
3.00 3.50 4.00 4.50 5.00 5.50 6.00 6.50 7.00 7.50 8.00 8.50 9.00 9.50 10.00
Atenolol and lercanidipine…                                                                  Part-A (Section-2) 
 
   87 
 
5.3.5 Accuracy: Recovery of atenolol and lercanidipine were determined at three 
different concentration levels. The mean recovery for atenolol was 98.54-101.54 % and 
98.81-100.86 % for lercanidipine (Table 2). The result indicating that the method was 
accurate. Chromatograms obtained during accuracy study were shown in Figure 23-25.  
 
Table 2: Results of accuracy study 
 
  
Drug Level % 
Theoretical 
concentration 
(µg/ml)a 
Observed 
concentration 
(µg/ml)a 
Mean 
recovery 
(%) 
Stdeva % RSDa 
  
Atenolol 
50 50.14 50.91 101.54 0.27 0.27 
100 100.01 98.92 98.91 0.15 0.15 
150 149.66 147.48 98.54 0.08 0.08 
Lercanidipine
50 10.13 10.22 100.86 0.80 0.79 
100 20.15 19.91 98.81 0.64 0.64 
150 30.13 30.36 100.77 0.08 0.08 
  
 
aEach value corresponds to the mean of three determinations. 
 
 
Figure 23: Accuracy study chromatogram of level-1 (50%) 
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Figure 24: Accuracy study chromatogram of level-2 (100%) 
 
 
Figure 25: Accuracy study chromatogram of level-3 (150%) 
 
 
 
 
5.3.6 Solution stability study: Sample solution stability was evaluated by shorting the 
solution at ambient temperature and at 2-5° C and analysis after 6, 12, 24, 36 and 48h. 
The responses from the aged solutions were compared with those from freshly prepared 
standard solution. Table 3 shows the results obtain in the solution stability study at 
different time intervals for test preparation. The results obtained from study of the 
stability of the test preparation, It was concluded the test solution was stable for up to 48 
h at 2-5° C and at ambient temperature, because difference between measured and 
original values were < 2.0 %. 
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Table 3: Evaluation data of solution stability study 
 
Time (h) 
Assay (%), test solution 
stored at 2-5° C    
Assay (%), test solution stored 
at ambient temperature 
  Atenolol  Lercanidipine   Atenolol  Lercanidipine 
        
Initial 100.44  98.69  100.44  98.69 
6 101.57  99.89  100.05  98.06 
12 101.74  99.95  100.31  98.28 
24 101.53  99.65  101.38  98.88 
36 101.78  99.46  100.08  98.25 
48 102.40  99.90   101.01  99.61 
 
 
5.3.7 Robustness: The robustness was studied by evaluating the effect of small but 
deliberate variations in the chromatographic conditions. The conditions studied were flow 
rate (altered by ± 0.1 /min), mobile phase composition (by using 57:43 and 53:47 v/v 
acetonitrile: buffer pH 3.5), buffer pH (altered by ± 0.2) and use of  HPLC columns from 
different batches. The result of robustness study of the developed assay method was 
established in Table 4 and Table 5. The result shown that during all variance conditions, 
assay value of the test preparation solution was not affected and it was in accordance with 
that of actual. System suitability parameters were also found satisfactory; hence the 
analytical method would be concluded as robust. Chromatogram obtain during robustness 
study were shown in Figure 26-32. 
 
Table 4: Evaluation data of robustness study of atenolol 
 
Robust conditions % Assay 
System Suitability Parameters 
Theoretical 
plates Asymmetry % RSD 
  
Flow 0.9 ml/min 98.38 2921 1.10 0.21 
Flow 1.1 ml/min 98.46 3012 1.14 0.20 
ACN:Buffer (57:43, v/v) 99.21 3214 1.11 0.24 
ACN:Buffer (53:47, v/v) 99.35 3124 1.17 0.47 
Buffer pH 3.3 99.33 3021 1.13 0.25 
Buffer pH 3.7 99.11 2941 1.15 0.37 
Column change 99.89 3158 1.06 0.67 
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Table 5: Evaluation data of robustness study for lercanidipine 
 
Robust conditions % Assay 
System Suitability Parameters 
Theoretical 
plates Asymmetry % RSD
  
Flow 0.9 ml/min 98.22 5679 1.09 0.48 
Flow 1.1 ml/min 98.23 4958 1.13 0.57 
ACN:Buffer (57:43, v/v) 99.79 5590 1.09 0.35 
ACN:Buffer (53:47, v/v) 98.86 5865 1.12 0.73 
Buffer pH 3.3 98.66 5492 1.10 0.69 
Buffer pH 3.7 98.00 5664 1.11 0.12 
Column change 98.71 5442 1.07 0.35 
  
 
 
 
 
Figure 26: Standard chromatogram (0.9 ml/min flow rate) 
 
 
Figure 27: Standard chromatogram (1.1 ml/min flow rate) 
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Figure 28: Standard chromatogram [ACN:Buffer (57:43, v/v)] 
 
 
 
Figure 29: Standard chromatogram [ACN:Buffer (53:47, v/v)] 
 
 
 
Figure 30: Standard chromatogram [Buffer pH 3.3] 
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Figure 31: Standard chromatogram [Buffer pH 3.7] 
 
 
Figure 32: Standard chromatogram (Column change) 
 
 
5.3.8 System suitability: A system suitability test of the chromatographic system was 
performed before each validation run. Five replicate injections of standard preparation 
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determined for same. Acceptance criteria for system suitability, asymmetry should not be 
more than 2.0, resolution should be more than 3.0 theoretical plate should not be less than 
3000 and % RSD of peak area should not be more then 2.0, were full fill during all 
validation parameters. 
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6.  Calculations and Data 
 
 Calculation formula used 
 
1.  Calculation formula for atenolol and lercanidipine 
 
% ܣݏݏܽݕ ൌ  ܣܶܣܵ ൈ
ܹ1
100 ൈ
10
50 ൈ
100
ܹ2 ൈ
50
10 ൈ
ܣܹ
ܮܥ ൈ 99.8 
 
 
Whereas, 
 AT = Average area of test preparation 
 AS = Average area of standard preparation 
 W1 = Weight taken of reference standard (mg) 
 W2 = Weight taken of test sample (mg) 
 AW = Average weight of tablets (mg) 
 LC = Label claim (mg) 
 P = Potency of reference standard (%) 
 
2.  Relative standard deviation 
 
 
% ܴܵܦ ൌ  ܵݐܽ݊݀ܽݎ݀ ݀݁ݒ݅ܽݐ݅݋݊ ݋݂ ݉݁ܽݏݑݎ݁݉݁݊ݐݏܯ݁ܽ݊ ݒ݈ܽݑ݁ ݋݂ ݉݁ܽݏݑݎ݁݉݁݊ݐݏ ൈ 100 
 
3.  Recovery 
 
 
% ܴ݁ܿ݋ݒ݁ݎݕ ൌ  ܣ݉݋ݑ݊ݐ ݂݋ݑ݊݀ܣ݉݋ݑ݊ݐ ܽ݀݀݁݀ ൈ 100 
 
 
4.  Amount Found 
 
 
 
ܣ݉݋ݑ݊ݐ ݂݋ݑ݊݀  ሺߤ݃ ݈݉ሻ⁄ ൌ   ܯ݁ܽ݊ ݐ݁ݏݐ ܽݎ݁ܽܯ݁ܽ݊ ݏݐܽ݊݀ܽݎ݀ ܽݎ݁ܽ ൈ ݏݐܽ݊݀ܽݎ݀ ܿ݋݊ܿ. 
 
 
 
5.  Amount added 
 
 
ܣ݉݋ݑ݊ݐ ܽ݀݀݁݀ ሺߤ݃ ݈݉⁄ ሻ ൌ  ܹݐ. ݐܸܽ݇݁݊݋݈ݑ݉݁ ൈ 1000 
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 Specificity study for analytical method validation of atenolol lercanidipine 
tablets 
 
 For Atenolol 
 
Observation 
  
Data for standard preparation 
 
Data for test preparation 
    
Replicate Area Replicate Area 
1 1789125 1 1791271 
2 1779685 2 1790870 
3 1787287 Average 1791070 
4 1799542     
5 1796678     
Average 1790463     
Stdev 7891.40     
% RSD 0.44     
    
Standard weight 50.02 mg Test weight 203.2 mg 
Standard potency 99.80% Label claim 50 mg 
 
 
Calculation: 
 Prototype calculation for one set: 
 
% ܣݏݏܽݕ ൌ  17910701790463 ൈ
50.02
100 ൈ
10
50 ൈ
100
203.2 ൈ
50
10 ൈ
202.5
50 ൈ 99.8 
 
            ൌ 99.53 % 
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 For Lercanidipine 
 
 
Observation 
  
Data for standard preparation 
 
Data for test preparation 
    
Replicate Area Replicate Area 
1 949112 1 949221 
2 949628 2 949334 
3 949529 Average 949277 
4 948934     
5 949054     
Average 949251     
Stdev 304.42     
% RSD 0.03     
    
Standard weight 10.09 mg Test weight 203.2 mg 
Standard potency 99.80% Label claim 10 mg 
 
 
Calculation: 
Prototype calculation for one set: 
 
% ܣݏݏܽݕ ൌ  949277949251 ൈ
10.09
100 ൈ
10
50 ൈ
100
203.2 ൈ
50
10 ൈ
202.5
10 ൈ 99.8 
 
             ൌ 100.35 % 
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 Linearity study for analytical method validation of atenolol lercanidipine tablets 
 
 For Atenolol 
 
Observation 
    
Data for standard preparation 
      
 
    
Replicate Area Standard weight 49.92 mg 
1 1790121 Standard potency 99.80% 
2 1780665       
3 1787287       
4 1795463       
5 1796678       
Average 1790043       
Stdev 6499.00       
% RSD 0.36     
 
 
 
 
Linearity level % Level Concentration (µg/ml) Mean area 
1 40 39.94 775819 
2 60 59.90 1088242 
3 80 79.87 1441914 
4 100 99.84 1751374 
5 120 119.81 2114859 
6 140 139.78 2427418 
7 160 159.74 2725586 
    
Correlation co-efficient 0.9993 
Slope 47672 
Intercept 7888.1 
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 For Lercanidipine 
 
Observation 
    
Data for standard preparation 
      
 
    
Replicate Area Standard weight 10.09 mg 
1 949252 Standard potency 99.80% 
2 949209       
3 948829       
4 949634       
5 948943       
Average 949173       
Stdev 312.77       
% RSD 0.03     
 
 
 
Linearity level % Level Concentration (µg/ml) Mean area 
1 40 8.07 401769 
2 60 12.11 574337 
3 80 16.14 781129 
4 100 20.18 954152 
5 120 24.22 1176938 
6 140 28.25 1357031 
7 160 32.29 1543998 
    
Correlation co-efficient 0.9995 
Slope 16456 
Intercept 117767 
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 Precision study for analytical method validation of atenolol lercanidipine tablets 
 
 For Atenolol 
 
Observation 
    
Data for standard preparation 
      
 
    
Replicate Area Standard weight 50.02 mg 
1 1790125 Standard potency 99.80% 
2 1780685       
3 1788287       
4 1799542       
5 1799678       
Average 1791663       
Stdev 8071.53       
% RSD 0.45     
 
 
Description Mean area Test weight (mg) % Assay 
Set 1 1792470 204.01 99.15 
Set 2 1792837 203.21 99.56 
Set 3 1794858 204.21 99.18 
Set 4 1791825 202.41 99.89 
Set 5 1786735 201.02 100.3 
Set 6 1791254 202.10 100.01 
  
Mean 99.68 
Stdev 0.467 
% RSD 0.47 
 
 
 
Calculation: 
Prototype calculation for one set: 
 
% ܣݏݏܽݕ ൌ  17924701791663 ൈ
50.02
100 ൈ
10
50 ൈ
100
204.01 ൈ
50
10 ൈ
202.5
50 ൈ 99.8 
 
           ൌ 99.15 
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 For Lercanidipine 
 
 
Observation 
    
Data for standard preparation 
      
 
    
Replicate Area Standard weight 10.09 mg 
1 949012 Standard potency 99.80% 
2 949625       
3 949519       
4 948834       
5 948954       
Average 948625       
Stdev 357.62       
% RSD 0.04     
 
 
Description Mean area Test weight (mg) % Assay 
Set 1 937340 204.01 98.76 
Set 2 935230 203.21 98.93 
Set 3 936744 204.21 98.60 
Set 4 934255 202.41 99.22 
Set 5 925468 201.02 98.26 
Set 6 925825 202.10 98.47 
  
Mean 98.83 
Stdev 0.268 
% RSD 0.27 
 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
 
% ܣݏݏܽݕ ൌ  937340948625 ൈ
10.09
100 ൈ
10
50 ൈ
100
204.01 ൈ
50
10 ൈ
202.5
10 ൈ 99.8 
 
           ൌ 98.76 
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 Intermediate precision study for analytical method validation of atenolol 
lercanidipine tablet 
 
 For Atenolol 
 
 
Observation 
    
Data for standard preparation 
      
 
    
Replicate Area Standard weight 50.11 mg 
1 1790152 Standard potency 99.80% 
2 1787193       
3 1800363       
4 1795824       
5 1799661       
Average 1794639       
Stdev 5808.72       
% RSD 0.32     
 
 
Description Mean area Test weight (mg) % Assay 
Set 1 1792128 202.53 99.86 
Set 2 1795422 201.72 100.45 
Set 3 1794648 202.02 100.26 
Set 4 1795578 203.11 100.02 
Set 5 1799396 203.00 100.04 
Set 6 1797254 202.42 100.2 
  
Mean 100.14 
Stdev 0.208 
% RSD 0.21 
 
 
Calculation: 
Prototype calculation for one set: 
 
% ܣݏݏܽݕ ൌ  17921281794639 ൈ
50.11
100 ൈ
10
50 ൈ
100
202.53 ൈ
50
10 ൈ
202.5
50 ൈ 99.8 
 
                                 ൌ 99.86 
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 For Lercanidipine 
 
 
Observation 
    
Data for standard preparation 
      
 
    
Replicate Area Standard weight 10.12 mg 
1 951032 Standard potency 99.80% 
2 950356       
3 957424       
4 959425       
5 955736       
Average 954795       
Stdev 3971.74       
% RSD 0.42     
 
 
 
Description Mean area Test weight (mg) % Assay 
Set 1 929089 202.53 98.26 
Set 2 930644 201.72 98.82 
Set 3 929573 202.02 98.56 
Set 4 930205 203.11 98.10 
Set 5 929376 203.00 98.07 
Set 6 930329 202.42 98.45 
  
Mean 98.38 
Stdev 0.291 
% RSD 0.30 
 
 
 
Calculation: 
Prototype calculation for one set: 
 
% ܣݏݏܽݕ ൌ  929089954795 ൈ
10.12
100 ൈ
10
50 ൈ
100
202.53 ൈ
50
10 ൈ
202.5
10 ൈ 99.8 
 
           ൌ 98.26 
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 Comparison of method precision and intermediate precision study for analytical 
method validation for atenolol lercanidipine tablets 
 
 For Atenolol 
Study Set No. Assay (%) 
Mean 
assay 
(%) 
Stdev RSD % 
95 % 
Confidence 
Interval 
Method 
precision 
1 99.15 
99.68 0.47 0.47 0.49 
2 99.56 
3 99.18 
4 99.89 
5 100.30 
6 100.01 
Intermediate 
precision 
1 99.86 
100.14 0.21 0.21 0.22 
2 100.45 
3 100.26 
4 100.02 
5 100.04 
6 100.20 
Overall 
Mean 99.91 Absolute difference between mean % 
assay values of Method precision and 
Intermediate precision= 0.46 
Stdev 0.42 
% RSD 0.42 
 
 For Lercanidipine 
 
Study Set No. Assay (%) 
Mean 
assay 
(%) 
Stdev RSD % 
95 % 
Confidence 
Interval 
Method 
precision 
1 98.76 
99.82 0.27 0.27 0.28 
2 98.93 
3 98.60 
4 99.22 
5 98.96 
6 98.47 
Intermediate 
precision 
1 98.26 
98.38 0.29 0.29 0.31 
2 98.82 
3 98.56 
4 98.10 
5 98.07 
6 98.45 
Overall 
Mean 98.36 Absolute difference between mean % 
assay values of Method precision and 
Intermediate precision= 1.44 
Stdev 0.35 
% RSD 0.36 
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 Accuracy study for analytical method validation of atenolol lercanidipine 
tablets 
 
 For Atenolol 
 
Observation 
    
Data for standard preparation 
    
Replicate Area 
 
Standard weight 49.72 mg 
1 1760542 Standard potency 99.80% 
2 1765616 Standard conc. 99.44 
3 1757718       
4 1765788       
5 1766010       
Average 1763135       
Stdev 3792.33       
% RSD 0.22     
 
 
 
 For Lercanidipine 
 
 
Observation 
    
Data for standard preparation 
    
Replicate Area 
 
Standard weight 10.02 mg 
1 959665 Standard potency 99.80% 
2 962412 Standard conc. 20.04 
3 959685       
4 962037       
5 964722       
Average 961704       
Stdev 2128.63       
% RSD 0.22     
 
 
 
 
  
 
 
 Atenolol 
 
Recovery 
level Set No. 
Mean 
area 
Weight 
(mg) 
Vol-1 
(ml) 
Vol-2 
(ml) 
Vol-3 
(ml) 
Amount 
added 
(µg/ml) 
Amount 
found 
(µg/ml) 
% 
Recovery 
Mean % 
recovery Stdev 
% 
RSD 
50% 
Set 1 901181 25.06 50 2.5 25 50.12 50.83 101.41 
101.54 0.27 0.27 Set 2 899904 25.04 50 2.5 25 50.08 50.75 101.35 
Set 3 906975 25.11 50 2.5 25 50.22 51.15 101.86 
100% 
Set 1 1752966 50.00 50 2.5 25 100.00 98.87 98.87 
98.91 0.15 0.15 Set 2 1755525 49.97 50 2.5 25 99.94 99.01 99.07 
Set 3 1753241 50.05 50 2.5 25 100.10 98.88 98.78 
150% 
Set 1 2608580 74.58 50 2.5 25 149.16 147.12 100.73 
98.54 0.08 0.08 Set 2 2621749 75.08 50 2.5 25 150.16 147.87 100.72 
Set 3 2614454 74.83 50 2.5 25 149.66 147.45 100.86 
 
 Calculation: Prototype calculation for one set: 
 
                                   % ܴ݁ܿ݋ݒ݁ݎݕ ൌ  50.8350.12 ൈ 100 ൌ 101.41 
          ܣ݉݋ݑ݊ݐ ݂݋ݑ݊݀ ሺߤ݃ ݈݉⁄ ሻ ൌ  9011811763135 ൈ 99.44 ൌ 50.83 
 
          ܣ݉݋ݑ݊ݐ ܽ݀݀݁݀ ሺߤ݃ ݈݉⁄ ሻ ൌ  25.0650 ൈ
2.5
25 ൈ 1000 ൌ 50.12 
 Lercanidipine 
 
Recovery 
level Set No. 
Mean 
area 
Weight 
(mg) 
Vol-1 
(ml) 
Vol-2 
(ml) 
Vol-3 
(ml) 
Amount 
added 
(µg/ml) 
Amount 
found 
(µg/ml) 
% 
Recovery
Mean % 
recovery Stdev 
% 
RSD 
50% 
Set 1 493128 5.06 50 2.5 25 10.12 10.28 101.58 
100.86 0.80 0.79 Set 2 489589 5.05 50 2.5 25 10.10 10.20 100.99 
Set 3 488485 5.09 50 2.5 25 10.18 10.18 100.00 
100% 
Set 1 948246 10.07 50 2.5 25 20.14 19.76 98.11 
98.81 0.64 0.64 Set 2 959514 10.10 50 2.5 25 20.20 19.99 98.98 
Set 3 959450 10.06 50 2.5 25 20.12 19.99 99.35 
150% 
Set 1 1454166 15.04 50 2.5 25 30.08 30.30 100.73 
100.77 0.08 0.08 Set 2 1457796 15.08 50 2.5 25 30.16 30.38 100.72 
Set 3 1458794 15.07 50 2.5 25 30.14 30.40 100.86 
 
Calculation: Prototype calculation for one set: 
 
                             % ܴ݁ܿ݋ݒ݁ݎݕ ൌ  10.2810.12 ൈ 100 ൌ 101.58 
    ܣ݉݋ݑ݊ݐ ݂݋ݑ݊݀ ሺߤ݃ ݈݉⁄ ሻ ൌ  493128961704 ൈ 20.04 ൌ 10.28 
 
    ܣ݉݋ݑ݊ݐ ܽ݀݀݁݀ ሺߤ݃ ݈݉⁄ ሻ ൌ  5.0650 ൈ
2.5
25 ൈ 1000 ൌ 10.12
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 Solution stability study for analytical method validation of atenolol lercanidipine 
tablets  
 
 Atenolol 
 
System suitability of standard preparation for solution stability 
Replicate Initial After 6 hrs 
After 12 
hrs 
After 24 
hrs 
After 36 
hrs 
After 48 
hrs 
1 1804738 1798255 1798254 1798254 1795121 1781351 
2 1802349 1801049 1788243 1788243 1796142 1780214 
3 1800363 1800363 1799665 1799665 1791324 1779686 
4 1795824 1792541 1795243 1807239 1801588 1787958 
5 1793256 1793256 1804098 1804098 1806382 1798304 
Mean 1799306 1797093 1797101 1799500 1798111 1785503 
Stdev 4706.66 3972.92 5890.20 7234.18 5902.95 7888.96 
% RSD 0.26 0.22 0.33 0.40 0.33 0.44 
 
 
 
 Lercanidipine 
 
System suitability of standard preparation for solution stability 
Replicate Initial After 6 hrs 
After 12 
hrs 
After 24 
hrs 
After 36 
hrs 
After 48 
hrs 
1 951324 951524 954213 960204 955962 930504 
2 945579 945551 952634 956634 956922 921124 
3 952243 949243 954221 963586 956843 920678 
4 955771 953752 960220 965220 958339 925635 
5 954324 954424 952654 963654 960892 931398 
Mean 951848 950899 954788 961860 957792 925868 
Stdev 3913.17 3615.91 3136.57 3447.48 1931.04 5039.08 
% RSD 0.41 0.38 0.33 0.36 0.20 0.54 
 
 
 
 
 
 
 
 
 
 Atenolol 
 
Solution stability at room temperature 
Duration Mean area of test 
Mean area of 
standard 
Standard 
weight (mg) 
Test weight 
(mg) 
Average test 
weight (mg) 
Label 
claim (mg) Potency % Assay 
Initial stage 1808738 1799306 50.05 202.46 202.50 50 99.8 100.44 
after 6 hrs 1800953 1797093 50.01 202.46 202.50 50 99.8 100.05 
after 12 hrs 1807658 1797101 49.95 202.46 202.50 50 99.8 100.31 
after 24 hrs 1827610 1799500 50.00 202.46 202.50 50 99.8 101.38 
after 36 hrs 1801389 1798111 50.04 202.46 202.50 50 99.8 100.08 
after 48 hrs 1805391 1785503 50.04 202.46 202.50 50 99.8 101.01 
 
Calculation: 
Prototype calculation for one set: 
% ܣݏݏܽݕ ൌ  18087381799306 ൈ
50.05
100 ൈ
10
50 ൈ
100
202.46 ൈ
50
10 ൈ
202.5
50 ൈ 99.8 
                                                                                       ൌ 100.44 
 
 
 
 Lercanidipine 
 
Solution stability  at room temperature 
Duration Mean area of test 
Mean area of 
standard 
Standard 
weight (mg) 
Test weight 
(mg) 
Average test 
weight (mg) 
Label claim 
(mg) Potency % Assay 
Initial stage 935422 951848 10.06 202.46 202.50 10 99.8 98.69 
after 6 hrs 934122 950899 10.00 202.46 202.50 10 99.8 98.06 
after 12 hrs 930716 954788 10.10 202.46 202.50 10 99.8 98.28 
after 24 hrs 945225 961860 10.08 202.46 202.50 10 99.8 98.88 
after 36 hrs 937998 957792 10.05 202.46 202.50 10 99.8 98.25 
after 48 hrs 929534 925868 9.94 202.46 202.50 10 99.8 99.61 
 
Calculation: 
Prototype calculation for one set: 
% ܣݏݏܽݕ ൌ  935422951848 ൈ
10.06
100 ൈ
10
50 ൈ
100
202.46 ൈ
50
10 ൈ
202.5
10 ൈ 99.8 
                                                                                       ൌ 98.69 
 
 
 
 Atenolol 
 
Solution stability at 2-5° C  
Duration Mean area of test 
Mean area of 
standard 
Standard 
weight (mg) 
Test weight 
(mg) 
Average test 
weight (mg) 
Label claim 
(mg) Potency % Assay 
Initial stage 1808738 1799306 50.05 202.46 202.50 50 99.8 100.44 
after 6 hrs 1828174 1797093 50.01 202.46 202.50 50 99.8 101.57 
after 12 hrs 1833522 1797101 49.95 202.46 202.50 50 99.8 101.74 
after 24 hrs 1830302 1799500 50.00 202.46 202.50 50 99.8 101.53 
after 36 hrs 1831895 1798111 50.04 202.46 202.50 50 99.8 101.78 
after 48 hrs 1830130 1785503 50.04 202.46 202.50 50 99.8 102.40 
 
Calculation: 
Prototype calculation for one set: 
% ܣݏݏܽݕ ൌ  18087381799306 ൈ
50.05
100 ൈ
10
50 ൈ
100
202.46 ൈ
50
10 ൈ
202.5
50 ൈ 99.8 
                                                                                       ൌ 100.44 
 
 
 
 Lercanidipine 
 
Solution stability  at 2-5° C  
Duration Mean area of test 
Mean area of 
standard 
Standard 
weight (mg) 
Test weight 
(mg) 
Average test 
weight (mg) 
Label claim 
(mg) Potency % Assay 
Initial stage 935422 951848 10.06 202.46 202.50 10 99.8 98.69 
after 6 hrs 951588 950899 10.00 202.46 202.50 10 99.8 99.89 
after 12 hrs 951430 959725 10.10 202.46 202.50 10 99.8 99.95 
after 24 hrs 952631 961860 10.08 202.46 202.50 10 99.8 99.65 
after 36 hrs 949631 957792 10.05 202.46 202.50 10 99.8 99.46 
after 48 hrs 932231 925868 9.94 202.46 202.50 10 99.8 99.90 
 
Calculation: 
Prototype calculation for one set: 
% ܣݏݏܽݕ ൌ  935422951848 ൈ
10.06
100 ൈ
10
50 ൈ
100
202.46 ൈ
50
10 ൈ
202.5
10 ൈ 99.8 
                                                                                       ൌ 98.69 
 
 
 Robustness study for analytical method validation of atenolol and lercanidipine tablets (Atenolol) 
 
Robustness study of Atenolol 
Robustness parameters 
Mean 
area of 
test 
Mean area 
of standard 
Standard 
weight  
(mg) 
Test 
weight  
(mg) 
Average 
test weight 
(mg) 
Label 
claim 
(mg) 
Potency % Assay 
Flow rate 0.9 ml/min 1982273 2011394 50.02 202.52 202.50 50 99.8 98.38 
Flow rate 1.1ml/min 1643991 1661902 50.04 203.21 202.50 50 99.8 98.46 
ACN:Buffer (57:43, v/v) 1932177 1932926 49.98 203.54 202.50 50 99.8 99.21 
ACN:Buffer (53:47, v/v) 1952635 1966571 50.00 201.98 202.50 50 99.8 99.35 
Buffer pH 3.3 1956910 1953237 50.04 204.00 202.50 50 99.8 99.33 
Buffer pH 3.7 1951792 1976754 50.06 201.57 202.50 50 99.8 99.11 
column change 1966278 1970081 50.02 202.00 202.50 50 99.8 99.89 
 
Calculation: 
Prototype calculation for one set: 
% ܣݏݏܽݕ ൌ  19822712011394 ൈ
50.02
100 ൈ
10
50 ൈ
100
202.52 ൈ
50
10 ൈ
202.5
50 ൈ 99.8 
                                                                                       ൌ 98.38 
 
 
 Robustness study for analytical method validation of atenolol lercanidipine tablets (Lercanidipine) 
 
Robustness study of Lercanidipine 
Robustness parameters Mean area of test 
Mean area 
of standard 
Standard 
weight  
(mg) 
Test 
weight  
(mg) 
Average 
test weight 
(mg) 
Label 
claim 
(mg) 
Potency % Assay 
Flow rate 0.9 ml/min 1029270 1050928 10.05 202.52 202.50 10 99.8 98.22 
Flow rate 1.1ml/min 850569 863712 10.03 203.21 202.50 10 99.8 98.23 
ACN:Buffer (57:43, v/v) 929780 931602 10.07 203.54 202.50 10 99.8 99.79 
ACN:Buffer (53:47, v/v) 924910 943592 10.08 201.98 202.50 10 99.8 98.86 
Buffer pH 3.3 937154 945724 10.05 204.00 202.50 10 99.8 98.66 
Buffer pH 3.7 925007 953880 10.08 201.57 202.50 10 99.8 98.00 
column change 929563 950596 10.09 202.00 202.50 10 99.8 98.71 
 
Calculation: 
Prototype calculation for one set:  
% ܣݏݏܽݕ ൌ  10292701050928 ൈ
10.05
100 ൈ
10
50 ൈ
100
202.52 ൈ
50
10 ൈ
202.5
10 ൈ 99.8 
                                                                                       ൌ 98.22 
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Rs   =  N
 4 (
 -1
  )       k     k+1 (     )
Retentivity SelectivitySystem 
Efficiency 
1. INTRODUCTION OF UPLC 
 
History of chromatography can give an idea about improvement in technology 
from conventional column chromatography to high performance liquid chromatography 
and finally at this stage an ultra performance liquid chromatography or in other way a 
combination of pressurized chromatographic technology and sub 2 (two) micron particle 
size of stationary phase technology leads to advance Ultra Performance Liquid 
Chromatography (UPLC) or Rapid Resolution Liquid Chromatography (RRLC) 
technology. 
 
Technology of sub 2 (two) micron particle size leads many modifications in 
hardware part of the system like reduction of system volume, higher pump pressure 
capacity, injector and needle part, and cell volume of detector as well as in software area, 
data acquisition rate or capacity was increased for sufficient data collection. 
 
In brief detail, small particle size columns leads to increase in pump pressure so 
that area was improved and for accurate and precise injection volume needle in needle 
technology with teflon material was came into the picture. Detector cell volume was 
reduced for better signals and resolution. 
 
Smaller particle size of 2 micron technology altered the machine and its 
application for faster way of analysis in current scenario of separation science. 
Requirement of this technology can be explained by van deemter equation[1, 4] and plot as 
shown in fig 1. From this plot it reveals that there is minimum HETP against the linear 
velocity with the almost constant relation or maximum the theoretical plates can be 
achieved with particle size less than 2 micron. Finally as a known fact increasing in N 
leads to increase in Resolution as shown in formula; 
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Figure1: Van Deemter plots-influence of particle size 
 
Now, for method conversion from HPLC to UPLC or for comparison of both the 
technology following aspects needs to take in consideration[2-3]. 
 
 Ratio of column length to particle size (L/dp) needs to keep constant. 
        i.e. 150 mm/5 µm = 30,000 is closest to 50mm/1.7 µm = 29,500 
 
 Column selection should be based on same basic column chemistry 
        i.e. C18 column should be replaced by C18 column 
 
 5 µm to 1.7 µm particle size leads to increase in speed of 9X along with 9X pressure 
 3 µm to 1.7 µm particle size leads to increase in speed of 3X along with 3X pressure 
 5 µm to 1.7 µm particle size leads to increase in peak height of 1.7X 
 3 µm to 1.7 µm particle size leads to increase in peak height of 1.3X 
 5 µm to 1.7 µm particle size leads to decrease in peak width of 0.6X 
 3 µm to 1.7 µm particle size leads to decrease in peak width of 0.8X 
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 Column efficiency (N) is inversely proportional to dp 
 
 
 
i.e. 5 µm to 1.7 µm particle size leads to increase in column efficiency (N) 3X but 
 
  
 
So, resolution also increase by 1.7X 
Based on above fact practically an example for chromatogram comparison against 
column dimension for run time and resolution is shown in fig 2. 
 
Remark 
Here, X is used to express the mathematical relation in multi fold. 
e.g. pressure increased by 3X i.e. pressure increase by three times 
 
Method Development 
 
Method development in UPLC remains same as of HPLC but few areas of 
chromatographic conditions are different e.g. for gradient elution column equilibration 
time is very less as compare to HPLC due to lower column volume. 
 
Advance technology in column filled material for HPLC as well as UPLC allows 
higher pH and temperature stability for column for wider choice of mobile phase for 
different applications. e.g. pH of mobile phase or its buffer can selected based on 
compound chemical nature and that can be explain by fig.3 for reversed phase retention 
plot. 
 
 
 
dp
N 1
NRs 
Introduction…                                               Part-B 
 
  117 
 
 
Figure 2: Chromatogram comparison against column dimension 
  
 
Figure 3: Reversed phase retention plot 
 
From the above plot and fundamental theory of solvent gives following information for 
development consideration. 
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Facts for basic compound  
1. Alkaline pH increases retention of basic analytes 
2. Methanol increases retention of all components compared to acetonitrile 
3. Similar basic analytes differ little in selectivity, respective to one another, when 
they are either fully charged or uncharged 
4. Largest selectivity differences between bonded phases occur with methanol and 
analytes in their unionized state 
 
Facts for acid compound  
1. Acidic pH increases retention of acidic analytes 
2. Methanol increases retention of all components compared to acetonitrile 
3. Large differences in selectivity are observed when change in pH alters charge 
state 
4. Largest selectivity differences between bonded phases occur with methanol and 
analytes in their unionized state 
Column chemistry for known columns UPLC are shown in fig 4. 
 
 
 Figure 4: Column chemistry of UPLC column 
 
By many recent research and development, UPLC presents the ability to extend 
and expand the utility of separation science at a time when many scientists have reached 
separation barriers, pushing the limits of conventional HPLC. New chemistry and 
instrumentation technology can provide more information per unit of work as UPLC 
begins to fulfil the promise of increased speed, resolution, and sensitivity predicted for 
liquid chromatography. As this is the concept for the scientist many of industries may 
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take time to use in routine but it can be the future of the liquid chromatography. Hence 
present research work includes the extended area of HPLC to UPLC as a part of 
technology updating or a balance form of present HPLC and improved LC or UPLC for 
future scope for separation science. 
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UPLC METHOD DEVELOPMENT AND VALIDATION STUDY OF COMBINE 
DOSAGE FORM OF ASPIRIN, CLOPIDOGREL BISULPHATE AND 
ATORVASTATIN CALCIUM 
 
1. Introduction of drugs  
1.1 Aspirin 
 Aspirin (ASP) is 2-acetyloxybenzoic acid, often used as an analgesic, antipyretic, 
anti-inflammatry and an antiplatelet[1]. It suppresses the production of prostaglandins and 
thromboxanes due to inactivation of the cyclooxygenas enzyme[2, 3]. Its molecular formula 
is C9H8O4 having molecular weight 180 g/mole[4]. It is slightly soluble in water, freely 
soluble in alcohol, soluble in chloroform and ether, sparingly soluble in absolute ether. 
 Aspirin, one of the first drugs to come into common usage, is still the most widely 
used drug in the world, is a non-steroidal anti-inflammatory drug that exhibits anti-
inflammatory, analgesic and antipyretic activities. Aspirin is now accepted as an 
important weapon in the prevention of heart disease. A single dose of 300 mg is now 
recommended for patients in the acute stages of a heart attack followed by a daily dose of 
75-100 mg. A similar low dose treatment regime is recommended for patients with 
angina, a history of heart problem or who have undergone coronary by-pass surgery. 
Major use of aspirin is as an anti-platelet aggregating agent. 
 
  
 
Figure 1: Chemical structure of aspirin 
 
1.2 Clopidogrel bisulphate 
 Clopidogrel bisulphate (CLP) is methyl (s)-2-chlorophenyl (4,5,6,7-
tetrahydrothioeno-[3,2-C] pyridine-5-yl) acetate bisulphate, an ADP antagonist. It is used 
as an anti thrombic agent[5, 6]. Clopidogrel bisulphate is not official in any pharmacopoeia. 
The empirical formula of clopidogrel bisulfate is C16H16ClNO2S•H2SO4 and its molecular 
weight is 419.9 g/mole. It is a white to off-white powder. It is practically insoluble in 
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water at neutral pH but freely soluble at pH 1. It also dissolves freely in methanol, 
dissolves sparingly in methylene chloride and is practically insoluble in ethyl ether. It has 
a specific optical rotation of about +56°. 
 
 
 
Figure 2: Chemical structure of clopidogrel bisulphate 
 
1.3 Atorvastatin calcium 
 Atorvastatin calcium (ATV) is [R-(R*,R*)]-2-(4-fluorophenyl)-β,ö-dihydroxy-5-
(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, a 
synthetic lipid-lowering agent which is about a 100 times as potent as the other drugs in 
its class and at lower costs than most of the others[7]. ATV is an inhibitor of 3-hydroxy-3-
methylglutaryl-coenzyme A reductase[8]. Its molecular formula is C66H68CaF2N4O10 
having molecular weight 1209.39 g/mole. White to off-white crystalline powder, freely 
soluble in methanol, slightly soluble in ethanol, very slightly soluble in acetonitrile, 
distilled water and phosphate buffer (pH 7.4)[4]. 
 
 
 
Figure 3: Chemical structure of atorvastatin calcium 
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2. Literature review 
Many dosage forms of ASP, CLP and ATV as a single or as combination dosage 
form with others are available on the local market for effective therapy. Literature survey 
revealed several analytical methods such as spectrometry, stability indicating HPTLC, 
GC, simple and stability indicating HPLC, LC-MS-MS and LC-ESI-MS have been 
reported for the determination of ASP[9-16], CLP[17-24] and ATV[25-35] in pharmaceutical 
dosage forms or in biological fluids are as under: 
 
2.1 Literature review for aspirin 
 
2.1.1 Ahmed M, Biswas HU and Sadik G have developed a spectrometric method for 
the determination of aspirin in blood samples. This is based on the formation of a color 
complex of the drug in serum with ferric-mercuric reagent. The absorbance of the colored 
complex was then measured at 540 nm for maximum absorption. This method shows 
linearity in the range of 0-100 µg/ml and useful for the routine analysis of drug in the 
serum[9]. 
 
2.1.2 Umapathi P, Parimoo P, Thomas SK and Agrawal V have developed 
spectrofluorometric estimation of aspirin and dipyridamole in pure admixtures and in 
dosage forms. Aspirin (2-12 mg/ml) was estimated in 1% v/v glacial acetic acid in 
chloroform using 246 and 345 nm for excitation and emission respectively. Dipyridamole 
(2-12 mg/ml) has been estimated in chloroform using 420 nm for excitation and 475 nm 
for emission.  The non-interference of the excipients as well as the drugs in the estimation 
of each other, as evidenced by the results, indicate that this method may be used for the 
routine estimation of aspirin and dipyridamole in tablet preparations[10]. 
 
2.1.3  Vora DN and Kadav AA have developed validated ultra HPLC method for the 
simultaneous determination of atorvastatin, aspirin, and their degradation products in 
capsules. The chromatographic separation was performed on acquity UPLC TM BEH C18 
column (2.1 × 50 mm, 1.7 μm). Using gradient elution of acetonitrile and phosphate 
buffer (0.01 M, pH 2.0) at a flow rate of 0.6 ml/min. UV detection was performed at 247 
nm. The separation method was applied to the assay of aspirin, atorvastatin and its major 
degradation in pharmaceutical dosage form[11].  
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2.1.4  Gandhimathi M, Ravi TK, Abraham A and Thomas R have developed a 
method for the simultaneous determination of aspirin and isosorbide 5-mononitrate in 
formulation by reversed phase high pressure liquid  chromatography. The method was 
carried out on a Thermo Quest C18 column using a mixture of water-methanol (water pH 
adjusted to 3.4 using dilute orthophosphoric acid) and detection was carried out at 215 nm 
using chlorzoxazone as an internal standard. Propose method can be use in routine quality 
control analysis of pharmaceutical formulations[12]. 
 
2.1.5 Sawyer M and Kumar V have developed a rapid reversed phase HPLC 
procedure and validated for the simultaneous quantitation of aspirin, salicylic acid and 
caffeine extracted from an effervescent tablet. The method uses a Hypersil C18 column 
(150 × 4.6 mm i.d., 5 μm particle size) for an isocratic elution in water-methanol- acetic 
acid mobile phase at a wavelength of 275 nm. The method could find application in 
routine quality control analysis of pharmaceutical tablet formulations[13]. 
 
2.1.6 Chao W, Vickers TJ and Mann CK have developed a method for direct assay 
and shelf-life monitoring of aspirin tablets using raman spectroscopy. A comparison was 
made between raman and high-performance liquid chromatography (HPLC) analysis of 
aspirin tablets.  The basis was an assay of aspirin content and the determination of 
salicylic acid produced by decomposition. Raman observations were performed directly 
on both intact and powdered tablet material.  The limit of detection of HPLC with an 
ultraviolet detector is lower than that of the Raman measurement, but both are adequate 
for this application. The reproducibility of the Raman measurement is somewhat better 
than that of the HPLC measurement.  Both methods were used in a degradation study in 
which samples were stored in a humid atmosphere for a maximum period of 8 
weeks.  Aside from somewhat higher salicylic acid responses from the HPLC method, 
which were attributed to hydrolysis during chromatography, results from the two methods 
were comparable. Direct Raman measurements are faster and do not require the use of 
solvents[14]. 
 
2.1.7 Abu-Qare AW and Abou-Donia MB have developed a validated HPLC method 
for the determination of pyridostigmine bromide, acetaminophen, acetylsalicylic acid and 
caffeine in rat plasma and urine. The compounds were extracted using C18 Sep-Pak(R) 
cartridges then analyzed by high-performance liquid chromatography (HPLC) with 
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reversed phase C18 column and UV detection at 280 nm. The compounds were separated 
using gradient of 1-85 % acetonitrile in water (pH 3.0) at a flow rate ranging between 1 
and 1.5 ml/min in a period of 14 min[15]. 
 
2.1.8 Shah DA, Bhatt KK, Mehta RS, Shankar MB, Baldania SL and Gandhi TR 
have developed a RP-HPLC method for determination of atorvastatin calcium and aspirin 
in a capsule dosage form. A Phemomenex Gemini C18 (250 × 4.6 mm i.d., 5μm) in 
isocratic mode, with mobile phase containing 0.02 M potassium dihydrogen phosphate: 
MeOH (20: 80, pH 4.0). The flow rate was 1.0 ml/min and effluents were monitored at 
240 nm. The proposed method was validated and successfully applied to the estimation of 
atorvastatin calcium and aspirin in combined capsule dosage forms[16]. 
 
2.2 Literature review for clopidogrel bisulphate 
 
2.2.1 Mishra P and Dolly A have developed a spectrophotometric method for 
determination of clopidogrel and aspirin in pharmaceutical formulation. First method was 
based on the aditivity of the absorbance. Second method was based on the determination 
of graphical absorbance ratio at two selected wavelengths, one being the isoabsorptive 
point for the two drugs (225 nm) and the other being the absorption maximum of 
hydrolyzed aspirin (235.7 nm). Method can be use for the analysis of pharmaceutical 
formulation[17]. 
 
2.2.2 Mitakos A and Panderi I have developed a validated LC method for the 
determination of clopidogrel in pharmaceutical preparations. The determination was 
performed on a semi-micro column BDS C8 (250 mm x 2.1 mm i.d., 5 μm particle size). 
The mobile phase consisted of a mixture of 0.010 M sodium dihydrogen phosphate and 
acetonitrile (35:65 v/v, pH 3.0), pumped at a flow rate 0.3 ml/min. The UV detector was 
operated at 235 nm. The method was applied in the quality control of commercial tablets 
and content uniformity test[18]. 
 
2.2.3 Kample NS and Venkalachalam A have developed a gas chromatographic 
determination of clopidogrel from tablet dosage forms. The method involves use of a DB-
17 capillary column. Column is of 30m length, 0.25 mm i.d. and 0.25 μ film thickness 
and hydrogen as a carrier gas with the flow rate of 2.0 ml/min. Oven temperature was 
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maintained at 250° C for 8 min. Split type of injector and flame ionization detector was 
used. The retention time of clopidogrel and dioctyl phthalate (internal standard) was 4.1 
min and 3.2 min, respectively. Linearity for the clopidogrel was in the range of 0.5 to 5.0 
mg/mL. Percentage recovery obtained was 99.89. The proposed method is accurate, 
precise and rapid for the estimation of clopidogrel[19].  
 
2.2.4 Patel RB, Shankar MB, Patel MR and Bhatt KK have developed a method for 
the simultaneous estimation of acetylsalicylic acid and clopidogrel bisulfate in pure 
powder and tablet formulations by HPLC and HPTLC. The HPLC separation was 
achieved on a Nucleosil C8 column (150 × 4.6 mm, 5 μm) using acetonitrile and 
phosphate buffer (55:45 v/v, pH 3.0) mobile phase at a flow rate of 1.0 ml/min at ambient 
temperature. The HPTLC separation was achieved on an aluminium backed layer of silica 
gel 60F254 using ethyl aetate-methanol-toluene-glacial acetic acid (5.0 + 1.0 +4.0 + 0.1, 
v/v/v/v) mobile phase. Quantitation was achieved with UV detection at 235 nm in HPLC 
and HPTLC. These methods are applicable for the simultaneous determination of aspirin 
and clopidogrel in pure powder and formulations[20]. 
2.2.5 Panchal HJ, Suhagia BN, Patel NJ, Rathod IS and Patel BH have developed a 
method for the simultaneous estimation of atorvastatin calcium, ramipril and aspirin in 
capsule dosage form by RP-LC. The method was developed using a Phenomenex Luna 
C18 (250 × 4.6 mm, 5 μm) column with a mobile phase consisting of orthophosphoric 
acid buffer: acetonitrile: methanol (45:50:5, v/v/v, pH 3.3) at a flow rate of 1 ml/min. 
Detection was carried out with ultra-violet detection at 210 nm. The retention times were 
about 12.19, 2.35 and 3.95 min for atorvastatin calcium, ramipril and aspirin, 
respectively. The proposed method can be used for the estimation of these drugs in 
combined dosage forms[21]. 
 2.2.6 Sultana N, Arayne MS, Nawaz M and Ali KA have developed a liquid 
chromatographic method for the determination of clopidogrel from pharmaceutical 
dosage form in the presence of flubiprofen as an internal  standard. The separation was 
achieved using Purospher start C18, 5 μm column having 250 × 4.6 mm i.d., with mobile 
phase consisting of methanol and water (80:20, v/v, pH 3.4) was used. The flow rate was 
1.0 ml/min and detector response was monitored at 235 nm. Limit of detection and limit 
of quantitation were 0.09 and 0.28 µg/ml respectively. The method could find application 
in routine quality control analysis of pharmaceutical tablet formulations[22]. 
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2.2.7 Gandhimathi M and Ravi TK have developed a high performance liquid 
chromatographic determination of aspirin and clopidogrel in tablets. The 
chromatographic resolution of aspirin and clopidogrel was obtained in a mobile phase 
consisting of 0.1 % v/v, triethylamine: acetonitrile in the ratio (25:75 v/v, pH 4.0) in an 
isocratic elution. A detection wavelength of 225 nm and flow rate of 1.0 ml/min was 
used in the study. Nimesulide (20 µg/ml) was used as an internal standard[23]. 
2.2.8 Kachhadia PK, Doshi AS and Joshi HS have developed a validated column 
high-performance liquid chromatographic method for determination of aspirin and 
clopidogrel in combined tablets in the presence of degradation products formed under 
ICH-recommended stress conditions. Separation of the drugs from the degradation 
products formed under stress conditions was achieved on an octasilyl C8 column using 
0.3 % ortho-phosphoric acid- acetonitrile (65:35, v/v) mobile phase. The method was 
found to be specific against placebo interference and during the forced degradation[24]. 
2.3 Literature review for atorvastatin calcium 
 
2.3.1 Manoj K, Shanmugapandiyan P and Anbazhagan S have developed a RP 
HPLC method for simultaneous estimation of atorvastatin and aspirin from capsule 
formulation. The maximum resolution was achieved by mobile phase acetonitrile: 0.05 
M potassium dihydrogen phosphate buffer: methanol in the ratio (50:30:20, v/v/v) at pH 
3.0.  This mixture was found to be appropriate allowing good separation of both the 
components at a flow rate of 1.5 ml/min and detection wavelength 240 nm.  In these 
condition atorvastatin calcium and aspirin were eluted at the 4.7 and 2.2 min resp. The 
concentration of atorvastatin calcium and aspirin estimation in the capsule was found to 
be in the range 99.33-101.43  % and 99.71-101.60 %[25].  
2.3.2 Raja RK, Sankar GG, Rao AL and Seshagirirao JVLN have developed a RP-
HPLC method for the simultaneous determination of atorvastatin and amlodipine in 
tablet dosage form. The mobile phase used was a mixture of acetonitrile and 0.03 M 
phosphate buffer (55:45 v/v, pH 2.9). The detection of atorvastatin and amlodipine was 
carried out on dual γ absorbance detector at 240 nm and 362 nm, respectively.  Results 
of the analysis were validated statistically, and by recovery studies.  The proposed 
method can be successfully used to determination of the drug contents of marketed 
formulation[26].  
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2.3.3 Yadav SS, Mhaske DV, Kakad AB, Patil BD, Kadam SS and Dhaneshwar 
SR have developed a simple and sensitive HPTLC method for the determination of 
content uniformity of atorvastatin calcium tablets. The stationary phase was precoated 
silica gel 60 F254. The mobile phase used was a mixture of benzene: methanol, (7:3 
v/v). Combination of benzene: methanol offered optimum migration (RF = 0.46 ± 
0.02).  Detection of the spots was carried out at 281 nm. The method was validated in 
terms of linearity (200-600 ng/spots), precision (intra-day variation: 0.25 to 1.01%, inter-
day variation: 0.21 to 0.88%), accuracy (99.2 ± 0.48) and specificity. The proposed 
HPTLC method can analyze ten or a formulation unit simultaneously on a single plate 
and provides a faster and cost-effective quality control tool for routine analysis of 
atorvastatin calcium tablet formulation[27].  
2.3.4 Chaudhri BG, Patel NM, Shah PB and Modi KP have developed a HPTLC 
method for the simultaneous estimation of atorvastatin calcium and ezetimibe. The 
stationary phase used was precoated silica gel 60F254. The mobile phase used was a 
mixture of chloroform: benzene: methanol: aceticacid (6.0:3.0:1.0:0.1, v/v/v/v). The 
detection of spots was carried out at 250 nm. The method was validated in terms of 
linearity, accuracy, precision, and specificity. The calibration curve was found to be 
linear between 0.8 and 4.0 μg/spot for atorvastatin calcium and 0.1 and 1.0 μg/spot for 
ezetimibe. The proposed method can be successfully used for the determination of drug 
content of marketed formulation[28].  
2.3.5 Jamshidi A and Nateghi AR have developed a HPTLC Determination of 
atorvastatin in plasma. In this study, 2-step isocratic chromatography on silica gel 
60F254 HPTLC layer and densitometric quantitation at λ = 280 nm was developed for 
the separation of atorvastatin from plasma constituencies and sodium diclofenac as peak 
tracer. The established HPTLC method was validated in terms of LOD/LOQ, linearity, 
recovery, and repeatability. The calibration function of the analyte was linear in the 
range 101-353.5 ng zone-1 and the correlation coefficient was 0.9969. The limits of 
detection and quantitation were 30.3 and 101 ng zone-1. The recovery and relative std. 
deviation obtained from between-days analysiswere 97.5-103.0 and 1.7-3.4%[29]. 
2.3.6 Bahrami G, Mohammadi B, Mirzaeei S and Kiani A have developed a method 
for the determination of atorvastatin in human serum by reversed-phase high-
performance liquid chromatography with UV detection. Chromatographic separation was 
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accomplished using C18 analytical column with a mobile phase consisting of sodium 
phosphate buffer (0.05 M, pH 4.0) and methanol (33:67, v/v).  Atorvastatin and the 
internal std. were detected by UV absorbance at 247 nm. The average recoveries of the 
drug and internal std. were 95 and 80 %, respectively. The analytical performance was 
studied and the method was applied in a randomized cross-over bioequivalence study of 
two different atorvastatin preparations in 12 healthy volunteers[30].  
2.3.7 Erturk S, Seninc AE, Ersoy L and Ficicioglu S have developed an HPLC 
method for the determination of atorvastatin and its impurities in bulk drug and tablets. 
This method has shown good resolution for atorvastatin (AT), desfluoro-atorvastatin 
(DFAT), diastereomer-atorvastatin (DSAT), unknown impurities and formulation 
excipients of tablets. A gradient reverse-phase HPLC assay was used with UV 
detection.  Some solvent systems prepared using methanol or acetonitrile and water or 
buffer systems with different pH values were tested. Capacity factors of related 
substances were calculated at all tested systems. Best resolution was achieved using a 
Luna C18 column with acetonitrile-ammonium acetate buffer pH 4-tetrahydrofuran 
(THF) as mobile phase. Samples were eluted with the mobile phase at a flow rate of 1.0 
ml/min and detected at 248 nm[31]. 
2.3.8 Mohammadi A, Rezanour N, Ansari DM, Ghorbani BF, Hashem M and 
Walker RB have developed a stability-indicating high performance liquid 
chromatographic (HPLC) assay for the simultaneous determination of atorvastatin and 
amlodipine in commercial tablets. The separation was achieved on a Perfectsil Target 
ODS-3 (250 × 4.6 mm i.d., 5 μm) column using a mobile phase consisting of 
acetonitrile-0.025 M NaH2PO4 buffer (55:45, v/v, pH 4.5) at a flow rate of 1 ml/min and 
UV detection at 237 nm. The drugs were subjected to oxidation, hydrolysis, photolysis 
and heat to apply stress conditions. Degradation products produced as a result of stress 
studies did not interfere with the detection  of AT and AM and the assay can thus be 
considered stability-indicating[32].  
2.3.9 Alla K has reported a stability-Indicating LC Method for the simultaneous 
determination of metoprolol, atorvastatin and ramipril in combined pharmaceutical 
dosage form. A chromatographic separation of the three drugs was achieved with a 
Hypersil C8, 15-cm analytical column using buffer-acetonitrile (55:45 v/v). The buffer 
used in mobile phase contains 0.02 M sodium perchlorate in double distilled water.  The 
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instrumental settings are flow rate of 1.0 ml/min, column temperature at ambient, and 
detector wavelength of 210 nm for ME, AT and RA using a ultra violet 
detection.  Methanol is used a diluent. The resolution among ME, AT and RA were 
found to be more than 2.0. Theoretical plates for ME, AT and RA were >2500. The 
proposed method was found to be suitable and accurate for quantitation and the stability 
study of ME, AT and RA in pharmaceutical preparations[33]. 
2.3.10 Ma L, Dong J, Chen XJ and Wang GJ have developed a LC–ESI–MS method 
for estimation of atorvastatin and application in bioequivalence research in healthy 
chinese volunteers. Plasma samples (1 ml) were extracted with 3 ml ethyl acetate and by 
a simple reversed-phase chromatography pitavastatin was used as internal standard 
(IS). The assay was linear from 0.25-20 ng/mL. The correlation coefficient for the 
calibration regression line was 0.9996 or better. Intra and inter-day accuracy were better 
than 15%. The method has been successfully used for a pharmacokinetic study with 
human subjects. A two-period crossover designed bioequivalence research was also 
progressed in healthy Chinese volunteers[34].  
2.3.11 Kadav AA and Vora DN have developed a stability indicating UPLC method for 
simultaneous determination of atorvastatin, fenofibrate and their degradation products in 
tablets. The chromatographic separation was performed on acquity UPLC BEH C18 
column (100 × 2.1 mm, 1.7 µm) using gradient elution of acetonitrile and ammonium 
acetate buffer (0.01 M, pH 4.7) at flow rate of 0.5 ml/min. UV detection was performed at 
247 nm. Total run time was 3 min within which main compounds and six other known 
and major unknown impurities were separated[35]. 
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3. Aim of Present Work 
Many dosage forms of ASP, CLP and ATV as a single or as combination dosage 
form with others are available on the local market for effective therapy. Literature survey 
revealed several analytical methods such as spectrometry, stability indicating HPTLC, 
GC, simple and stability indicating HPLC, LC-MS-MS and LC-ESI-MS have been 
reported for the determination of ASP, CLP and ATV in pharmaceutical dosage forms 
and biological samples. 
 
To our present knowledge, there is no method reported for the estimation of ASP, 
CLP and ATV in combination formulation. Hence, the aim was to develop a rapid, 
sensitive, simple and accurate UPLC method which can estimate the three components 
simultaneously. The present investigation describes a simple, sensitive, rapid and precise 
LC method for the simultaneous estimation of ASP, CLP and ATV in marketed 
pharmaceutical dosage form. With the developed method, only this mobile phase is 
sufficient for quantification of ASP, CLP and ATV either in combination (i.e., ASP + 
CLP, ASP + ATV, ATV + CLP) or in single dosage form as per availability of 
formulation. Many pharmaceutical industries manufacture their formulation of all 
mentioned drugs either in combination or in single dosage form. Most of the 
pharmaceutical industries use time consuming LC method and different mobile phases for 
different dosage form of drugs. But with the proposed method developed, time and cost 
required for changing different mobile phases could be saved, because only one mobile 
phase can be used for all the drugs and their combinations.  
 
The aim and scope of the proposed work are as under 
 To develop a rapid, simple and reliable UPLC method for simultaneous 
determination of aspirin, clopidogrel and atorvastatin in marketed pharmaceutical 
dosage form.  
 Perform the validation for the developed method. 
 The developed method is suitable for the routine analysis in quality control 
laboratories. 
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4. Experimental 
 
4.1 Materials 
ASP, CLP and ATV working standards with 99.95, 99.98 and 99.93 % purity, 
respectively, were provided as a gift sample by Torrent Research Centre (Ahmedabad, 
India). Capsule dosage form (Ecosprin GOLD 20; 75 mg ASP, 75 mg CLP and 20 mg 
ATV per capsule) of USV Ltd. (Mumbai, India) was purchased from local market. 
Methanol and acetonitrile (HPLC grade) were obtained from Finar Chemicals 
(Ahmedabad, India). HPLC grade orthophosphoric acid (88 %) was from Spectrochem 
(Mumbai, India). Distilled water was prepared using a Milli-Q system, Millipore 
(Milford, MA, USA). Nylon syringe filters (0.22 µm) were from Millipore (Mumbai, 
India). 
 
4.2 Instrumentation 
 The chromatographic separation was carried out using a Waters UPLC Acquity 
system (Waters, Milford, MA, USA), consisted of a Binary solvent manager, a sample 
manager, column oven and a PDA detector. The output signal was monitored and processed 
by Empower software. A Sartorius CPA2P analytical micro-balance (Gottingen, Germany), 
an ultra sonic cleaner SONICA from Spincotech Pvt. Ltd. (Mumbai, India) and pH meter 
LI 610 ELICO (Mumbai, India) were also used. 
 
4.3 Mobile phase preparation 
 The mobile phase was consisted of 0.1 % orthophosphoric acid acetonitrile 
(55:45, v/v). Mobile phase was filtered through a 0.22 µm membrane filter before use and 
degassed in an ultrasonic bath (Spincotech Pvt. Ltd., Mumbai). 
 
4.4 Diluent preparation 
 Methanol used as a diluent. 
 
4.5 Standard preparation 
Accurately weighed ASP (75 mg), CLP (75 mg) and ATV (20 mg) were transferred 
to 100 mL volumetric flasks, dissolved and diluted to the mark with methanol to obtain a 
standard stock solution of ASP (750 µg/mL), CLP (750 µg/mL) and ATV (200 µg/mL). An 
aliquot of the stock solution (1 mL) was transferred to a 25 mL volumetric flask, and 
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diluted to the mark with mobile phase to obtain a mixed working standard solution of ASP 
(30 µg/mL), CLP (30 µg/mL) and ATV (8 µg/mL). 
 
4.6 Test preparation 
 Powder of twenty capsules (Ecosprin GOLD 20), each containing 75 mg ASP, 75 
mg CLP and 20 mg ATV, were weighed and analysed: a quantity of powder equivalent to 
one capsule was weighed and transferred to a 100 mL volumetric flask containing 50 mL 
methanol and sonicated for 15 min. The flask was allowed to cool down to room 
temperature and the volume was made up to the mark with methanol to obtain sample 
stock solution of ASP (750 µg/mL), CLP (750 µg/mL) and ATV (200 µg/mL). The 
solution was filtered using a nylon 0.22 µm membrane filter. An aliquot of the sample 
stock solution (1 mL) was transferred to a 25 mL volumetric flask and diluted to the mark 
with mobile phase to obtain a working sample solution of ASP (30 µg/mL), CLP (30 
µg/mL) and ATV (8 µg/mL). 
 
4.7 Chromatographic conditions 
 The separation was achieved on Waters Acquity UPLC BEH C18 column (2.1 × 50 
mm i.d., 1.7 µm particle size). The isocratic mobile phase consisted of 0.1 % 
orthophosphoric acid and acetonitrile (55:45, v/v) was used throughout the analysis. The 
flow rate of mobile phase was 0.35 ml/min and the detection was monitored at a 
wavelength of 230 nm. The mobile phase was filtered through a nylon 0.22 µm 
membrane filter and was degassed before use. The column temperature was maintained at 
25°C and injection volume was 5 µl. 
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5. Result and Discussion 
 
5.1 Development and Optimization of the HPLC Method 
For successful method validation, preliminary tests were performed with the 
objective to select adequate and optimum condition. Parameters, such as choice of 
analytical column, pH of buffer, mobile phase composition and proportion, detection 
wavelength and other factors were exhaustively studied. Various reversed columns and 
isocratic mobile phase system were tried.  
 
Development trial-1: 
 When chromatography was carried out at 25° C on a 250 × 4.6 mm i.d., 5µm 
Phenomenex Gemini C18 column with the isocratic mobile phase of 0.02 M aqueous 
phosphate buffer and methanol (30:70 v/v, pH 4.0) at a flow rate of 1.0 ml/min, late 
elution of analyte with peak tailing and high column pressure were observed (Figure 4). 
Hence, the second experiment was carried out with acetonitrile as an organic modifier. 
 
Development trial-2: 
 When chromatography was carried out at 25° C on a 250 × 4.6 mm i.d., 5µm 
Phenomenex Gemini C18 column with the isocratic mobile phase of 0.1 % 
orthophosphoric acid and acetonitrile (50:50 v/v) at a flow rate of 1.0 ml/min, a 
satisfactory separation of the three drugs was achieved with good resolution and minimal 
tailing (Figure 5). Both the trials were done on HPLC. 
 
System used for above development trails: 
 The chromatographic system used to perform development trial was comprised of 
a LC-10ATvp binary pump, a SPD-M10Avp photo diode array detector and a rheodyne 
manual injector model 7725i with 20 µl loop (Shimadzu, Kyoto, Japan) connected to a 
multi-instrument data acquisition and data processing system (Class-VP 6.13 SP2, 
Shimadzu). 
 
Method transfer on UPLC: 
 But our aim was to develop a rapid, sensitive, simple and reliable UPLC method 
which can estimate the three components in less than five minutes. Hence, the above 
method was transferred on UPLC system using column selection chart and calculator. A 
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satisfactory separation of the three drugs was achieved on a Acquity BEH C18 column 
with a mobile phase of 0.1 % orthophosphoric acid and acetonitrile (55:45, v/v) at a flow 
rate of 0.35 ml/min. Quantification was achieved with PDA detection at 230 nm based on 
the peak area. Better resolution of the peaks with clear base line separation was found. 
Figure 6 and Figure 7 represent the chromatograms of standard and test preparation 
respectively.  
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Figure 4: Chromatogram of standard preparation  
(Mobile phase: methanol: buffer (70:30, v/v, pH 4.0) 
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Figure 5: Chromatogram of standard preparation  
(Mobile phase: acetonitrile: 0.1% orthophosphoric acid (50:50, v/v) 
Aspirin, clopidogrel and atorvastatin…                                                 Part-B (Section-1) 
 
   135 
 
 
Figure 6: Chromatogram of standard preparation 
 
Figure 7: Chromatogram of test preparation 
 
5.2  Method Validation 
 The developed LC method was validated to confirm that the present method was 
suitable for its intended purpose as described in ICH guidelines Q2 (R1)[36]. The 
described method extensively validated in terms of specificity, system suitability, 
linearity, accuracy, precision, limit of detection, limit of quantification and robustness. 
 
5.2.1 Specificity 
The specificity of the RP-UPLC method was checked by comparison of 
chromatograms obtained from standard, sample and the corresponding placebo. The peak 
purity of the aspirin, clopidogrel bisulphate and atorvastatin calcium were found 
satisfactory. Additives in capsules are practically insoluble in methanol or the mobile 
phase whereas the active constituents are freely soluble. No interference from additives of 
the capsules was obtained. 
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5.2.2 Linearity 
The linearity of the method was determined at seven concentration levels ranging 
from 12 - 48 µg/mL for ASP, CLP and 3.2 - 12.8 µg/mL for ATV. The calibration curves 
were constructed by plotting peak areas versus concentration of ASP, CLP and ATV. The 
slope, Y-intercept and correlation coefficient were calculated. The response of the drug 
was found to be linear in the investigation concentration range and the linear regression 
equation for aspirin was y = 32727.95x + 6072.57 with correlation coefficient 0.9995 
(Figure 8), for clopidogrel was y = 17956.31x – 1066.28 with correlation coefficient 
0.9998 (Figure 9) and for atorvastatin was y = 28648.79x + 1739.92 with correlation 
coefficient 0.9996 (Figure 10). Where x is the concentration in µg/ml and y is the peak 
area in absorbance unit. Chromatogram obtain during linearity study were shown in 
Figure 11-17. 
 
 
 
Figure 8: Linearity curve for aspirin 
 
 
 
 
Figure 9: Linearity curve for clopidogrel bisulphate 
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Figure 10: Linearity curve for atorvastatin calcium 
 
 
 
 
Figure 11: Linearity study chromatogram of level-1 (40%) 
 
 
 
Figure12: Linearity study chromatogram of level-2 (60%) 
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Figure13: Linearity study chromatogram of level-3 (80%) 
 
 
 
 
Figure 14: Linearity study chromatogram of level-4 (100%) 
 
 
 
 
Figure 15: Linearity study chromatogram of level-5 (120%) 
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Figure 16: Linearity study chromatogram of level-6 (140%) 
 
 
 
 
Figure 17: Linearity study chromatogram of level-7 (160%) 
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5.2.3 LOD and LOQ 
The limit of detection and limit of quantification were evaluated by serial dilutions 
of aspirin, clopidogrel and atorvastatin stock solution in order to obtain signal to noise 
ratio of 3:1 for LOD and 10:1 for LOQ as per ICH guidelines. The LODs for ASP, CLP 
and ATV were found to be 0.03, 0.06 and 0.07 µg/ml, while the LOQs were 0.08, 0.15 
and 0.18 µg/ml respectively. Chromatogram of LOD and LOQ study were shown in 
Figure 18-23.  
 
 
 
 
Figure 18: Chromatogram of LOD study of aspirin 
 
 
 
Figure 19: Chromatogram of LOD study of aspirin 
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Figure 20: Chromatogram of LOD study of clopidogrel bisulphate 
 
 
 
 
Figure 21: Chromatogram of LOQ study of clopidogrel bisulphate 
 
 
 
 
Figure 22: Chromatogram of LOD study of atorvastatin calcium 
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Figure 23: Chromatogram of LOQ study of atorvastatin calcium 
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5.2.4 Precision study 
Precision was investigated using the sample preparation procedure for six real 
samples of commercial capsules (Ecosprin GOLD 20). 
 
Method Precision (Intra-day): The precision of the method was evaluated by 
carrying out six independent assays of ASP, CLP and ATV (30 µg/ml of ASP, CLP and 8 
µg/ml of ATV) test samples against qualified reference standard. 
 
Intermediate Precision (Inter-day): A different analyst on a different day in the 
same laboratory evaluated the intermediate precision % RSD of the method. Six test 
samples were assayed against reference standard.  
 
Data obtain from precision experiments are  given in Table 1 for intra-day and 
inter-day precision study for aspirin, clopidogrel and atorvastatin. The percentage RSD 
values for intra-day precision study and inter-day precision study was < 2.0 % for aspirin, 
clopidogrel and atorvastatin. This is confirming a good precision. 
 
Table 1: Results of precision study 
 
% Assay 
Set 
Aspirin  Clopidogrel  Atorvastatin  
Intraday 
(n=6) 
Interday 
(n=6) 
Intraday 
(n=6) 
Interday 
(n=6) 
Intraday 
(n=6) 
Interday 
(n=6) 
  
1 100.83 99.88 100.73 99.74 101.27 100.28 
2 100.47 99.50 100.11 99.46 100.61 99.98 
3 99.51 99.69 99.41 99.89 99.76 99.66 
4 100.11 100.42 99.84 100.29 100.29 100.62 
5 100.62 99.69 100.46 99.56 101.08 99.39 
6 99.76 100.95 99.83 100.9 100.01 101.18 
Mean 100.22 100.02 100.06 99.97 100.50 100.19 
Stdev 0.514 0.555 0.476 0.539 0.596 0.654 
% RSD 0.51 0.56 0.48 0.54 0.59 0.65 
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5.2.5 Accuracy 
The accuracy of the method was evaluated in triplicate at three concentration 
levels, 50, 100 and 150 % of the target test concentration (30 µg/ml of ASP, CLP and 8 
µg/ml of ATV). The percentages of recoveries were calculated. The recovery experiments 
were carried out by the standard addition method. The percentages of the recoveries 
obtained were 99.83 ± 0.21, 99.44 ± 0.59 and 99.11 ± 0.72 for ASP, CLP and ATV, 
respectively (Table 2). The recovery of the method was good. Chromatogram obtain 
during accuracy study were shown in Figure 24-26.  
 
Table 2: Results of accuracy study 
 
  
Drug Level % 
Amount 
added 
(µg/ml) 
Amount 
found 
(µg/ml) 
% 
Recovery
Mean 
recovery 
(%) 
Stdev % RSD 
  
Aspirin 
50 14.99 14.95 99.85 
99.83 0.21 0.21 100 30.02 29.99 99.89 
150 45.00 44.88 99.76 
Clopidogrel 
50 14.97 14.94 99.79 
99.44 0.59 0.59 100 30.02 29.67 98.85 
150 44.97 44.83 99.68 
Atorvastatin
50 4.02 3.95 98.58 
99.11 0.71 0.72 100 8.00 7.90 98.81 
150 12.01 12.00 99.93 
  
 
Each value corresponds to the mean of three determinations. 
 
 
 
Figure 24: Accuracy study chromatogram of level-1 (50%) 
Aspirin, clopidogrel and atorvastatin…                                                 Part-B (Section-1) 
 
   145 
 
 
 
 
Figure 25: Accuracy study chromatogram of level-2 (100%) 
 
 
Figure 26: Accuracy study chromatogram of level-3 (150%) 
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5.2.6 Robustness  
The robustness was studied by evaluating the effect of small but deliberate 
variations in the chromatographic conditions. The conditions studied were flow rate (± 
0.01), composition of mobile phase (53:47 and 57:43, v/v), column temperature (± 2°C) 
and wavelength of detection (± 5 nm). The result of robustness study of the developed 
assay method was established in Table 3-5. The result shown that during all variance 
conditions, assay value of the test preparation solution was not affected and it was in 
accordance with that of actual. System suitability parameters were also found satisfactory; 
hence the analytical method would be concluded as robust. Chromatogram obtain during 
robustness study were shown in Figure 27-34. 
 
Table 3: Evaluation data of robustness study of aspirin 
 
Robust Conditions % Assay 
System Suitability Parameters 
Theoretical 
plates Asymmetry 
% 
RSD 
  
Flow rate 0.34 ml/min 100.08 2442 1.24 0.23 
Flow rate 0.36 ml/min 99.77 2426 1.22 0.15 
Buffer: ACN (53:47, v/v) 99.63 2435 1.25 0.22 
Buffer: ACN (57:43, v/v) 100.01 2444 1.24 0.47 
Column temperature 23° C 99.88 2430 1.23 0.28 
Column temperature 27° C 100.03 2435 1.24 0.27 
Wave length 225 nm 99.99 2432 1.24 0.17 
Wave length 235 nm 100.11 2435 1.25 0.16 
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Table 4: Evaluation data of robustness study for clopidogrel bisulphate 
 
 
Robust conditions % Assay 
System Suitability Parameters 
Theoretical 
plates Asymmetry 
% 
RSD 
  
Flow rate 0.34 ml/min 100.01 4125 1.15 0.28 
Flow rate 0.36 ml/min 99.67 4081 1.16 0.27 
Buffer: ACN (53:47, v/v) 99.68 4102 1.18 0.15 
Buffer: ACN (57:43, v/v) 99.91 4063 1.16 0.33 
Column temperature 23° C 99.70 4086 1.18 0.19 
Column temperature 27° C 99.97 4045 1.18 0.12 
Wave length 225 nm 99.29 4102 1.17 0.35 
Wave length 235 nm 100.15 4089 1.16 0.22 
  
 
 
Table 5: Evaluation data of robustness study for atorvastatin calcium 
 
 
Robust conditions % Assay 
System Suitability Parameters 
Theoretical 
plates Asymmetry 
% 
RSD 
  
Flow rate 0.34 ml/min 100.13 6455 1.09 0.18 
Flow rate 0.36 ml/min 99.91 6485 1.11 0.17 
Buffer: ACN (53:47, v/v) 100.21 6423 1.09 0.25 
Buffer: ACN (57:43, v/v) 99.99 6501 1.12 0.23 
Column temperature 23° C 99.64 6488 1.10 0.19 
Column temperature 27° C 99.44 6475 1.06 0.12 
Wave length 225 nm 100.09 6452 1.07 0.25 
Wave length 235 nm 99.92 6423 1.07 0.23 
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Figure 27: Standard chromatogram (0.34 ml/min flow rate) 
 
 
 
Figure 28: Standard chromatogram (0.36 ml/min flow rate) 
 
 
 
Figure 29: Standard chromatogram [Buffer - ACN (53:47, v/v)] 
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Figure 30: Standard chromatogram [Buffer - ACN (57:43, v/v)] 
 
 
Figure 31: Standard chromatogram (Column temperature 23° C) 
 
 
 
Figure 32: Standard chromatogram (Column temperature 27° C) 
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Figure 33: Standard chromatogram (Detection wavelength 225 nm) 
 
 
 
 
 
Figure 34: Standard chromatogram (Detection wavelength 235 nm) 
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5.2.7 System suitability 
The system suitability tests represent an integral part of the method and are used to 
ensure adequate performance of the chromatographic system. The parameters, retention 
time (RT), theoretical plates (N), tailing factor (T), peak asymmetry (As) and repeatability 
were evaluated using five replicate injections of the drugs at a concentration of ASP (30 
µg/mL), CLP (30 µg/mL) and ATV (8 µg/mL). Acceptance criteria for system suitability, 
asymmetry should not be more than 2.0, theoretical plate should not be less than 2000 and 
% RSD of peak area should not be more then 2.0, were full fill during all validation 
parameters. The result of system suitability study of the developed assay method was 
shown in Table 6. 
 
Table: 6 Summary of system suitability parameters 
 
Parameters Aspirin Clopidogrel Atorvastatin 
  
Retention time (min) ± % RSD 0.59 ± 0.09 1.04 ± 0.05 2.89 ± 0.04 
Theoretical plates ± % RSD 2427.94 ± 0.60 4079.71 ± 0.48 6453.73 ± 0.25 
Asymmetry ± % RSD 1.25 ± 0.12 1.18 ± 0.08 1.09 ± 0.13 
Repeatability (% RSD) 0.095 0.121 0.262 
  
 
RSD = Relative standard deviation 
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6.   Calculations and Data 
 
  Calculation formula used 
 
1.  Calculation formula for aspirin, clopidogrel and atorvastatin 
 
% ܣݏݏܽݕ ൌ  ܣܶܣܵ ൈ
ܹ1
100 ൈ
1
25 ൈ
100
ܹ2 ൈ
25
1 ൈ
ܣܹ
ܮܥ ൈ ܲ 
 
 
Whereas, 
 AT = Average area of test preparation 
 AS = Average area of standard preparation 
 W1 = Weight taken of reference standard (mg) 
 W2 = Weight taken of test sample (mg) 
 AW = Average weight of tablets (mg) 
 LC = Label claim (mg) 
 P = Potency of reference standard (%) 
 
2.  Relative standard deviation 
 
 
% ܴܵܦ ൌ  ܵݐܽ݊݀ܽݎ݀ ݀݁ݒ݅ܽݐ݅݋݊ ݋݂ ݉݁ܽݏݑݎ݁݉݁݊ݐݏܯ݁ܽ݊ ݒ݈ܽݑ݁ ݋݂ ݉݁ܽݏݑݎ݁݉݁݊ݐݏ ൈ 100 
 
3.  Recovery 
 
% ܴ݁ܿ݋ݒ݁ݎݕ ൌ  ܣ݉݋ݑ݊ݐ ݂݋ݑ݊݀ܣ݉݋ݑ݊ݐ ܽ݀݀݁݀ ൈ 100 
 
 
4.  Amount Found 
 
 
ܣ݉݋ݑ݊ݐ ݂݋ݑ݊݀  ሺߤ݃ ݈݉ሻ⁄ ൌ   ܯ݁ܽ݊ ݐ݁ݏݐ ܽݎ݁ܽܯ݁ܽ݊ ݏݐܽ݊݀ܽݎ݀ ܽݎ݁ܽ ൈ ݏݐܽ݊݀ܽݎ݀ ܿ݋݊ܿ. 
 
 
 
5.  Amount added 
 
ܣ݉݋ݑ݊ݐ ܽ݀݀݁݀ ሺߤ݃ ݈݉⁄ ሻ ൌ  ܹݐ. ݐܸܽ݇݁݊݋݈ݑ݉݁ ൈ 1000 
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 Specificity study for aspirin, clopidogrel and atorvastatin capsules 
 
 For Aspirin 
 
Observation 
  
Data for standard preparation 
 
Data for test preparation 
    
Replicate Area Replicate Area 
1 995412 1 997521 
2 995024 2 997453 
3 995601 Average 997487 
4 994677     
5 994569     
Average 995057     
Stdev 448.77     
% RSD 0.05     
    
Standard weight 75.08 mg Test weight 356.0 mg 
Standard potency 99.95% Label claim 75 mg 
 
 
Calculation: 
 Prototype calculation for one set: 
 
% ܣݏݏܽݕ ൌ  997487995057 ൈ
75.08
100 ൈ
1
25 ൈ
100
356.0 ൈ
25
1 ൈ
355.0
75 ൈ 99.95 
 
            ൌ 100.02 % 
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 For Clopidogrel bisulphate 
 
Observation 
  
Data for standard preparation 
 
Data for test preparation 
    
Replicate Area Replicate Area 
1 538905 1 538564 
2 540012 2 538695 
3 536241 Average 538630 
4 534213     
5 538412     
Average 537557     
Stdev 2317.83     
% RSD 0.43     
    
Standard weight 75.04mg Test weight 355.4 mg 
Standard potency 99.98% Label claim 75 mg 
 
 
Calculation: 
Prototype calculation for one set: 
 
% ܣݏݏܽݕ ൌ  538630537557 ൈ
75.04
100 ൈ
1
25 ൈ
100
355.4 ൈ
25
1 ൈ
355.0
75 ൈ 99.98 
 
             ൌ 100.12 % 
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 For Atorvastatin calcium 
 
Observation 
  
Data for standard preparation 
 
Data for test preparation 
    
Replicate Area Replicate Area 
1 232512 1 234012 
2 234467 2 234056 
3 233481 Average 234034 
4 232450     
5 232043     
Average 232991     
Stdev 979.73     
% RSD 0.42     
    
Standard weight 20.02 mg Test weight 355.2 mg 
Standard potency 99.93% Label claim 20 mg 
 
 
Calculation: 
Prototype calculation for one set: 
 
% ܣݏݏܽݕ ൌ  234034232991 ൈ
20.02
100 ൈ
1
25 ൈ
100
355.2 ൈ
25
1 ൈ 20 ൈ 99.93 
 
               ൌ 100.42 % 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aspirin, clopidogrel and atorvastatin…                                                 Part-B (Section-1) 
 
   156 
 
 Linearity study for aspirin, clopidogrel and atorvastatin capsule 
 
 For Aspirin 
 
Observation 
    
Data for standard preparation 
      
 
    
Replicate Area Standard weight 75.00 mg 
1 995412 Standard potency 99.95% 
2 995024       
3 995601       
4 994677       
5 994569       
Average 995057       
Stdev 448.77       
% RSD 0.05     
 
 
Linearity level %  Level Concentration (µg/ml) Mean area 
1 40 12 401466 
2 60 18 578161 
3 80 24 805761 
4 100 30 993896 
5 120 36 1182665 
6 140 42 1378175 
7 160 48 1575254 
    
Correlation co-efficient 0.9995 
Slope 32727.95 
Intercept 6072.57 
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 For Clopidogrel bisulphate 
 
 
Observation 
    
Data for standard preparation 
      
 
    
Replicate Area Standard weight 75.00 mg 
1 538641 Standard potency 99.98% 
2 538652       
3 538241       
4 537212       
5 537952       
Average 538140       
Stdev 595.79       
% RSD 0.11     
 
 
Linearity level %  Level Concentration (µg/ml) Mean area 
1 40 12 212515 
2 60 18 323255 
3 80 24 430057 
4 100 30 536325 
5 120 36 652592 
6 140 42 751829 
7 160 48 858678 
    
Correlation co-efficient 0.9998 
Slope 17956.31 
Intercept -1066.28 
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 For Atorvastatin calcium 
 
Observation 
    
Data for standard preparation 
      
 
    
Replicate Area Standard weight 20.00 mg 
1 233618 Standard potency 99.93% 
2 233271       
3 233581       
4 232864       
5 232377       
Average 233142       
Stdev 524.03       
% RSD 0.22     
 
 
Linearity level %  Level Concentration (µg/ml) Mean area 
1 40 3.2 92928 
2 60 4.8 136853 
3 80 6.4 185944 
4 100 8.0 234114 
5 120 9.6 278266 
6 140 11.2 321587 
7 160 12.8 366820 
    
Correlation co-efficient 0.9996 
Slope 28648.79 
Intercept 1739.92 
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 Precision study for aspirin, clopidogrel and atorvastatin capsule 
 
 For Aspirin 
 
Observation 
    
Data for standard preparation 
      
 
    
Replicate Area Standard weight 75.05 mg 
1 995354 Standard potency 99.95% 
2 995021       
3 995512       
4 996132       
5 993552       
Average 995114       
Stdev 961.88       
% RSD 0.10     
 
 
Description Mean area Test weight (mg) % Assay 
Set 1 995872 352.41 100.83 
Set 2 996941 354.03 100.47 
Set 3 996029 357.14 99.51 
Set 4 996721 355.22 100.11 
Set 5 995532 353.02 100.62 
Set 6 995512 356.04 99.76 
  
Mean 100.22 
Stdev 0.514 
% RSD 0.51 
 
 
Calculation: 
Prototype calculation for one set: 
 
% ܣݏݏܽݕ ൌ  995872995114 ൈ
75.05
100 ൈ
1
25 ൈ
100
352.41 ൈ
25
1 ൈ
355.0
75 ൈ 99.95 
 
           ൌ 100.83 
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 For Clopidogrel bisulphate 
 
 
Observation 
    
Data for standard preparation 
      
 
    
Replicate Area Standard weight 74.93 mg 
1 538990 Standard potency 99.98% 
2 538752       
3 538241       
4 537514       
5 538403       
Average 538380       
Stdev 565.75       
% RSD 0.11     
 
Description Mean area Test weight (mg) % Assay 
Set 1 538929 352.41 100.73 
Set 2 538081 354.03 100.11 
Set 3 539001 357.14 99.41 
Set 4 538430 355.22 99.84 
Set 5 538412 353.02 100.46 
Set 6 539629 356.04 99.83 
  
Mean 100.06 
Stdev 0.476 
% RSD 0.48 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
 
% ܣݏݏܽݕ ൌ  538929538380 ൈ
74.93
100 ൈ
1
25 ൈ
100
352.41 ൈ
25
1 ൈ
355.0
75 ൈ 99.98 
 
           ൌ 100.73 
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 For Atorvastatin calcium 
 
Observation 
    
Data for standard preparation 
      
 
    
Replicate Area Standard weight 20.04 mg 
1 232618 Standard potency 99.93% 
2 234207       
3 233581       
4 232527       
5 232381       
Average 233063       
Stdev 794.91       
% RSD 0.34     
 
Description Mean area Test weight (mg) % Assay 
Set 1 234003 352.41 101.27 
Set 2 233536 354.03 100.61 
Set 3 233602 357.14 99.76 
Set 4 233574 355.22 100.29 
Set 5 233968 353.02 101.08 
Set 6 233459 356.04 100.01 
  
Mean 100.50 
Stdev 0.596 
% RSD 0.59 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
 
% ܣݏݏܽݕ ൌ  234003233063 ൈ
20.04
100 ൈ
1
25 ൈ
100
352.41 ൈ
25
1 ൈ
355.0
20 ൈ 99.93 
 
           ൌ 101.27 
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 Intermediate precision study for aspirin, clopidogrel and atorvastatin capsule  
 
 For Aspirin 
 
Observation 
    
Data for standard preparation 
      
 
    
Replicate Area Standard weight 75.08 mg 
1 995412 Standard potency 99.95% 
2 995024       
3 995601       
4 994677       
5 994569       
Average 995057       
Stdev 448.77       
% RSD 0.05     
 
Description Mean area Test weight (mg) % Assay 
Set 1 997354 356.46 99.88 
Set 2 995221 357.04 99.50 
Set 3 994212 356.00 99.69 
Set 4 996432 354.20 100.42 
Set 5 996552 356.84 99.69 
Set 6 997853 352.83 100.95 
  
Mean 100.02 
Stdev 0.555 
% RSD 0.56 
 
 
Calculation: 
Prototype calculation for one set: 
 
 
% ܣݏݏܽݕ ൌ  997354995057 ൈ
75.08
100 ൈ
1
25 ൈ
100
356.46 ൈ
25
1 ൈ
355.0
75 ൈ 99.95 
 
                                 ൌ 99.88 
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 For Clopidogrel bisulphate 
 
 
Observation 
    
Data for standard preparation 
      
 
    
Replicate Area Standard weight 75.02 mg 
1 538641 Standard potency 99.98% 
2 538652       
3 538241       
4 537212       
5 537952       
Average 538140       
Stdev 595.79       
% RSD 0.11     
 
Description Mean area Test weight (mg) % Assay 
Set 1 538934 356.46 99.74 
Set 2 538257 357.04 99.46 
Set 3 539053 356.00 99.89 
Set 4 538430 354.20 100.29 
Set 5 538501 356.84 99.56 
Set 6 539633 352.83 100.90 
  
Mean 99.97 
Stdev 0.539 
% RSD 0.54 
 
 
 
Calculation: 
Prototype calculation for one set: 
 
% ܣݏݏܽݕ ൌ  538934538140 ൈ
75.02
100 ൈ
1
25 ൈ
100
356.46 ൈ
25
1 ൈ
235.0
75 ൈ 99.98 
 
           ൌ 99.74 
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 For Atorvastatin calcium 
 
Observation 
    
Data for standard preparation 
      
 
    
Replicate Area Standard weight 20.06 mg 
1 233618 Standard potency 99.93% 
2 233271       
3 233581       
4 232864       
5 232377       
Average 233142       
Stdev 524.03       
% RSD 0.22     
 
Description Mean area Test weight (mg) % Assay 
Set 1 234211 356.46 100.28 
Set 2 233907 357.04 99.98 
Set 3 232481 356.00 99.66 
Set 4 233527 354.20 100.62 
Set 5 232381 356.84 99.39 
Set 6 233912 352.83 101.18 
  
Mean 100.19 
Stdev 0.654 
% RSD 0.65 
 
 
Calculation: 
Prototype calculation for one set: 
 
% ܣݏݏܽݕ ൌ  234211233142 ൈ
20.06
100 ൈ
1
25 ൈ
100
356.46 ൈ
25
1 ൈ
235.0
20 ൈ 99.93 
 
           ൌ 100.28 
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 Comparison study of method precision and intermediate precision 
 For Aspirin 
Study Set No. Assay (%) 
Mean 
assay 
(%) 
Stdev RSD % 
95 % 
Confidence 
Interval 
Method 
precision 
1 100.83 
100.22 0.514 0.51 0.54 
2 100.47 
3 99.51 
4 100.11 
5 100.62 
6 99.76 
Intermediate 
precision 
1 99.88 
100.02 0.555 0.56 0.59 
2 99.50 
3 99.69 
4 100.42 
5 99.69 
6 100.95 
Overall 
Mean 100.12 Absolute difference between mean % 
assay values of Method precision and 
Intermediate precision= 0.2 
Stdev 0.520 
RSD % 0.52 
 
 For Clopidogrel bisulphate 
 
Study Set No. Assay (%) 
Mean 
assay 
(%) 
Stdev RSD % 
95 % 
Confidence 
Interval 
Method 
precision 
1 100.73 
100.06 0.476 0.48 0.51 
2 100.11 
3 99.41 
4 99.84 
5 100.46 
6 99.83 
Intermediate 
precision 
1 99.74 
99.97 0.539 0.54 0.57 
2 99.46 
3 99.89 
4 100.29 
5 99.56 
6 100.90 
Overall 
Mean 100.02 Absolute difference between mean % 
assay values of Method precision and 
Intermediate precision= 0.09 
Stdev 0.487 
RSD % 0.49 
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 For Atorvastatin calcium 
 
Study Set No. Assay (%) 
Mean 
assay 
(%) 
Stdev RSD % 
95 % 
Confidence 
Interval 
Method 
precision 
1 101.27 
100.50 0.596 0.59 0.62 
2 100.61 
3 99.76 
4 100.29 
5 101.08 
6 100.01 
Intermediate 
precision 
1 100.28 
100.19 0.654 0.65 0.68 
2 99.98 
3 99.66 
4 100.62 
5 99.39 
6 101.18 
Overall 
Mean 100.34 Absolute difference between mean % 
assay values of Method precision and 
Intermediate precision= 0.31 
Stdev 0.619 
RSD % 0.62 
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 Accuracy study for analytical method validation of aspirin, clopidogrel and 
atorvastatin capsules 
 
 For aspirin, clopidogrel and atorvastatin 
 
Observation 
    
Data for standard preparation 
     Aspirin Clopidogrel Atorvastatin 
Replicate Area   
1 995324 538905 232512 
2 995021 540012 234467 
3 995501 536241 233481 
4 996121 534213 232450 
5 993562 538412 232043 
Average 995106 537557 232991 
Stdev 951.96 2317.83 979.73 
% RSD 0.10 0.43 0.42 
Standard weight (mg) 75.03 75.06 20.04 
Standard potency (%) 99.95 99.98 99.93 
Concentration (µg/ml) 30.01 30.02 8.02 
 
 
 
 
 
 
 
 
 
 
 Aspirin 
 
Recovery 
level Set No.
Mean 
area 
Weight 
(mg) 
Vol-1 
(ml) 
Vol-2 
(ml) 
Vol-3 
(ml) 
Amount 
added 
(µg/ml) 
Amount 
found 
(µg/ml) 
% 
Recovery
Mean % 
Recovery Stdev 
% 
RSD 
50% 
Set 1 495125 37.52 100 1 25 15.01 14.93 99.47 
99.83 0.21 0.21 
Set 2 497021 37.43 100 1 25 14.97 14.99 100.13 
Set 3 494812 37.48 100 1 25 14.99 14.92 99.95 
100% 
Set 1 994042 75.06 100 1 25 30.02 29.98 99.86 
Set 2 993753 75.09 100 1 25 30.04 29.97 99.77 
Set 3 995241 75.01 100 1 25 30.00 30.01 100.05 
150% 
Set 1 1488352 112.47 100 1 25 44.99 44.86 99.78 
Set 2 1486023 112.52 100 1 25 45.01 44.81 99.57 
Set 3 1491063 112.50 100 1 25 45.00 44.97 99.93 
 
Calculation: Prototype calculation for one set: 
 
                                                                               % ܴ݁ܿ݋ݒ݁ݎݕ ൌ  14.9315.01 ൈ 100 ൌ 99.47 
ܣ݉݋ݑ݊ݐ ݂݋ݑ݊݀ ሺߤ݃ ݈݉⁄ ሻ ൌ  495125995106 ൈ 30.01 ൌ 14.93 
 
   ܣ݉݋ݑ݊ݐ ܽ݀݀݁݀ ሺߤ݃ ݈݉⁄ ሻ ൌ  37.52100 ൈ
1
25 ൈ 1000 ൌ 15.01 
 
 Clopidogrel bisulphate 
 
Recovery 
level Set No.
Mean 
area 
Weight 
(mg) 
Vol-1 
(ml) 
Vol-2 
(ml) 
Vol-3 
(ml) 
Amount 
added 
(µg/ml) 
Amount 
found 
(µg/ml) 
% 
Recovery
Mean % 
Recovery Stdev 
% 
RSD 
50% 
Set 1 268121 37.32 100 1 25 14.93 14.97 100.29 
99.44 0.59 0.59 
Set 2 267510 37.52 100 1 25 15.01 14.93 99.53 
Set 3 267016 37.46 100 1 25 14.98 14.91 99.54 
100% 
Set 1 528947 75.07 100 1 25 30.03 29.53 98.33 
Set 2 532325 75.04 100 1 25 30.02 29.73 99.03 
Set 3 533171 75.05 100 1 25 30.02 29.76 99.18 
150% 
Set 1 802346 112.41 100 1 25 44.96 44.81 99.66 
Set 2 800119 112.54 100 1 25 45.02 44.68 99.25 
Set 3 805875 112.34 100 1 25 44.94 45.00 100.14 
 
Calculation: Prototype calculation for one set: 
 
                                                                               % ܴ݁ܿ݋ݒ݁ݎݕ ൌ  14.9714.93 ൈ 100 ൌ 100.29 
ܣ݉݋ݑ݊ݐ ݂݋ݑ݊݀ ሺߤ݃ ݈݉⁄ ሻ ൌ  268121537557 ൈ 30.02 ൌ 14.97 
 
  ܣ݉݋ݑ݊ݐ ܽ݀݀݁݀ ሺߤ݃ ݈݉⁄ ሻ ൌ  37.32100 ൈ
1
25 ൈ 1000 ൌ 14.93
 Atorvastatin calcium 
 
Recovery 
level Set No.
Mean 
area 
Weight 
(mg) 
Vol-1 
(ml) 
Vol-2 
(ml) 
Vol-3 
(ml) 
Amount 
added 
(µg/ml) 
Amount 
found 
(µg/ml) 
% 
Recovery
Mean % 
Recovery Stdev 
% 
RSD 
50% 
Set 1 115129 10.07 100 1 25 4.03 3.96 98.26 
99.11 0.71 0.72 
Set 2 114225 10.08 100 1 25 4.03 3.93 98.24 
Set 3 115312 10.01 100 1 25 4.00 3.97 99.23 
100% 
Set 1 229557 20.03 100 1 25 8.01 7.90 98.65 
Set 2 228971 19.94 100 1 25 7.98 7.88 98.77 
Set 3 230114 20.00 100 1 25 8.00 7.92 99.01 
150% 
Set 1 347918 30.08 100 1 25 12.03 11.98 99.55 
Set 2 349805 30.06 100 1 25 12.02 12.04 100.17 
Set 3 348211 29.94 100 1 25 11.98 11.99 100.08 
 
Calculation: Prototype calculation for one set: 
 
                                                                               % ܴ݁ܿ݋ݒ݁ݎݕ ൌ  3.964.03 ൈ 100 ൌ 98.26 
ܣ݉݋ݑ݊ݐ ݂݋ݑ݊݀ ሺߤ݃ ݈݉⁄ ሻ ൌ  115129232991 ൈ 8.02 ൌ 3.96 
 
   ܣ݉݋ݑ݊ݐ ܽ݀݀݁݀ ሺߤ݃ ݈݉⁄ ሻ ൌ  10.07100 ൈ
1
25 ൈ 1000 ൌ 4.03 
 
 Robustness study for analytical method validation of aspirin, clopidogrel and atorvastatin capsule 
 
Robustness study of aspirin 
Robustness parameters 
Mean 
area of 
test 
Mean area 
of standard 
Standard 
weight  
(mg) 
Test 
weight  
(mg) 
Average 
test weight 
(mg) 
Label 
claim 
(mg) 
Potency % Assay 
Flow rate 0.34 ml/min 998532 997041 75.03 355.22 355.00 75 99.95 100.08 
Flow rate 0.36 ml/min 995512 995784 75.12 356.12 355.00 75 99.95 99.77 
Buffer: ACN (53:47, v/v) 996721 995137 74.59 354.74 355.00 75 99.95 99.63 
Buffer: ACN (57:43, v/v) 995532 995874 75.08 355.06 355.00 75 99.95 100.01 
Column temperature 23° C 996941 995387 75.04 356.00 355.00 75 99.95 99.88 
Column temperature 27° C 996523 996172 75.11 355.36 355.00 75 99.95 100.03 
Wave length 225 nm 999514 999382 75.08 355.27 355.00 75 99.95 99.99 
Wave length 235 nm 995422 995546 75.14 355.04 355.00 75 99.95 100.11 
 
Calculation: 
Prototype calculation for one set: 
% ܣݏݏܽݕ ൌ  998532997041 ൈ
75.03
100 ൈ
1
25 ൈ
100
355.22 ൈ
25
1 ൈ
355.0
75 ൈ 99.95 
                                                                                       ൌ 100.08 
  Robustness study for analytical method validation of aspirin, clopidogrel and atorvastatin capsule  
 
Robustness study of clopidogrel bisulphate 
Robustness parameters 
Mean 
area of 
test 
Mean area 
of standard 
Standard 
weight  
(mg) 
Test 
weight  
(mg) 
Average 
test 
weight 
(mg) 
Label 
claim 
(mg) 
Potency % Assay 
Flow rate 0.34 ml/min 539232 538845 75.05 355.22 355.00 75 99.98 100.06 
Flow rate 0.36 ml/min 538454 538567 75.02 356.12 355.00 75 99.98 99.67 
Buffer: ACN (53:47, v/v) 538876 538652 74.69 354.74 355.00 75 99.98 99.68 
Buffer: ACN (57:43, v/v) 538514 538960 75.02 355.06 355.00 75 99.98 99.91 
Column temperature 23° C 538467 538743 75.04 356.00 355.00 75 99.98 99.70 
Column temperature 27° C 538503 538631 75.09 355.36 355.00 75 99.98 99.97 
Wave length 225 nm 539055 539115 74.55 355.27 355.00 75 99.98 99.29 
Wave length 235 nm 538542 538227 75.09 355.04 355.00 75 99.98 100.15 
 
Calculation: 
Prototype calculation for one set: 
% ܣݏݏܽݕ ൌ  539232538845 ൈ
75.05
100 ൈ
1
25 ൈ
100
355.22 ൈ
25
1 ൈ
355.0
75 ൈ 99.98 
                                                                                       ൌ 100.06 
  Robustness study for analytical method validation of aspirin, clopidogrel and atorvastatin capsule  
 
Robustness study of atorvastatin calcium 
Robustness parameters 
Mean 
area of 
test 
Mean area 
of standard 
Standard 
weight  
(mg) 
Test 
weight  
(mg) 
Average 
test 
weight 
(mg) 
Label 
claim 
(mg) 
Potency % Assay 
Flow rate 0.34 ml/min 234012 233643 20.02 355.22 355.00 20 99.93 100.13 
Flow rate 0.36 ml/min 233740 233520 20.04 356.12 355.00 20 99.93 99.91 
Buffer: ACN (53:47, v/v) 233874 233974 20.05 354.74 355.00 20 99.93 100.21 
Buffer: ACN (57:43, v/v) 233591 233422 20.00 355.06 355.00 20 99.93 99.99 
Column temperature 23° C 233612 233750 20.01 356.00 355.00 20 99.93 99.64 
Column temperature 27° C 233589 233457 19.91 355.36 355.00 20 99.93 99.44 
Wave length 225 nm 234178 234099 20.04 355.27 355.00 20 99.93 100.09 
Wave length 235 nm 233452 233682 20.02 355.04 355.00 20 99.93 99.92 
 
Calculation: 
Prototype calculation for one set: 
% ܣݏݏܽݕ ൌ  234012233643 ൈ
20.02
100 ൈ
1
25 ൈ
100
355.22 ൈ
25
1 ൈ
355.0
20 ൈ 99.93 
                                                                                       ൌ 100.13 
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UPLC METHOD DEVELOPMENT AND VALIDATION STUDY OF SIX DRUGS 
USED FOR COMBINED HYPERTENSION THERAPY 
 
1. Introduction of drugs  
 
1.1 Atenolol (Given in part-A section-2) 
1.2 Hydrochlorothiazide 
 Hydrochlorothiazide (HYD) is a diuretic agent, chemically described as a 6-
chloro-3, 4-dihydro-2H-1, 2, 4-benzothiadiazine-7-sulfonamide 1, 1-dioxide, which is 
widely used in antihypertensive pharmaceutical preparations, reduce active sodium 
reabsorption and peripheral vascular resistance. Its molecular formula is C7H8ClN3O4S2 
having molecular weight 297.74 g/mole. It is insoluble in water, freely soluble in 
methanol, soluble in diluted ammonia or sodium hydroxide[1-3]. 
 
 
Figure 1: Chemical structure of hydrochlorothiazide 
 
1.3 Amlodipine besylate 
 Amlodipine besylate (AML), 2-[(2-aminoethoxy)-methyl]-4-(2-chlorophenyl) 1,4-
dihydro-6-methyl-3,5-pyridine-dicarboxylic acid-3 ethyl-5 methyl ester, is a calcium 
channel blocker. It is used in the treatment of hypertension and angina. Its molecular 
formula is ClN2O5-C6H5SO3H having molecular weight 567.05 g/mole. It is slightly 
soluble in water and sparingly soluble in ethanol[1].  
  
H
N
O
H2N
O
OO
O
Cl
.C6H5SO3H
 
Figure 2: Chemical structure of amlodipine besylate 
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1.4 Indapamide 
 Indapamide (IND), 4-chloro-N-(2-methylindolin-1-yl)-3-sulfamoylbenzamide, is 
the first of the new class of antihypertensive diuretics, the indulines, and it is also 
prescribed to treat the salt and fluid retention associated with congestive heart failure[4]. 
Its molecular formula is C16H16ClN3O3S having molecular weight 365.83 g/mole. It is 
slightly soluble in chloroform, freely soluble in methanol, acetic acid and ethyl acetate[1]. 
 
 
Figure 3: Chemical structure of indapamide 
 
1.5 Nifedipine 
 Nifedipine (NIF), (1,4-dihydro-2,6-dimethyl-4-(nitrophenyl) pyridine-3,5-
dicarboxylate) is a dihydropyridine calcium channel blocker used in the management of 
hypertension, in the prophylaxis of angina pectoris and in the treatment of other vascular 
and non-vascular diseases. Nifedipine is almost insoluble in water and is very sensitive to 
light. For this reason it can be degraded and after some time occurs with impurities[5]. Its 
molecular formula is C17H18N2O6 having molecular weight 346.33 g/mole[1]. 
 
 
 
Figure 4: Chemical structure of nifedipine 
 
1.6 Lercanidipine hydrochloride (Given in part-A section-1) 
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2. Literature review 
Many dosage forms of ATE, HYD, AML, IND, NIF and LER as a single or as 
combination with others are available on the local market for effective therapy. Literature 
survey reveals that a variety of analytical methods such as spectrophotometry, 
Spectrofluorimetry, HPLC, LC-MS and HPTLC have been reported for the determination 
of ATE[6-10], HYD[11-17], AML[18-22], IND[23-27], NIF[28-32] and LER (given in part-A 
section-1) in pharmaceutical dosage forms.  
 
2.1 Literature review for atenolol 
2.1.1 Ceresole R, Moyano MA, Pizzorno MT and Segall AI have developed a 
reversed-phase liquid chromatographic (RP-LC) assay method for the quantification of 
atenolol in the presence of its degrading products. The assay involved an isocratic elution 
of atenolol in a Waters C18 column using a mobile phase consisting of acetonitrile - 0.08 
M sodium phosphate monobasic (10:90 v/v, pH 3.0). The flow rate was 1.0 ml/min and 
the analyte monitored at 284 nm. The assay method was found to be linear from 0.4 to 
12.8 µg/ml injected. The developed method was successfully applied to estimation the 
amount of atenolol in tablets[6].    
 
2.2.2 Patel YP, Patil S, Bhoir IC and Sundaresan M have developed an isocratic, RP-
HPLC method for estimation of six drugs for combined hypertension therapy. The 
chromatographic separation was performed on JASCO-metaphase ODS column (250 × 
4.0 mm, 5 μm particle size). The drugs were resolved by elution with a pH 4.5 
equivolume mobile phase of acetonitrile-0.01 M KH2PO4, with pH adjustment done with 
H3PO4 (flow rate 1.5 ml/min). The column effluent was monitored at 250 nm. The 
suggested procedure has the advantage that all the five drugs can be quantified alone or in 
formulation with atenolol[7]. 
 
2.1.3  Kavitha J and Murlidharan S have developed a RP-HPLC method for the 
atenolol, hydrochlorothiazide and losartan potassium in tablet formulation. Best 
resolution was achieved on a reverse-phase Phenomenex C18 column using acetonitrile 
and 50 mM potassium dihydrogen phosphate buffer (50:50 v/v, pH 3.5) mobile phase 
with a flow rate of 1 ml/min and isocratic elution with a total run time of 14 min. The 
present newly developed method was useful for routine quality control analysis 
laboratory[8].  
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2.1.4  Sivakumar T, Venkatesan R, Manavalan R and Valliappan K have developed 
a method for the simultaneous determination of atenolol and losartan potassium by 
reversed phase high pressure liquid chromatography. The separation was achieved on 
Supelcosil ODS analytical column (250 × 4.6 mm i.d., 5 μm particle size) using 
acetonitrile and 25 mM potassium dihydrogen phosphate buffer (45:55 v/v, pH 3.0±0.05)  
as mobile phase with a flow rate of 1.2 ml/min. the detection was carried out using a UV 
detector at 227 nm. The proposed method can be used for routine quality control of 
tablets containing these two drugs[9]. 
 
2.1.5 Sathe SR and Bari SB have developed a HPTLC method for the separation and 
quantitative analysis of losartan potassium, atenolol and hydrochlorothiazide in bulk and 
in pharmaceutical formulations. After extraction with methanol, sample  and standard 
solutions were applied to prewashed silica gel plates and developed with toluene-
methanol-triethylamine (6.5:4:0.5 v/v/v) as mobile phase. Zones were scanned 
densitometrically at 274 nm. The Rf values of losartan potassium, atenolol and 
hydrochlorothiazide were 0.60, 0.43 and 0.29 respectively[10]. 
 
2.2 Literature review for hydrochlorothiazide 
2.2.1 Wankhede SB, Tajne MR, Gupta KR and Wadodkar SG have developed and 
validated reverse phase high performance liquid chromatographic method for 
simultaneous estimation of telmisartan and hydrochlorothiazide in tablet formulation.  
Chromatography was performed on a ODS Hypersil C18 (250 × 4.6 mm I.D) column from 
thermo in isocratic mode with mobile phase consisting of acetonitrile: 0.05 M KH2PO4 
(60:40 v/v, pH 3.0).  The flow rate was 1.0 ml/min and the eluent was monitored at 271 
nm. The proposed method was found to be accurate, precise, reproducible and specific 
and can be used for simultaneous analysis of these drugs in tablet formulation[11]. 
 
2.2.2 Garg G, Saraf S and Saraf S have developed a simple, accurate, economical, 
and reproducible UV spectrophotometric and column high-performance liquid 
chromatographic (HPLC) methods were developed for simultaneous estimation of a 2-
component drug mixture of metoprolol tartrate and hydrochlorothiazide in combined 
tablet dosage form.  The first method used the simultaneous equation method with 7 
mixed standards and the absorption maxima at 223 and 271 nm, respectively, for 
metoprolol tartrate and hydrochlorothiazide in MeOH.  Linearity  was observed in the 
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concentration ranges of 4-24 and 2-16 µg/ml for metoprolol tartrate and 
hydrochlorothiazide, respectively.  The developed HPLC method used a reversed-phase 
C18 column and MeOH-water (95 ± 5) mobile phase at an ambient temperature of 27° C 
and UV detection at 225 nm; the run time was 10 min, and quantification was based on 
peak area. The proposed methods were successfully applied for the determination of 
metoprolol tartrate and hydrochlorothiazide in bulk powder and dosage form[12]. 
2.2.3 Shaikh S, Thusleem OA, Muneera MS, Akmal J, Kondaguli AV and 
Ruckmani K have developed a simple and precise HPLC method for the simultaneous 
determination of bisoprolol fumarate (BF), and hydrochlorothiazide (HCTZ) in a tablet 
formulation. Chromatography was carried out at 25° C on a 4.6 × 250 mm, 5 µm cyano 
column with the isocratic mobile phase of 0.1 M phosphate buffer, acetonitrile and THF 
(85:10:5 v/v) at a flow rate of 1.0 ml/min. The UV detection was carried out at 225 nm.  
HCTZ and BF were separated in less than 10 min with good resolution and minimal 
tailing, without interference of excipients. The method was validated according to ICH 
guidelines and the acceptance criteria for accuracy, precision, linearity, specificity and 
system suitability were met in all cases[13].  
2.2.4 Bhat LR, Godge RK, Vora AT and Damle MC have developed a simple, 
selective and precise reverse phase high performance liquid chromatographic method for 
the simultaneous determination of telmisartan and hydrochlorothiazide from 
pharmaceutical formulation.  The mobile phase consisted of methanol and acetonitrile 
(70:30 v/v) at a flow rate of 1 ml/min and the wavelength of detection was 270 nm.  
Rabeprazole was used as an internal standard. The retention times of telmisartan, 
hydrochlorothiazide and rabeprazole were 1.79 ± 0.01, 2.80 ± 0.01, and 3.19 ± 0.01 min, 
respectively. The developed method was validated according to ICH guidelines[14]. 
2.2.5 Sagirli O, Onal A, Toker SE and Sensoy D have developed and validated 
method for the simultaneous determination of olmesartan (OLM) medoximil and 
hydrochlorothiazide (HCT) in combined tablets.  Chromatography was carried out on a 
4.6 × 200 mm i.d., 5 µm cyano column with MeOH-10 mM phosphoric acid containing 
0.1% triethylamine (pH 2.5, 50:50 v/v) at a flow rate of 1.0 ml/min and UV detector was 
set at 260 nm.  Valsartan was used as internal standard. The method was applied 
successfully for quality control assay of OLM and HCT in combined tablets and in vitro 
dissolution studies[15].    
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2.2.6  Chheta N and Gandhi SP have developed a stability indicating liquid 
chromatographic method for the estimation of atenolol and hydrochlorothiazide in pure 
form and tablet form. The separation was achieved using Hypersil-BDS C18 column (250 
× 4.6 mm i.d., 5 μm). The mobile phase was 25 mM phosphate buffer and acetonitrile 
(85:15 v/v, pH 3±0.05) at 0.7 ml/min satisfactorily resolved the binary mixture. The 
optimized method could find application in routine quality control analysis of 
pharmaceutical tablet formulations[16]. 
2.2.7 Zaveri M and Khandhar A have developed a RP-HPLC method for the 
simultaneous estimation of atenolol and hydrochlorothiazide in pharmaceutical dosage 
form. The quantification was carried out by using Zorbax SB-CN (250 × 4.6 mm, 5µm) 
column in isocratic mode with mobile phase, water: buffer: methanol (50:35:15 v/v). The 
flow rate was 1.2 ml/min. The peak purity of atenolol and hydrochlorothiazide were 
0.999 and 1.000 respectively[17]. 
2.3 Literature review for amlodipine besylate 
2.3.1 Sharma A, Tailang M, Gupta B and Acharya A have developed a RP HPLC 
method for the determination of amlodipine in its pharmaceutical dosage form. The 
separation was achieved on hypersil C18 column, Phenomenex Gemini (250 × 4.6 mm, 
5µm) size with rheodyne injector. The mobile phase used acetonitrile, methanol and 
KH2PO4 was in the ration of 250:250:500. The flow rate was 1.0 ml/min and UV 
detection at 238 nm. This method can be successfully employed for the quantitative 
analysis of amlodipine[18].  
2.3.2 Wankhede SB, Raka KC, Wadkar SB and Chitlange SS have developed a 
spectrophotometric and HPLC method for the simultaneous determination of amlodipine 
besylate, losartan potassium and hydrochlorothiazide in tablet dosage form. The first UV 
spectrophotometric method was a determination using the simultaneous equation method 
at 236.5, 254 and 271 nm over the concentration ranges 5-25, 10-50 and 5-25 µg/ml for 
amlodipine, losartan potassium and hydrochlorothiazide, respectively. In RP-HPLC 
analysis is carried out using 0.025 M phosphate buffer and acetonitrile (57:43 v/v, pH 
3.7) as the mobile phase and Kromasil C18 (4.6 × 250 mm) column as stationary phase 
with detection wavelength of 232 nm. The proposed method can be successfully used to 
determination of the drug contents of marketed formulation[19].  
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2.3.3 Safeer K. Anbarasi B and Senthil KN have developed a simple and sensitive 
HPLC method for the determination of amlodipine and hydrochlorothiazide from 
combined dosage form by reverse phase Phenomenex C18 column (4.6 × 250 mm i.d., 5 
µm. the sample was analyzed using triethylamine: acetonitrile: methanol in the ratio of 
(50:25:25 v/v/v, pH 3.0) as a mobile phase at a flow rate of 2.0 ml/min and detection at 
235 nm. The method can be used for estimation of combination of these drugs in 
combined dosage form[20].  
2.3.4 Barman R, Islam MA, Ahmed M, Islam R, Khan A, Hossain BM and 
Rahman MB have developed a HPLC method for the quantitative simultaneous 
estimation of atenolol and amlodipine in combined pharmaceutical dosage form. The 
separation was achieved using shim-pack CLC, ODS C18, (250 × 4.6 mm) column. The 
mobile phase of ammonium acetate buffer, acetonitrile and methanol (35:30:35 v/v/v, pH 
4.5±0.05). The chromatographic flow rate was 1.5 ml/min, column temperature at 40° C 
and detector wavelength of 237 nm. The proposed method was successfully applied to 
the pharmaceutical dosage forms containing the above mentioned drug combination 
without any interference by the excipient[21].  
2.3.5 Sankar SR, Nanjan MJ, Vasudevan M, Shaat N and Suresh B have developed 
a HPLC method for the simultaneous determination of atenolol and amlodipine from 
pharmaceutical formulation. The recovery and statistical validations were carried out to 
find its applicability in routine quality control[22]. 
2.4 Literature review for indapamide 
2.4.1 Ates Z, Ozden T, Ozilhan S and Eren S have developed a simple, rapid, 
sensitive and selective method for the analysis of indapamide in human plasma, utilizing 
ultra performance liquid chromatography (UPLC). The analyte and the internal standard, 
sulfamethazine, were isolated from plasma samples by liq.-liq. extraction with diethyl 
ether. Separation was performed with an Acquity C18 column. The gradient mobile phase 
was composed of acetonitrile and sodium dihydrogen phosphate buffer (adjusted to pH 
3.33 with 85% o-phosphoric acid) at a flow rate of 0.5 ml/min. The assay exhibited a 
linear dynamic range of 1-100 ng/ml for indapamide in human plasma. The method was 
successfully applied to the pharmacokinetic and bioequivalence studies of indapamide 
formulations[23].  
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2.4.2 Li L and Zhang X have developed an HPLC method for determination of 
indapamide content in indapamide tablets. HPLC was conducted with C18 column and 
methanol-water-glacial acetic acid (40:60:0.1 v/v) at flow rate of 1.0 ml/min, detection 
wavelength of 240 nm, column was kept at of room temperature and sample volume of 20 
µl. The linear range of concentration and peak area was 10-80 µg/ml, r2 = 0.9997.  
Average recovery was 99.30 % (n = 5). The method was accurate and reliable[24].  
 
2.4.3 Fernandes N, Nimdeo MS, Choudhari VP, Kulkarni RR, Pande VV and 
Nikalje AG have developed simple, accurate, and precise UV spectroscopic methods for 
the simultaneous estimation of atenolol and indapamide in their combined dosage form. 
First method employs formation and solving of simultaneous equation using 246.4 nm 
and 266 nm as 2 wavelengths for formation of simultaneous equations. The second 
method being dual wavelength method, in which 2 wavelengths were selected for each 
drug, so that the difference in absorbance is zero for another drug.  Atenolol has equal 
absorbance at 246.4 nm and 254.2 nm, where the differences in absorbance were 
measured for the determination of indapamide; similarly differences in absorbance at 266 
nm and 270.2 nm were measured for the determination of atenolol. These methods obey 
Beer's law in the concentration range 100 to 350 and 5 to 17.5 µg/ml for atenolol and 
indapamide, respectively[25].    
 
2.4.4 Elshanawane AA, Mostafa SM and Elgawish, MS have developed a new 
sensitive, simple, rapid and precise RP-LC method with hydrochlorothiazide as internal 
standard has been developed for resolving two binary mixtures, perindopril with 
indapamide and captopril with indapamide, in pharmaceutical formulations. The drugs 
were separated at room temperature on a 250 mm × 4.6 mm, 5µm particle, cyanopropyl 
column with 10 mM KH2PO4, methanol (55:45 v/v, pH 6.0) as mobile phase at a flow 
rate of 1 ml/min.  Detection was at 210 nm. Factors affecting the separation process were 
studied and optimized. The method was successfully applied to the determination of the 
two binary combinations in synthetic mixtures and pharmaceutical products[26].    
 
2.4.5 Nadia FY has developed a sensitive spectrophotometric, spectrofluorimetric and 
densitometric method for the determination of indapamide. The first and second methods 
are based on the oxidative coupling reaction of indapamide with 3-methyl-2-
benzothiazolinone hydrazone HCl in the presence of cerium ammonium sulfate in an 
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acidic medium. The absorbance of the reaction product is measured at the 601 nm. With 
the same reaction, indapamide is determined by its quenching effect on the fluorescence 
of excess cerous ions at the emission 350 nm, and the excitation at 300 nm. The third 
method, a stability-indicating densitometric assay, was developed for the determination of 
indapamide, using toluene-ethyl acetate-glacial acetic acid (69:30:1, v/v/v) as the 
developing system and scanning at the λmax 242 nm, in the presence of the degradation 
product and related substance. The proposed methods were successfully applied to the 
determination of indapamide in bulk powder and commercial tablets[27]. 
 
2.5 Literature review for nifedipine 
2.5.1 Beaulieu N, Curran NM, Graham SJ, Sears RW and Lovering EG have 
modified USP HPLC method for related compounds in nifedipine to improve resolution 
and sensitivity. The modified method uses a Novopak C18 column with a mobile phase 
consisting of 48% MeOH in water. This method was validated for the determination of 
drug and related compounds in bulk.  It resolved at least 7 known related compounds 
from the drug, with quantitation limits ranging from 0.01 to 0.10%. Total impurities in 15 
samples of drug raw material were between 0.02 and 0.85%. The drug content of these 
samples ranged between 97.9 and 102.0 %[28].    
 
2.5.2 Chang J, Deng S and Wang H have developed a HPLC method for 
determination of atenolol and nifedipine in tablets was established with a Kromasil C18 
column (4.6 × 150 mm), the mobile phase of methanol-water- phosphate buffer solution 
(pH 3.0, 55:42:3, containing 6.0 mmol/L sodium octanesulfonate), the flow rate of 0.8 
ml/min and the detection wavelength of 274 nm. The calibration curves of atenolol and 
nifedipine were linear in concentration range of 20-80 µg/ml and 8-32 µg/ml, 
respectively. The average recoveries were 100.2% (RSD 0.45%) and 100.4% (RSD 
0.77%), respectively[29].    
 
2.5.3 Erram SV and Tipnis HP have developed a simple, accurate, fast and precise 
reversed phase RP- HPLC method was developed for the determination of atenolol and 
nifedipine in single and combined dosage forms. A spherisorb ODS surface column was 
used with a mobile phase of MeOH- 0.1M Na2HPO4 (75:25 v/v), pH adjusted to 3 with 
acetic acid and detection at 238 nm.  Sample as low as 16 ng/ml of nifedipine and 100 
ng/ml atenolol were detected. The method was applied to component available 
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formulations and for in vitro analysis, using external standard method at ambient 
temperature[30].    
 
2.5.4 Abou-Auda HS, Najjar TA, Al-Hadiya BM, Ghilzai NM and Al-Fawzan NF 
have developed a highly sensitive, selective and reproducible reversed-phase high-
performance liquid chromatographic method for the determination of nifedipine in human 
plasma. The method is sensitive to 3 ng/ml in plasma, with acceptable within and between 
day reproducibility and linearity over a concentration range from 10-200 ng/ml. Acidified 
plasma samples were extracted using diethyl ether containing diazepam as internal 
standard and chromatographic separation was accomplished on C18 column using a 
mobile phase consisting of acetonitrile, methanol and water (35:17:48, v/v). The within-
day precision ranged from 2.22 to 4.64% and accuracy ranged from 102.4-106.4%. The 
day-to-day precision ranged from 2.34-7.07% and accuracy from 95.1-100.1%. The 
relative recoveries of nifedipine from plasma ranged from 91.0-107.3% whereas 
extraction recoveries were 88.6-93.3%. The method is sensitive and reliable for 
pharmacokinetic studies and therapeutic drug monitoring of nifedipine in humans after 
the oral administration of immediate-release capsules and sustained-release tablets to five 
healthy subjects[31].    
 
2.5.5 Milenovic DM, Lazic ML, Veljkovic VB and Todorovic ZB have developed a 
simple and convenient HPLC method for the analysis of nifedipine residue on the 
stainless-steel surface of equipment used in drug manufacture. Cotton swabs moistened 
with methanol were used to remove residues of the drug from the surfaces; recoveries 
were 82.26, 86.88 and 88.95 % for 25, 125 and 250 µg per swab. The method was 
validated over the concentration range 3-50 µg/ml. small quantity of residues of the drug 
and its impurities were determined by HPLC on an ODS column with methanol-water-
phosphate buffer –sodium heptanes sulphonate (65:35:3:0.13, v/v/v/w) as mobile phase at 
a flow rate of 0.8 ml/min. Detection was at 235 nm[32]. 
 
2.6 Literature review for lercanidipine hydrochloride  
(Given in part-A section-1) 
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3. Aim of Present Work 
 Many dosage forms of ATE, HYD, AML, IND, NIF and LER as a single or as 
combination with others are available on the local market for effective therapy. Literature 
survey reveals that a variety of analytical methods such as spectrophotometry, 
Spectrofluorimetry, HPLC, LC-MS and HPTLC have been reported for the determination 
of ATE, HYD, AML, IND, NIF and LER in pharmaceutical dosage forms.  
 The present investigation describes the development and validation of RP-UPLC 
method for the assay of HYD, AML, IND, NIF and LER in combination with ATE in 
tablets by use of single isocratic mobile phase. Atenolol an aryloxypropanolamine blocker 
is one of the most used, showing longer half-life and minor of side effects than other 
members of its class of drugs.  
 Chromatographic parameters (such as, mobile phase, analytical column, flow rate, 
run time etc.) used in reported methods are different for each dosage forms. Hence, the 
aim was to develop a rapid, simple, sensitive, selective and reliable LC method which can 
estimate the six drugs simultaneously. The total run time was less than 4 min within 
which six drugs were separated. With the developed method, only one mobile phase is 
sufficient for quantification of all mentioned drugs either in combination or in single 
dosage forms as per availability of formulation. It is superior to previously described 
methods. 
 Many pharmaceutical industries manufacture their formulation of all mentioned 
drugs either in combination or in single dosage form. Most of the pharmaceutical 
industries use time consuming method and different mobile phases for different dosage 
form of drugs. But with the proposed method developed, time and cost required for 
changing different mobile phases could be saved, because only one mobile phase can be 
used for six drugs and their combinations.  
 Ultra performance liquid chromatography (UPLC), which utilizes solid phase 
particles of 1.7 µm diameter, makes it possible to perform very high resolution 
separations in a short period of time with little solvent consumption[33, 34]. 
 
The aim and scope of the proposed work are as under 
 To develop a rapid, simple and reliable UPLC assay method for simultaneous 
determination of atenolol, hydrochlorothiazide, amlodipine besylate, indapamide, 
nifedipine and lercanidipine hydrochloride of which atenolol is administered with 
anyone of the other five drugs in combined hypertension therapy.  
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 Perform the validation for the developed method. 
 The developed method is suitable for the routine analysis in quality control 
laboratories. 
 
4. Experimental 
4.1 Materials 
 All active Pharmaceutical ingredients were obtained from Hetero drugs Ltd. 
Hyderabad, India and Emcure Pharmaceuticals Ltd. Pune, India (99.80 - 99.95 % purity). 
Tablet dosage form (ATEN-H, AMLOPRESS-AT, ATEN-D, NILOL and LOTENSYL-
AT) was purchased from local market. HPLC-grade Potassium dihydrogen phosphate and 
acetonitrile were obtained from Finar Chemicals (Ahmedabad, India). HPLC grade 
orthophosphoric acid (88 %) was from Spectrochem (Mumbai, India). Distilled water was 
prepared using a Milli-Q system, Millipore (Milford, MA, USA). Nylon syringe filters 
(0.22 µm) were from Millipore (Mumbai, India). 
 
4.2 Instrumentation 
 The chromatographic separation was carried out using a Waters UPLC Acquity 
system (Waters, Milford, MA, USA), consisted of a Binary solvent manager, a sample 
manager, column oven and a PDA detector. The output signal was monitored and processed 
by Empower software. A Sartorius CPA2P analytical micro-balance (Gottingen, Germany), 
an ultra sonic cleaner SONICA from Spincotech Pvt. Ltd. (Mumbai, India) and pH meter 
LI 610 ELICO (Mumbai, India) were also used. 
 
4.3 Mobile phase preparation 
 The mobile phase was consisted of 0.01 M potassium dihydrogen phosphate and 
acetonitrile (50:50, v/v). Mobile phase was filtered through a 0.22 µm membrane filter 
before use and degassed in an ultrasonic bath (Spincotech Pvt. Ltd., Mumbai). 
 
4.4 Diluent preparation 
 Water and acetonitrile (50:50, v/v) used as a diluent. 
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4.5 Preparation of standard solutions 
4.5.1 Stock and Working Standard Solution for ATE and HYD: 
Accurately weighed ATE (50 mg) and HYD (25 mg) were transferred to 100 ml 
volumetric flask, dissolved and diluted to the mark with mobile phase to obtain a standard 
stock solution of ATE (500 µg/ml) and HYD (250 µg/ml). An aliquot of the stock solution 
(1 ml) was transferred to a 10 ml volumetric flask and diluted to the mark with mobile 
phase to obtain a mixed working standard solution of ATE (50 µg/ml) and HYD (25 
µg/ml).  
 
4.5.2 Stock and Working Standard Solution for ATE and AML: 
Accurately weighed ATE (25 mg) and AML (5 mg) were transferred to 100 ml 
volumetric flask, dissolved and diluted to the mark with mobile phase to obtain a standard 
stock solution of ATE (250 µg/ml) and AML (50 µg/ml). An aliquot of the stock solution 
(1 ml) was transferred to a 10 ml volumetric flask and diluted to the mark with mobile 
phase to obtain a mixed working standard solution of ATE (25 µg/ml) and AML (5 µg/ml).  
 
4.5.3 Stock and Working Standard Solution for ATE and IND: 
Accurately weighed ATE (50 mg) and IND (2.5 mg) were transferred to 100 ml 
volumetric flask, dissolved and diluted to the mark with mobile phase to obtain a standard 
stock solution of ATE (500 µg/ml) and IND (25 µg/ml). An aliquot of the stock solution (1 
ml) was transferred to a 10 ml volumetric flask and diluted to the mark with mobile phase 
to obtain a mixed working standard solution of ATE (50 µg/ml) and IND (2.5 µg/ml).  
 
4.5.4 Stock and Working Standard Solution for ATE and NIF: 
Accurately weighed ATE (50 mg) and NIF (20 mg) were transferred to 100 ml 
volumetric flask, dissolved and diluted to the mark with mobile phase to obtain a standard 
stock solution of ATE (500 µg/ml) and NIF (200 µg/ml). An aliquot of the stock solution (1 
ml) was transferred to a 10 ml volumetric flask and diluted to the mark with mobile phase 
to obtain a mixed working standard solution of ATE (50 µg/ml) and NIF (20 µg/ml).  
 
4.5.5 Stock and Working Standard Solution for ATE and LER: 
Accurately weighed ATE (50 mg) and LER (10 mg) were transferred to 100 ml 
volumetric flask, dissolved and diluted to the mark with mobile phase to obtain a standard 
stock solution of ATE (500 µg/ml) and LER (100 µg/ml). An aliquot of the stock solution 
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(1 ml) was transferred to a 10 ml volumetric flask and diluted to the mark with mobile 
phase to obtain a mixed working standard solution of ATE (50 µg/ml) and LER (10 µg/ml).  
 
4.6 Preparation of sample solutions 
4.6.1 ATE and HYD (Brand Name: ATEN-H) 
Powder of 20 tablets, each containing 50 mg ATE and 25 mg HYD, were weighed 
and analysed: An amount of powder equivalent to one tablet was weighed accurately, 
mixed with mobile phase in a 100 ml volumetric flask, sonicated for approximately 10 min, 
cooled to room temperature and diluted to volume with same solvent. The solution was 
filtered using a nylon 0.22 µm membrane filter to remove any insoluble matter. An aliquot 
(1 ml) of the sample stock solution was transferred to a 10 ml volumetric flask and diluted 
to the mark with mobile phase to obtain a working sample solution of ATE (50 µg/ml) and 
HYD (25 µg/ml). 
 
4.6.2 ATE and AML (Brand Name: AMLOPRES-AT) 
Powder of 20 tablets, each containing 25 mg ATE and 5 mg AML, were weighed 
and analysed: An amount of powder equivalent to one tablet was weighed accurately, 
mixed with mobile phase in a 100 ml volumetric flask, sonicated for approximately 10 min, 
cooled to room temperature and diluted to volume with same solvent. The solution was 
filtered using a nylon 0.22 µm membrane filter to remove any insoluble matter. An aliquot 
(1 ml) of the sample stock solution was transferred to a 10 ml volumetric flask and diluted 
to the mark with mobile phase to obtain a working sample solution of ATE (25 µg/ml) and 
AML (5 µg/ml). 
 
4.6.3 ATE and IND (Brand Name: ATEN-D) 
Powder of 20 tablets, each containing 50 mg ATE and 2.5 mg IND, were weighed 
and analysed: An amount of powder equivalent to one tablet was weighed accurately, 
mixed with mobile phase in a 100 ml volumetric flask, sonicated for approximately 10 min, 
cooled to room temperature and diluted to volume with same solvent. The solution was 
filtered using a nylon 0.22 µm membrane filter to remove any insoluble matter. An aliquot 
(1 ml) of the sample stock solution was transferred to a 10 ml volumetric flask and diluted 
to the mark with mobile phase to obtain a working sample solution of ATE (50 µg/ml) and 
IND (2.5 µg/ml). 
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4.6.4 ATE and NIF (Brand Name: NILOL) 
Powder of 20 tablets, each containing 50 mg ATE and 20 mg NIF, were weighed 
and analysed: An amount of powder equivalent to one tablet was weighed accurately, 
mixed with mobile phase in a 100 ml volumetric flask, sonicated for approximately 10 min, 
cooled to room temperature and diluted to volume with same solvent. The solution was 
filtered using a nylon 0.22 µm membrane filter to remove any insoluble matter. An aliquot 
(1 ml) of the sample stock solution was transferred to a 10 ml volumetric flask and diluted 
to the mark with mobile phase to obtain a working sample solution of ATE (50 µg/ml) and 
NIF (20 µg/ml). 
 
4.6.5 ATE and LER (Brand Name: LOTENSYL-AT) 
Powder of 20 tablets, each containing 50 mg ATE and 10 mg LER, were weighed 
and analysed: An amount of powder equivalent to one tablet was weighed accurately, 
mixed with mobile phase in a 100 ml volumetric flask, sonicated for approximately 10 min, 
cooled to room temperature and diluted to volume with same solvent. The solution was 
filtered using a nylon 0.22 µm membrane filter to remove any insoluble matter. An aliquot 
(1 ml) of the sample stock solution was transferred to a 10 ml volumetric flask and diluted 
to the mark with mobile phase to obtain a working sample solution of ATE (50 µg/ml) and 
LER (10 µg/ml). 
 
4.7 Chromatographic conditions 
 Waters Acquity UPLC BEH C18 column (2.1 × 50 mm i.d., 1.7 µm particle size; 
Waters) was used as a stationary phase. The isocratic mobile phase consisted of buffer 
(0.01 M potassium dihydrogen phosphate, pH 4.0 adjusted with ortho-phosphoric acid) 
and acetonitrile in the ratio of (50:50, v/v) was used throughout the analysis. The flow 
rate of mobile phase was 0.35 ml/min and the detection was monitored at a wavelength of 
230 nm. The mobile phase was filtered through a nylon 0.22 µm membrane filter and was 
degassed before use. The column temperature was kept 25°C and injection volume was 5 
µl. 
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5. Results and Discussion 
 
5.1 Development and Optimization of the UPLC Method 
For successful method validation, preliminary tests were performed with the 
objective to select adequate and optimum condition. Parameters, such as choice of 
analytical column, pH of buffer, mobile phase composition and proportion, detection 
wavelength and other factors were exhaustively studied. Various reversed columns and 
isocratic mobile phase system were tried. When experiments were performed with 
methanol instead of acetonitrile as the organic modifier in the mobile phase, late elution 
of analyte with peak tailing and high column pressure were observed. Hence, the 
experiments were carried out with acetonitrile as an organic modifier. 
 
Development trial-1: 
 When chromatography was carried out at room temperature on a 250 × 4.6 mm 
i.d., 5µm Phenomenex Gemini C18 column with the isocratic mobile phase of acetonitrile 
and 0.1% orthophosphoric acid buffer (50:50 v/v) at a flow rate of 1.0 ml/min, but poor 
resolution between hydrochlorothiazide and amlodipine were observed (Figure 5).  
Development trial-2: 
 When chromatography was carried out at ambient temperature on a 250 × 4.6 mm 
i.d., 5µm Phenomenex Gemini C18 column with the isocratic mobile phase of acetonitrile 
and 0.01 M potassium dihydrogen phosphate (50:50 v/v, pH 3.5) at a flow rate of 1.0 
ml/min, late elution and poor resolution between amlodipine and indapamide were found 
(Figure 6). Both the trials were done on HPLC. 
Development trial-3: 
 When chromatography was carried out at ambient temperature on a 250 × 4.6 mm 
i.d., 5µm Phenomenex Gemini C18 column with the isocratic mobile phase of acetonitrile 
and 0.01 M potassium dihydrogen phosphate (50:50 v/v, pH 4.0) at a flow rate of 1.0 
ml/min, a satisfactory separation of the six drugs was achieved with good resolution and 
minimal tailing (Figure 7). 
HPLC System used for above development trails: 
 HPLC system (Waters 2489, Milford, USA) consisting of quaternary gradient 
pump (TM 600), rheodyne manual injector with 20 µl loop, column oven and UV 
detector was employed for analysis. Chromatographic data was acquired using Empower 
software. 
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Method transfer on UPLC: 
 But our aim was to develop a rapid, sensitive, simple and reliable UPLC method 
which can estimate the six components in less than five minutes. Hence, the above 
method was transferred on UPLC system using column selection chart and calculator. A 
satisfactory separation of the six drugs was achieved on a Acquity BEH C18 column with 
a mobile phase of 0.1 % ortho-phosphoric acid and acetonitrile (50:50 v/v, pH 4.0) at a 
flow rate of 0.35 ml/min. Quantification was achieved with PDA detection at 230 nm 
based on the peak area. Better resolution of the peaks with clear base line separation was 
found. Figure 8 represent the chromatograms of standard preparation.  
 
 
Figure 5: Chromatogram of standard preparation  
(Mobile phase: Acetonitrile: 0.1 % orthophosphoric acid (50:50, v/v) 
 
 
Figure 6: Chromatogram of standard preparation  
(Mobile phase: Acetonitrile: 0.01M potassium dihydrogen phosphate 
 (50:50 v/v, pH 3.5) 
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Figure 7: Chromatogram of standard preparation  
(Mobile phase: Acetonitrile: 0.01M potassium dihydrogen phosphate 
 (50:50 v/v, pH 4.0) 
 
Figure 8: Chromatogram of standard preparation (10 µg/ml of each drug) 
 
5.2  Method Validation 
5.2.1 Specificity 
The specificity of the RP-UPLC method was checked by comparison of 
chromatograms obtained from standard, sample and the corresponding placebo. The peak 
purity of the atenolol, hydrochlorothiazide, amlodipine, indapamide, nifedipine and 
lercanidipine were found satisfactory. Additives in tablets are practically insoluble in 
diluents or the mobile phase whereas the active constituents are freely soluble. No 
interference from additives of the capsules was obtained. 
 
5.2.2 Linearity 
The linearity of the method was determined at five concentration levels ranging 
from 1-20 µg/ml for each drug. The calibration curves were constructed by plotting peak 
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areas versus concentrations of ATE, HYD, AML, IND, NIF and LER, and the regression 
equations were calculated. Each response was the average of three determinations. 
 The response of the drug was found to be linear in the investigation concentration 
range and the linear regression equation for atenolol was y = 24006.88x – 1308.60 with 
correlation coefficient 0.9998 (Figure 9), for hydrochlorothiazide was y = 54414.49x – 
701.04 with correlation coefficient 1.0000 (Figure 10), for amlodipine besylate was y = 
23781.44x - 2244.88 with correlation coefficient 1.0000 (Figure 11). For indapamide was 
y = 37338.43x - 1428.75 with correlation coefficient 1.0000 (Figure 12), for nifedipine 
was y = 46210.16x - 10017.01 with correlation coefficient 0.9998 (Figure 13), for 
lercanidipine was y = 28282.08x - 4219.38 with correlation coefficient 1.0000 (Figure 
14), Where x is the concentration in µg/ml and y is the peak area in absorbance unit. 
Chromatogram obtain during linearity study were shown in Figure 15-19. 
 
 
Figure 9: Linearity curve for atenolol 
 
 
 
Figure 10: Linearity curve for hydrochlorothiazide 
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Figure 11: Linearity curve for amlodipine besylate 
 
 
 
 
Figure 12: Linearity curve for indapamide 
 
 
 
 
Figure 13: Linearity curve for nifedipine 
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Figure 14: Linearity curve for lercanidipine hydrochloride 
 
 
 
Figure 15: Linearity study chromatogram of level-1 (10%) 
 
 
 
Figure16: Linearity study chromatogram of level-2 (50%) 
 
 
y = 28282.08x - 4219.38
R² = 1.0000
0
1
2
3
4
5
6
0 5 10 15 20 25
Pe
ak
 a
re
a 
×
10
5
Concentration (µg/ml)
Linearity study of lercanidipine
A
TE
H
Y
D
A
M
L
IN
D N
IF
LE
R
AU
0.000
0.005
0.010
0.015
0.020
0.025
0.030
Minutes
0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00
A
TE
H
Y
D
A
M
L
IN
D N
IF
LE
R
AU
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
Minutes
0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00
Antihypertensive drugs…                                                                        Part-B (Section-2) 
 
   197 
 
 
Figure17: Linearity study chromatogram of level-3 (100%) 
 
 
 
 
Figure 18: Linearity study chromatogram of level-4 (150%) 
 
 
 
 
Figure 19: Linearity study chromatogram of level-5 (200%) 
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5.2.3 LOD and LOQ 
The limit of detection (LOD) and limit of quantitation (LOQ) were estimated at a 
signal-to-noise ratio of 3:1 and 10:1 by injecting a series of dilute solutions with known 
concentration. The LODs for atenolol, hydrochlorothiazide, amlodipine, indapamide, 
nifedipine and lercanidipine were found to be 0.04, 0.02, 0.03, 0.03, 0.02 and 0.01µg/ml, 
while LOQs were 0.13, 0.06, 0.11, 0.10, 0.05 and 0.04 µg/ml; respectively. 
Chromatogram of LOD and LOQ study were shown in Figure 20-31.  
 
 
Figure 20: Chromatogram of LOD study of atenolol 
 
 
 
 
Figure 21: Chromatogram of LOQ study of atenolol 
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Figure 22: Chromatogram of LOD study of hydrochlorothiazide 
 
 
 
Figure 23: Chromatogram of LOQ study of hydrochlorothiazide 
 
 
 
Figure 24: Chromatogram of LOD study of amlodipine 
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Figure 25: Chromatogram of LOQ study of amlodipine 
 
 
 
Figure 26: Chromatogram of LOD study of indapamide 
 
 
 
Figure 27: Chromatogram of LOQ study of indapamide 
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Figure 28: Chromatogram of LOD study of nifedipine 
 
 
 
Figure 29: Chromatogram of LOQ study of nifedipine 
 
 
 
 
Figure 30: Chromatogram of LOD study of lercanidipine 
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Figure 31: Chromatogram of LOQ study of lercanidipine 
 
 
5.2.4 Precision study 
 For, (A) Atenolol + Hydrochlorothiazide 
 (B) Atenolol + Amlodipine 
 (C) Atenolol + Indapamide 
 (D) Atenolol + Nifedipine 
 (E) Atenolol + Lercanidipine 
 Instrumental precision was determined by six replicate determinations of standard 
solution and the relative standard deviations were calculated. 
 Method precision of the analytical method was determined by analyzing five sets 
of sample preparation. Assay of all six replicate sample preparations was determined and 
mean % assay value, standard deviation and % relative standard deviation were 
calculated. 
 
(A) Precision study for atenolol and hydrochlorothiazide 
 
 Product Information:  
Name  : Atenolol and Hydrochlorothiazide tablet  
 (Brand Name: ATEN-H) 
 Label claim : 50 mg for atenolol; 25 mg for hydrochlorothiazide 
 
For method precision, blank, standard preparation and five sets of test preparations was 
prepared as per method as under: 
Blank preparation: Diluent was used as a blank 
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Standard preparation: 
Accurately weighed ATE (50 mg) and HYD (25 mg) were transferred to 100 ml volumetric 
flask, dissolved and diluted to the mark with mobile phase to obtain a standard stock 
solution of ATE (500 µg/ml) and HYD (250 µg/ml). An aliquot of the stock solution (1 ml) 
was transferred to a 10 ml volumetric flask and diluted to the mark with mobile phase to 
obtain a mixed working standard solution of ATE (50 µg/ml) and HYD (25 µg/ml). The 
solution was filtered through 0.22 µm membrane filter and 5 µl was injected. 
 
Test preparation (Set 1): 
Powder of 20 tablets, each containing 50 mg ATE and 25 mg HYD, were weighed and 
analysed: An amount of powder equivalent to one tablet was weighed accurately, mixed 
with mobile phase in a 100 ml volumetric flask, sonicated for approximately 10 min, cooled 
to room temperature and diluted to volume with same solvent. The solution was filtered 
using a nylon 0.22 µm membrane filter to remove any insoluble matter. An aliquot (1 ml) 
of the sample stock solution was transferred to a 10 ml volumetric flask and diluted to the 
mark with mobile phase to obtain a working sample solution of ATE (50 µg/ml) and HYD 
(25 µg/ml). 
 
Average weight of tablets: 
Average weight of tablets was performed on 20 tablets. 20 tablets are randomly selected 
and weighed (3390.8 mg) for the same. The average weight (169.54 mg) is calculated 
 
Table 1: Summary of method precision study 
Analyte Set No. 
Assay 
(%) 
Mean 
assay 
(%) 
Stdev  RSD (%) 
95 % 
Confidence 
Interval 
Atenolol 
1 97.94 
98.46 0.518 0.53 0.56 
2 98.08 
3 99.26 
4 98.56 
5 98.46 
Hydrochlorothiazide 
1 100.72
101.43 0.477 0.47 0.49 
2 101.69
3 102.01
4 101.35
5 101.39
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Figure 32: Chromatogram of standard preparation 
 
(B)  Precision study for atenolol and amlodipine 
 
 Product Information:  
 Name  : Atenolol and Amlodipine tablet  
    (Brand Name: AMLOPRES-AT) 
 Label claim : 25 mg for atenolol; 5 mg for amlodipine 
 
For method precision, blank, standard preparation and five sets of test preparations was 
prepared as per method as under: 
 
Blank preparation: Diluent was used as a blank 
 
Standard preparation: 
Accurately weighed ATE (25 mg) and AML (5 mg) were transferred to 100 mL volumetric 
flask, dissolved and diluted to the mark with mobile phase to obtain a standard stock 
solution of ATE (250 µg/mL) and AML (50 µg/mL). An aliquot of the stock solution (1 
mL) was transferred to a 10 mL volumetric flask and diluted to the mark with mobile phase 
to obtain a mixed working standard solution of ATE (25 µg/mL) and AML (5 µg/mL).  The 
solution was filtered through 0.22 µm membrane filter and 5 µl was injected. 
 
Test preparation (Set 1): 
Powder of 20 tablets, each containing 25 mg ATE and 5 mg AML, were weighed and 
analysed: An amount of powder equivalent to one tablet was weighed accurately, mixed 
with mobile phase in a 100 mL volumetric flask, sonicated for approximately 10 min, 
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cooled to room temperature and diluted to volume with same solvent. The solution was 
filtered using a nylon 0.22 µm membrane filter to remove any insoluble matter. An aliquot 
(1 mL) of the sample stock solution was transferred to a 10 mL volumetric flask and diluted 
to the mark with mobile phase to obtain a working sample solution of ATE (25 µg/mL) and 
AML (5 µg/mL). 
 
Average weight of tablets: 
Average weight of tablets was performed on 20 tablets. 20 tablets are randomly selected 
and weighed (4365.0 mg) for the same. The average weight (218.25 mg) is calculated. 
 
Table 2: Summary of method precision study 
 
Analyte Set No. Assay (%) 
Mean 
assay 
(%) 
Stdev  RSD (%) 
95 % 
Confidence 
Interval 
Atenolol 
1 101.62 
101.51 0.484 0.48 0.51 
2 100.81 
3 101.30 
4 101.70 
5 102.11 
Amlodipine 
1 100.90 
101.15 0.400 0.40 0.42 
2 101.21 
3 101.12 
4 100.73 
5 101.78 
 
 
Figure 33: Chromatogram of standard preparation 
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(C)  Precision study for atenolol and indapamide 
 
 Product Information:  
 Name  : Atenolol and Indapamide tablet (Brand Name: ATEN-D) 
 Label claim : 50 mg for atenolol; 2.5 mg for indapamide 
 
For method precision, blank, standard preparation and five sets of test preparations was 
prepared as per method as under: 
 
Blank preparation: Diluent was used as a blank 
 
Standard preparation: 
Accurately weighed ATE (50 mg) and IND (2.5 mg) were transferred to 100 mL 
volumetric flask, dissolved and diluted to the mark with mobile phase to obtain a standard 
stock solution of ATE (500 µg/mL) and IND (25 µg/mL). An aliquot of the stock solution 
(1 mL) was transferred to a 10 mL volumetric flask and diluted to the mark with mobile 
phase to obtain a mixed working standard solution of ATE (50 µg/mL) and IND (2.5 
µg/mL). The solution was filtered through 0.22 µm membrane filter and 5 µL was injected. 
 
Test preparation (Set 1): 
Powder of 20 tablets, each containing 50 mg ATE and 2.5 mg IND, were weighed and 
analysed: An amount of powder equivalent to one tablet was weighed accurately, mixed 
with mobile phase in a 100 mL volumetric flask, sonicated for approximately 10 min, 
cooled to room temperature and diluted to volume with same solvent. The solution was 
filtered using a nylon 0.22 µm membrane filter to remove any insoluble matter. An aliquot 
(1 mL) of the sample stock solution was transferred to a 10 mL volumetric flask and diluted 
to the mark with mobile phase to obtain a working sample solution of ATE (50 µg/mL) and 
IND (2.5 µg/mL). 
 
Average weight of tablets: 
Average weight of tablets was performed on 20 tablets. 20 tablets are randomly selected 
and weighed (3770.4 mg) for the same. The average weight (188.52 mg) is calculated. 
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Table 3: Summary of method precision study 
Analyte Set No. 
Assay 
(%) 
Mean 
assay (%) Stdev 
 RSD 
(%) 
95 % 
Confidence 
Interval 
Atenolol 
1 100.24 
100.92 0.518 0.51 0.54 
2 100.90 
3 101.52 
4 100.62 
5 101.31 
Indapamide 
1 100.89 
100.69 0.567 0.56 0.59 
2 100.26 
3 101.37 
4 100.98 
5 99.97 
 
 
Figure 34: Chromatogram of standard preparation 
 
(D)  Precision study for atenolol and nifedipine 
 
 Product Information:  
 Name  : Atenolol and Nifedipine tablet (Brand Name: NILOL) 
 Label claim : 50 mg for atenolol; 20 mg for nifedipine 
 
For method precision, blank, standard preparation and five sets of test preparations was 
prepared as per method as under: 
 
Blank preparation: Diluent was used as a blank 
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Standard preparation: 
Accurately weighed ATE (50 mg) and NIF (20 mg) were transferred to 100 mL volumetric 
flask, dissolved and diluted to the mark with mobile phase to obtain a standard stock 
solution of ATE (500 µg/mL) and NIF (200 µg/mL). An aliquot of the stock solution (1 
mL) was transferred to a 10 mL volumetric flask and diluted to the mark with mobile phase 
to obtain a mixed working standard solution of ATE (50 µg/mL) and NIF (20 µg/mL). The 
solution was filtered through 0.22 µm membrane filter and 5 µL was injected. 
 
Test preparation (Set 1): 
Powder of 20 tablets, each containing 50 mg ATE and 20 mg NIF, were weighed and 
analysed: An amount of powder equivalent to one tablet was weighed accurately, mixed 
with mobile phase in a 100 mL volumetric flask, sonicated for approximately 10 min, 
cooled to room temperature and diluted to volume with same solvent. The solution was 
filtered using a nylon 0.22 µm membrane filter to remove any insoluble matter. An aliquot 
(1 mL) of the sample stock solution was transferred to a 10 mL volumetric flask and diluted 
to the mark with mobile phase to obtain a working sample solution of ATE (50 µg/mL) and 
NIF (20 µg/mL). 
 
Average weight of tablets: 
Average weight of tablets was performed on 20 tablets. 20 tablets are randomly selected 
and weighed (4802.4 mg) for the same. The average weight (240.12 mg) is calculated. 
 
Table 4: Summary of method precision study 
Analyte Set No. Assay (%) 
Mean 
assay (%) Stdev 
 RSD 
(%) 
95 % 
Confidence 
Interval 
Atenolol 
1 100.31 
99.77 0.558 0.56 0.59 
2 99.46 
3 99.96 
4 98.95 
5 100.17 
Nifedipine 
1 100.86 
100.71 0.546 0.54 0.57 
2 100.84 
3 100.83 
4 99.78 
5 101.23 
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Figure 35: Chromatogram of standard preparation 
 
(E)  Precision study for atenolol and lercanidipine 
 
 Product Information:  
 Name  : Atenolol and Lercanidipine tablet  
    (Brand Name: LOTENSYL-AT) 
 Label claim : 50 mg for atenolol; 10 mg for lercanidipine 
 
For method precision, blank, standard preparation and five sets of test preparations was 
prepared as per method as under: 
 
Blank preparation: Diluent was used as a blank 
 
Standard preparation: 
Accurately weighed ATE (50 mg) and LER (10 mg) were transferred to 100 mL volumetric 
flask, dissolved and diluted to the mark with mobile phase to obtain a standard stock 
solution of ATE (500 µg/mL) and LER (100 µg/mL). An aliquot of the stock solution (1 
mL) was transferred to a 10 mL volumetric flask and diluted to the mark with mobile phase 
to obtain a mixed working standard solution of ATE (50 µg/mL) and LER (10 µg/mL). The 
solution was filtered through 0.22 µm membrane filter and 5 µL was injected. 
 
Test preparation (Set 1): 
Powder of 20 tablets, each containing 50 mg ATE and 10 mg LER, were weighed and 
analysed: An amount of powder equivalent to one tablet was weighed accurately, mixed 
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with mobile phase in a 100 mL volumetric flask, sonicated for approximately 10 min, 
cooled to room temperature and diluted to volume with same solvent. The solution was 
filtered using a nylon 0.22 µm membrane filter to remove any insoluble matter. An aliquot 
(1 mL) of the sample stock solution was transferred to a 10 mL volumetric flask and diluted 
to the mark with mobile phase to obtain a working sample solution of ATE (50 µg/mL) and 
LER (10 µg/mL). 
 
Average weight of tablets: 
Average weight of tablets was performed on 20 tablets. 20 tablets are randomly selected 
and weighed (4020.0 mg) for the same. The average weight (201.0 mg) is calculated. 
 
Table 5: Summary of method precision study 
Analyte Set No. Assay (%) 
Mean 
assay (%) Stdev 
 RSD 
(%) 
95 % 
Confidence 
Interval 
Atenolol 
1 99.04 
98.56 0.462 0.47 0.49 
2 98.12 
3 98.56 
4 99.01 
5 98.08 
Lercanidipine 
1 99.50 
99.29 0.354 0.36 0.38 
2 99.09 
3 98.86 
4 99.77 
5 99.25 
 
 
Figure 35: Chromatogram of standard preparation 
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5.2.5 System suitability 
The system suitability tests represent an integral part of the method and are used to 
ensure adequate performance of the chromatographic system. The parameters, retention 
time (tR), theoretical plates (N), peak resolution (R), peak asymmetry (T) and repeatability 
were evaluated using five replicate injections of the drugs at a concentration of (10 µg/ml) 
for each drug. Acceptance criteria for system suitability, asymmetry should not be more 
than 2.0, resolution should not be more than 2.0, theoretical plate should not be less than 
1500 and % RSD of peak area should not be more then 2.0, were full fill during all 
validation parameters. The result of system suitability study of the developed assay 
method was shown in Table 6. 
 
Table: 6 Summary of system suitability parameters (n=5) 
Drug tR ± % RSD R ± % RSD T ± % RSD N ± % RSD Repeatability
ATE 0.67 ± 0.08 ‐‐‐‐‐  1.45 ± 0.14 1565.76 ± 0.26 0.13 
HYD 0.86 ± 0.05 2.13 ± 0.15 1.32 ± 0.19 2100.93± 0.38 0.07 
AML 1.05 ± 0.05 2.25 ± 0.20 1.37 ± 0.11 3000.86 ± 0.17 0.15 
IND 1.32 ± 0.04 2.91 ± 0.07 1.38 ± 0.12 4503.18 ± 0.06 0.06 
NIF 1.77± 0.08 4.50 ± 0.07 1.26 ± 0.15 4749.61 ± 0.20 0.05 
LER 2.82 ± 0.16 7.80 ± 0.15 1.37 ± 0.12 6126.55 ± 0.27 0.17 
 
 tR =  Retention time 
 R = Resolution 
 T = Peak asymmetry factor 
 N = Number of theoretical plates 
 Repeatability = % RSD of peak area for replicate injections 
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6.  Calculations and Data 
 
 Calculation formula used: 
 
1. Calculation formula for atenolol, hydrochlorothiazide, amlodipine, indapamide, 
nifedipine and lercanidipine 
 
% ܣݏݏܽݕ ൌ  ܣܶܣܵ ൈ
ܹ1
100 ൈ
1
10 ൈ
100
ܹ2 ൈ
10
1 ൈ
ܣܹ
ܮܥ ൈ ܲ 
 
 
Whereas,  
 AT = Average area of test preparation 
 AS = Average area of standard preparation 
 W1 = Weight taken of reference standard (mg) 
 W2 = Weight taken of test sample (mg) 
 AW = Average weight of tablets (mg) 
 LC = Label claim (mg) 
 P = Potency of reference standard (%) 
 
2.  Relative standard deviation 
 
% ܴܵܦ ൌ  ܵݐܽ݊݀ܽݎ݀ ݀݁ݒ݅ܽݐ݅݋݊ ݋݂ ݉݁ܽݏݑݎ݁݉݁݊ݐݏܯ݁ܽ݊ ݒ݈ܽݑ݁ ݋݂ ݉݁ܽݏݑݎ݁݉݁݊ݐݏ ൈ 100 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Linearity Study data for atenolol, hydrochlorothiazide, amlodipine, indapamide, nifedipine and 
lercanidipine 
 
Linearity 
level 
%  
Level 
Concentration 
(µg/ml) 
Mean peak area 
ATE HYD AML IND NIF LER 
1 10 1 21880 54732 22235 36672 41796 25181 
2 50 5 122289 270726 116990 184851 216982 136940 
3 100 10 236070 544090 234512 372507 448556 277611 
4 150 15 356595 812290 352984 555885 681057 418496 
5 120 20 480974 1089796 474923 747201 918242 563061 
              
Correlation co-efficient (r2) 0.9998 1.0000 1.0000 1.0000 0.9998 1.0000 
Slope (m) 24006.88 54414.49 23781.44 37338.43 46210.16 28282.08 
Intercept (c) -1308.60 -701.04 -2241.88 -1428.75 -10017.01 -4219.38 
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 Precision study for atenolol and hydrochlorothiazide (Tablet dosage form 1) 
 
 For Atenolol 
 
Observation 
    
Data for standard preparation 
Replicate Area Standard weight 51.02 mg 
1 1243467 Standard potency 99.80% 
2 1242213 Label claim 50 mg 
3 1242990       
4 1243254       
5 1243631       
Average 1243111       
Stdev 556.47       
% RSD 0.04     
Data for test preparation 
Description Mean area Test weight (mg) % Assay 
Set 1 1194991 169.46 97.94 
Set 2 1187175 168.11 98.08 
Set 3 1186416 166.00 99.26 
Set 4 1193090 168.12 98.56 
Set 5 1190119 167.88 98.46 
  
Mean 98.46 
Stdev 0.518 
% RSD 0.53 
 
 
 
 
Calculation: 
Prototype calculation for one set: 
 
% ܣݏݏܽݕ ൌ  11949911243111 ൈ
51.02
100 ൈ
1
10 ൈ
100
169.46 ൈ
10
1 ൈ
169.54
50 ൈ 99.8 
 
           ൌ 97.94 
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 For Hydrochlorothiazide 
 
 
Observation 
    
Data for standard preparation 
Replicate Area Standard weight 24.63 mg 
1 1288216 Standard potency 99.92% 
2 1288060 Label claim 25 mg 
3 1289315       
4 1288204       
5 1288745       
Average 1288508       
Stdev 521.01       
% RSD 0.04     
Data for test preparation 
Description Mean area Test weight (mg) % Assay 
Set 1 1317721 169.46 100.72 
Set 2 1319826 168.11 101.69 
Set 3 1307279 166.00 102.01 
Set 4 1315506 168.12 101.35 
Set 5 1314165 167.88 101.39 
  
Mean 101.43 
Stdev 0.477 
% RSD 0.47 
 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
 
% ܣݏݏܽݕ ൌ  13177211288508 ൈ
24.63
100 ൈ
1
10 ൈ
100
169.46 ൈ
10
1 ൈ
169.54
25 ൈ 99.92 
 
           ൌ 100.72 
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 Precision study for atenolol and amlodipine (Tablet dosage form 2) 
 
 For Atenolol 
 
Observation 
    
Data for standard preparation 
Replicate Area Standard weight 25.09 mg 
1 620282 Standard potency 99.80% 
2 623541 Label claim 25 mg    
3 624071       
4 623542       
5 621823       
Average 622652       
Stdev 1573.22       
% RSD 0.25     
Data for test preparation 
Description Mean area Test weight (mg) % Assay 
Set 1 640051 221.12 101.62 
Set 2 635248 221.23 100.81 
Set 3 633457 219.54 101.30 
Set 4 633128 218.57 101.70 
Set 5 639001 219.71 102.11 
  
Mean 101.51 
Stdev 0.484 
% RSD 0.48 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
 
% ܣݏݏܽݕ ൌ  640051622652 ൈ
25.09
100 ൈ
1
10 ൈ
100
221.12 ൈ
10
1 ൈ
218.25
25 ൈ 99.8 
 
           ൌ 101.62 
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 For Amlodipine 
 
Observation 
    
Data for standard preparation 
Replicate Area Standard weight 5.02 mg 
1 108469 Standard potency 99.95% 
2 108608 Label claim 5 mg    
3 108469       
4 108645       
5 108551       
Average 108548       
Stdev 79.84       
% RSD 0.07     
Data for test preparation 
Description Mean area Test weight (mg) % Assay 
Set 1 110581 221.12 100.90 
Set 2 110972 221.23 101.21 
Set 3 110022 219.54 101.12 
Set 4 109114 218.57 100.73 
Set 5 110828 219.71 101.78 
  
Mean 101.15 
Stdev 0.400 
% RSD 0.40 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
 
% ܣݏݏܽݕ ൌ  110581108548 ൈ
5.02
100 ൈ
1
10 ൈ
100
221.12 ൈ
10
1 ൈ
218.25
5 ൈ 99.95 
 
           ൌ 100.90 
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 Precision study for atenolol and indapamide (Tablet dosage form 3) 
 
 For Atenolol 
 
Observation 
    
Data for standard preparation 
Replicate Area Standard weight 51.12 mg 
1 1254390 Standard potency 99.80% 
2 1253410 Label claim 50 mg 
3 1254420       
4 1255058       
5 1253862       
Average 1254228       
Stdev 623.52       
% RSD 0.05     
Data for test preparation 
Description Mean area Test weight (mg) % Assay 
Set 1 1243844 190.31 100.24 
Set 2 1244990 189.23 100.90 
Set 3 1244627 188.02 101.52 
Set 4 1246968 190.07 100.62 
Set 5 1245245 188.51 101.31 
  
Mean 100.92 
Stdev 0.518 
% RSD 0.51 
 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
 
% ܣݏݏܽݕ ൌ  12438441254228 ൈ
51.12
100 ൈ
1
10 ൈ
100
190.31 ൈ
10
1 ൈ
188.52
50 ൈ 99.8 
 
           ൌ 100.24 
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 For Indapamide 
 
 
Observation 
    
Data for standard preparation 
Replicate Area Standard weight 2.55 mg 
1 95450 Standard potency 99.90% 
2 96105 Label claim 2.5 mg 
3 95672       
4 95238       
5 96007       
Average 95694       
Stdev 365.67       
% RSD 0.38     
Data for test preparation 
Description Mean area Test weight (mg) % Assay 
Set 1 95644 190.31 100.89 
Set 2 94509 189.23 100.26 
Set 3 94941 188.02 101.37 
Set 4 95615 190.07 100.98 
Set 5 93879 188.51 99.97 
  
Mean 100.69 
Stdev 0.567 
% RSD 0.56 
 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
 
% ܣݏݏܽݕ ൌ  9564495694 ൈ
2.55
100 ൈ
1
10 ൈ
100
190.31 ൈ
10
1 ൈ
188.52
2.5 ൈ 99.90 
 
           ൌ 100.89 
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 Precision study for atenolol and nifedipine (Tablet dosage form 4) 
 
 For Atenolol 
 
Observation 
    
Data for standard preparation 
Replicate Area Standard weight 50.75 mg 
1 1242620 Standard potency 99.80% 
2 1244583 Label claim 50 mg 
3 1244521       
4 1243985       
5 1243249       
Average 1243792       
Stdev 845.99       
% RSD 0.07     
Data for test preparation 
Description Mean area Test weight (mg) % Assay 
Set 1 1220759 238.00 100.31 
Set 2 1223227 240.51 99.46 
Set 3 1222325 239.14 99.96 
Set 4 1223576 241.81 98.95 
Set 5 1221773 238.52 100.17 
  
Mean 99.77 
Stdev 0.558 
% RSD 0.56 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
 
% ܣݏݏܽݕ ൌ  12207591243792 ൈ
50.75
100 ൈ
1
10 ൈ
100
238.0 ൈ
10
1 ൈ
240.12
50 ൈ 99.8 
 
           ൌ 100.31 
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 For Nifedipine 
 
Observation 
    
Data for standard preparation 
Replicate Area Standard weight 20.08 mg 
1 849749 Standard potency 99.90% 
2 847529 Label claim 20 mg 
3 848841       
4 845832       
5 847012       
Average 847793       
Stdev 1537.00       
% RSD 0.18     
Data for test preparation 
Description Mean area Test weight (mg) % Assay 
Set 1 845024 238.00 100.86 
Set 2 853707 240.51 100.84 
Set 3 848787 239.14 100.83 
Set 4 849314 241.81 99.78 
Set 5 849940 238.52 101.23 
  
Mean 100.708 
Stdev 0.546 
% RSD 0.54 
 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
 
% ܣݏݏܽݕ ൌ  845024847793 ൈ
20.08
100 ൈ
1
10 ൈ
100
238.0 ൈ
10
1 ൈ
240.12
20 ൈ 99.90 
 
           ൌ 100.86 
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 Precision study for atenolol and lercanidipine (Tablet dosage form 5) 
 
 For Atenolol 
 
Observation 
    
Data for standard preparation 
Replicate Area Standard weight 50.04 mg 
1 1236984 Standard potency 99.80% 
2 1234770 Label claim 50 mg 
3 1235650       
4 1234842       
5 1235201       
Average 1235489       
Stdev 905.46       
% RSD 0.07     
Data for test preparation 
Description Mean area Test weight (mg) % Assay 
Set 1 1219647 200.11 99.04 
Set 2 1214393 201.12 98.12 
Set 3 1220824 201.27 98.56 
Set 4 1218922 200.05 99.01 
Set 5 1216568 201.55 98.08 
  
Mean 98.56 
Stdev 0.462 
% RSD 0.47 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
 
% ܣݏݏܽݕ ൌ  12196471235489 ൈ
50.04
100 ൈ
1
10 ൈ
100
200.11 ൈ
10
1 ൈ
201.0
50 ൈ 99.8 
 
           ൌ 99.04 
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 For Lercanidipine 
 
Observation 
    
Data for standard preparation 
Replicate Area Standard weight  10.04 mg 
1 289288 Standard potency  99.85% 
2 291296 Label claim  10 mg 
3 292254       
4 290546       
5 291529       
Average 290983       
Stdev 1126.45       
% RSD 0.39     
Data for test preparation 
Description Mean area Test weight (mg) % Assay 
Set 1 287528 200.11 99.50 
Set 2 287801 201.12 99.09 
Set 3 287321 201.27 98.86 
Set 4 288218 200.05 99.77 
Set 5 288878 201.55 99.25 
  
Mean 99.29 
Stdev 0.354 
% RSD 0.36 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
 
% ܣݏݏܽݕ ൌ  287528290983 ൈ
10.04
100 ൈ
1
10 ൈ
100
200.11 ൈ
10
1 ൈ
201.0
10 ൈ 99.85 
 
           ൌ 99.50 
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Summary 
 
A comprehensive summary of the work to be incorporated in the thesis entitled 
“Analytical study of pharmaceutical substances: Method development and 
validation study: Few case studies” has been describe as under, 
 
PART [A]: HPLC METHOD DEVELOPMENT AND VALIDATION OF SOME   
PHARMACEUTICAL FORMULATION. 
 
The research work undertaken in these studies mainly addresses analysis, development of 
stability indicating HPLC methods and validation protocol, according to ICH guidelines. 
 
Section-1 Deals with the development and validation of a stability-indicating high 
performance liquid chromatographic method for assay of lercanidipine hydrochloride in 
tablets and for determining content uniformity.  
 
A simple, precise and accurate HPLC method has been developed and validated as 
per ICH guidelines. An isocratic separation was achieved using a Chromasil YMC Pack C8 , 
150×4.6 mm i.d., 5μm particle size columns with a flow rate of 1 ml/min and using a UV 
detector to monitor the elute at 240 nm. The mobile phase consisted of 0.02 M ammonium 
dihydrogen phosphate buffer: methanol (35:65, v/v) with pH 3.5 adjusted with phosphoric 
acid. The method was validated for specificity, linearity, limit of detection, limit of 
quantitation, precision, accuracy, robustness and solution stability. The specificity of the 
method was determined by assessing interference from the placebo and by stress testing of 
the drug (forced degradation). The method was linear over the concentration range of 20-80 
μg/ml (r2 = 0.9992) with a limit of detection and quantitation of 0.1 and 0.3 μg/ml 
respectively. Intraday and interday system and method precision were determined and 
accuracy was between 99.3-101.9 %. The method was found to be robust and suitable for 
assay of lercanidipine hydrochloride in a tablet formulation and for determination of content 
uniformity. Degradation products resulting from the stress studies did not interfere with the 
detection of lercanidipine hydrochloride and the assay is thus stability-indicating. Hence, the 
method is useful for routine quality control analysis and also for determination of stability. 
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Section-2 Deals with the stability-indicating high performance liquid chromatographic 
assay for the simultaneous determination of atenolol and lercanidipine hydrochloride in 
tablets. 
 
The chromatographic separation was achieved on phenomenex Gemini C18 
(250×4.6mm, 5 μm) column using a mobile phase consisting of acetonitrile and buffer (20 
mM potassium dihydrogen phosphate pH 3.5) in the ratio of (55:45, v/v) at a flow rate of 1.0 
ml/min and UV detection at 235 nm. The linearity of the proposed method was investigated 
in the range of 40-160 μg/ml (r2 = 0.9995) for atenolol and 8-32 μg/ml (r2 = 0.9993) for 
lercanidipine. Degradation products produced as a result of stress studies did not interfere 
with the detection of atenolol and lercanidipine and the assay can thus be considered stability-
indicating. 
 
The developed procedure has been evaluated for the specificity, linearity, 
accuracy, precision, limit of detection, limit of quantification and robustness in order to 
ascertain the stability of the analytical method. It has been proved that it was specific, 
linear, precise, accurate and robust and stability indicating. Hence, the method is useful 
for routine quality control analysis and also for determination of stability.   
 
PART [B]: UPLC METHOD DEVELOPMENT AND VALIDATION OF SOME   
PHARMACEUTICAL FORMULATION. 
 
To develop a rapid, simple and reliable ultra performance liquid chromatographic method 
for the estimation of some active pharmaceutical ingredients from their single and 
combine pharmaceutical dosage forms by UPLC and to perform the validation procedure 
for same. 
 
Section-1 Deals with the simultaneous estimation of aspirin (ASP), clopidogrel bisulphate 
(CLP) and atorvastatin calcium (ATV) from capsule dosage form. Chromatography was 
carried out at 25°C on a 50 × 2.1 mm i.d., 1.7 µm Acquity BEH C18 column with isocratic 
mobile phase 0.1% orthophosphoric acid and acetonitrile (55:45, v/v) at a flow rate of 0.35 
mL/min. The detection was carried out at 230 nm. The retention times were about 0.59, 
1.04 and 2.89 min for ASP, CLP and ATV, respectively. The total runtime was less than 4 
min. The method was validated according to ICH guidelines and the acceptance criteria for 
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accuracy, precision, linearity, specificity and system suitability were met in all cases. The 
method was linear in the range of 12-48 µg/mL for ASP, 12-48 µg/mL for CLP and 3.2-
12.8 µg/mL for ATV. Limit of detection obtained were 0.03 µg/mL for ASP, 0.06 µg/mL 
for CLP and 0.07 µg/mL for ATV. With the developed method, only this mobile phase is 
sufficient for quantification of ASP, CLP and ATV either in combination (i.e., ASP + CLP, 
ASP + ATV, ATV + CLP) or in single dosage form as per availability of formulation for 
many pharmaceutical industries. It can be successfully used for routine analysis of ASP, 
CLP and ATV in combined dosage form without any interference from common excipients 
and impurity. 
 
Section-2 Deals with the RP-UPLC method for the simultaneous estimation of orally 
administered hypertension drugs (atenolol, hydrochlorothiazide, amlodipine besylate, 
indapamide, nifedipine and lercanidipine hydrochloride) of which atenolol is 
administered with anyone of the other five drugs in combined hypertension therapy. 
Chromatography was carried out at 25°C on a 2.1 × 50 mm i.d., 1.7 µm Acquity BEH 
C18 column with the isocratic mobile phase of 0.01 M, 4.0 pH, aqueous phosphate buffer 
and acetonitrile (50: 50, v/v) at a flow rate of 0.35 mL/min. All drugs were separated in 
less than 4 min with good resolution and minimal tailing, without interference of 
excipients. The method was validated according to ICH guidelines and the acceptance 
criteria for accuracy, precision, linearity, specificity and system suitability were met in all 
case. The column effluent was monitored at 230 nm. The detector response was linear in 
the range of 1-20 µg/mL of these drugs. Limit of detection obtained were 0.04 µg/mL for 
atenolol, 0.02 µg/mL for hydrochlorothiazide, 0.03 µg/mL for amlodipine besylate, 0.03 
µg/mL for indapamide, 0.02 µg/mL for nifedipine and 0.01 µg/mL for lercanidipine 
hydrochloride. The suggested method has advantage that all the drugs can be quantified 
alone or in combination with atenolol using single mobile phase. 
 
Many pharmaceutical industries manufacture their formulation of all mentioned drugs 
either in combination or in single dosage form. Most of the pharmaceutical industries use 
time consuming method and different mobile phases for different dosage form of drugs. But 
with the proposed method developed, time and cost required for changing different mobile 
phases could be saved, because only one mobile phase can be used for six drugs and their 
combinations. This makes the method suitable for routine analysis in quality control 
laboratories.  
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Kaila, et al.: RP-HPLC Determination of Lercanidipine Hydrochloride
A simple, precise and accurate HPLC method has been developed and validated for assay of lercanidipine 
hydrochloride in tablets and for determination of content uniformity. An isocratic separation was achieved using a 
Chromasil YMC Pack C
8
 , 150 × 4.6 mm i.d., 5µm particle size columns with a fl ow rate of 1 ml/min and using a UV 
detector to monitor the elute at 240 nm. The mobile phase consisted of 0.02 M ammonium dihydrogen phosphate 
buffer:methanol (35:65, v/v) with pH 3.5 adjusted with phosphoric acid. The method was validated for specifi city, 
linearity, pre cision, accuracy, robustness and solution stability. The specifi city of the method was deter mined by 
assessing interference from the placebo and by stress testing of the drug (forced degradation). The method was 
linear over the concentration range of 20-80 µg/ml (r2 = 0.9992) with a limit of detection and quantitation of 0.1 
and 0.3 µg/ml respectively. Intraday and interday system and method precision were determined and accuracy was 
between 99.3-101.9 %. The method was found to be robust and suitable for assay of lercanidipine hydrochloride 
in a tablet formulation and for determination of content uniformity. Degradation products resulting from the stress 
studies did not interfere with the detection of lercanidipine hydrochloride and the assay is thus stability-indicating.
Key words: Calcium channel blocker, column liquid chromatography, degradation, stability- indicating, lercanidipine 
hydrochloride
Lercanidipine hydrochloride, a calcium-channel 
blocker, which is chemically 2[(3,3-diphenylpropyl)
methylamino]-1 ,1-d imethyle thylmethyl -2 ,6-
dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-
3,5-dicarboxylate (fig. 1). Its molecular formula 
is C36H41N3O6 HCl and molecular weight 648.19. 
Lercan idipine is used for treating angina pectoris and 
hypertension[1].
There are few references to the anal ysis of 
lercanidipine hydrochloride and its impurities 
in pharmaceutical dosage forms[2] and UV 
spectrophotometric determination of lercanidipine 
hydrochloride in bulk and tablet are reported[3]. The 
development and validation of high performance 
liquid chromatographic method for estimation of 
lercanidipine in rabbit serum[4] and determination 
of lercanidipine and its impurities using DryLab 
software also reported[5]. Only one HPLC 
method reported in the literature for the assay 
determination of lercanidipine hydrochloride in bulk 
and pharmaceutical dosage form[6]. There are no 
reports of methods for study of the effect of stress 
on pharmaceutical dosage forms and there is no 
validated HPLC method, which enable both assay and 
determination of content uniformity of lercanidipine 
hydrochloride in pharmaceuticals dosage forms.  
The objective of this work was to de velop a 
stability-indicating liquid chromatographic analytical 
method for assay of lercanidipine hydrochloride and 
for determination of the content uniformity of a 
tablet formula tion. The validation procedure followed 
the guidelines of ICH[7] and USP 30[8]. 
Fig 1: Structure formula of lercanidipine hydrochloride
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Lercanidipine hydrochloride reference standard was 
provided by Glenmark Pharmaceuticals, Ankleshwar, 
India. Tablets of lercanidipine hydrochloride, Lerka 
(10 mg, Piramal HealthCare, Mumbai, India) were 
procured from a local pharmacy. All chemicals used 
were of analytical grade. Methanol and water both 
HPLC grade, were from spectrochem (Mumbai, 
India). Nylon syringe filters 0.45 μm were from 
Millex-HN (Mumbai, India).
Liquid chromatography was performed with Waters 
equip ment with TM 600 quaternary pump, Waters 
2489 UV/Vis detector, Waters 600 controller, Waters 
in-line degasser AF and manual injector with 20 
μl loop. The equipment was connected to a multi-
instrument data-acquisition and data-processing 
system (Empower software). The chromatographic 
separation was performed using a Chromasil YMC 
Pack C8, 5 μm, 150×4.6 mm i.d. column. Separation 
was achieved using a mobile phase consisted of 
0.02 M ammonium dihydrogen phosphate buffer 
pH 3.5-methanol (35:65, v/v) solution at a fl ow rate 
of 1 ml/min. The eluent was monitored using UV 
detection at a wavelength of 240 nm. The column 
was maintained at 30° temperature and injec tion 
volume 20 μl was used. The total runtime was 10 
min. The mobile phase was fi ltered through 0.45 μm 
micron fi lter prior to use.
A stock solution (500 μg/ml) of lercanidipine 
hydrochloride reference standard was pre pared in 
water:methanol (30:70, v/v). To prepare standard 
solution 50 μg/ml for assay 5 ml standard stock 
solution was transferred to 50 ml volumetric fl ask and 
volume was adjusted with water:methanol (30:70, v/v). 
To prepare a stock solution (500 μg/ml) for assay, 20 
tablets were weighed and mixed. An aliquot of powder 
equivalent to the weight of 5 tablets was accurately 
weighed and transferred to 100 ml volumetric flask 
and dissolved in 40 ml of water:methanol (30:70, 
v/v) and the mixture was sonicated for 30 min. The 
contents of the fl ask were then left to return to room 
temperature and volume was adjusted with the same 
solvent mixture. This solution 10 ml was filtered 
through a 0.45 μm nylon syringe fi lter. To prepare test 
solution 50 μg/ml for assay 5 ml test stock solution 
was transferred to 50 ml volumetric fl ask and volume 
was adjusted with water:methanol (30:70, v/v). For 
content uniformity one tablet was taken to prepare test 
solution 50 μg/ml. 
To perform the forced degradation study drug was 
subjected to acidic, alkaline, oxidizing, thermal and 
photolytic conditions[9]. For acidic deg radation the 
drug was heated under reflux with 1 N HCl at 80° 
for 1 h and the mixture was neutralized. For alkaline 
degradation the drug was treated with 0.1 N NaOH 
at room temperature for 100 min and the mixture 
was neutralized. For degradation under oxidizing 
conditions the drug was heated under reflux with 
3% hydrogen peroxide at 80° for 1 h. For thermal 
degrada tion the powdered drug was exposed at 70° 
for 72 h. For photolytic degra dation the powdered 
drug was exposed to sunlight for 72 h. The placebo 
was also subjected to the same stress con ditions to 
determine whether any peaks arose from the declared 
excipients. After completion of the treatments the 
solutions were left to return to room temperature and 
diluted with water:methanol (30:70, v/v) to furnish 50 
μg/ml solutions. Fig. 2 shows the chromatogram of 
untreated drugs in tablet solution. 
In this work an analytical HPLC method for 
assay and determination of content uniformity 
of lercanidipine hydrochloride in a tablet for-
mulation was developed and validated. The basic 
chromatographic conditions were designed to be 
simple and easy to use and reproduce and were 
selected after testing the different conditions that 
affect HPLC analysis, for example column, aqueous 
and organic components of the mobile phase, 
proportion of mobile phase components, detection 
wave length, diluents, concentration of analyte etc. 
The Chromasil YMC Pack C8 column was used 
because of its advantages of high resolving capacity, 
better reproducibility, low-back pressure and low 
tailing. For mobile phase selection, preliminary 
trials using mobile phases of different composition 
containing water adjusted to acid pH by addition of 
orthophosphoric acid and methanol resulted in poor 
peak shape. When water was replaced by ammonium 
Fig 2: Chromatogram of untreated drug in tablet solution
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dihydrogen phosphate buffer adjusted to acid pH by 
addition of orthophosphoric acid better peak shape 
was obtained. The proportion of the mobile phase 
compo nents was optimized to reduce retention 
times and enable good resolution of lercanidipine 
hydrochloride from the degradation products. A 
detection wavelength of 240 nm was selected 
after scanning the standard solution over the range 
190-370 nm by use of the UV spectrophotometer. 
Detection at 240 nm resulted in good response and 
good linearity.
The specificity of the method was determined by 
checking for interference with the drug from placebo 
components. In forced degradation study, major 
degradation 44% occurred under alkaline conditions. 
Under acidic conditions the drug was degraded by 
approxi mately 7%. The drug was approximately 
15% degraded under oxi dizing conditions. The drug 
was degraded 6% under thermal condition and 10% 
degradation occurred under photolytic conditions.
To determine linearity a calibration graph was 
obtained by plotting lercanidipine hydrochloride 
concentration against peak area. Linearity was 
good in the concentration range 20-80 μg/ml. The 
regression equation was y=48,443x+20,928 where x 
is the concentration in μg/ml and y is the peak area 
in absorbance units; the correlation coeffi cient was 
0.9992.
For assay (n=6) and determination of content 
uniformity (n=10), RSD for the system precision 
was 0.43% and 0.37%, respectively, on the same day 
(intraday) and 0.40% and 0.55% on dif ferent days 
(interday). The mean values of method precision 
(repeatability) were 101.5%, RSD 0.28% for assay 
and 101.4%, RSD 0.46% for content uniformity on 
the same day (intraday) and 100.8%, RSD 0.61% 
for assay and 100.9%, RSD 0.82% for content uni-
formity on different days (interday). Intermediate 
precision was established by determining the 
overall (intraday and interday) method precision 
for assay and determination of content uniformity. 
For intermediate precision, overall assay value 
(n=12) was 101.2%, RSD 0.37% and overall content 
uniformity (n=20) was 101.4%, RSD 0.70%. The 
precise result for content uniformity was indicative of 
uniform distribution of the drug in the tablets without 
significant variation; this is in accordance with the 
USP[8], which stipulates acceptance limits for drug 
content uniformity and RSD as 85-115 and <6%, 
respectively.
The accuracy of the method was assessed by 
determination of recovery for three concentrations 
(corresponding to 50, 100 and 150% of test solution 
concentration) covering the range of the method. 
For each concentration three sets were prepared 
and injected in duplicate. The mean recovery of 
lercanidipine hydrochloride was between 99.3-
101.9% and RSD of recoveries between 0.4-1.44 %. 
The robustness of the method was evalu ated by 
assaying test solutions after slight but deliberate 
changes in the analytical conditions flow rate 
(±0.1 ml/min), the proportions of buffer:methanol 
(33:67 and 37:63, v/v) and changing the column 
temperature 35°. For each different analytical 
condition the standard solution and test solution were 
prepared separately. The result obtained from assay 
of the test solution was not affected by varying 
the conditions and was in accordance with the true 
value. System suitability data were also found to 
be satisfactory during variation of the analytical 
conditions. The analytical method there fore remained 
unaffected by slight but deliberate changes in the 
analytical con ditions.
Stability in solution was evaluated for the standard 
solution and the test preparation. The solutions were 
stored at 5° and at ambient temperature. Without 
protection of light and tested after 12, 24, 36 and 
48 h. the responses for the aged solution were 
evaluated by comparison with freshly prepared 
TABLE 1: SYSTEM SUITABILITY DATA
System suitability data
In-house limit
% RSDa
NMTb 2.0
Theoretical 
plates
NLTc 3000
Asymmetry
NMTb 2.0
Validation data
Specifi city
Linearity
Limit of detection
Limit of quantitation
Method precision
For assay
For content uniformity
Intermediate precision
For assay
For content uniformity
Accuracy
Solution stability
Robustness
0.52
0.43
0.34
0.41
0.43
0.37
0.40
0.55
0.34
0.27
0.46
4221
4324
4421
4213
4532
4357
4231
4436
4315
4231
4328
1.02
1.00
1.03
1.01
1.00
0.98
1.01
0.99
1.00
1.01
1.02
arelative standard deviation, bnot more than, cnot less than
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solutions. During study of the stability of stored 
solutions of standards and test prepara tions for assay 
determination the solu tions were found to be stable 
for up to 36 h[10]. Assay values obtained after 36 
h were statistically identical with the initial value 
without measurable loss. 
Before each measurement of valida tion data a system 
suitability test was performed by measurement of 
general characteristics such as peak asymmetry, number 
of theoretical plates and % RSD of peak area observed 
for a standard solution. The values obtained were 
satisfactory and in accordance with in-house limits 
(Table 1).
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RP-HPLC Method for Simultaneous Estimation of 
Frusemide and Amiloride Hydrochloride in Tablet 
Formulation
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Nagori and Solanki: Simultaneous RP-HPLC Estimation of Frusemide and Amiloride
A new reverse phase high performance liquid chromatography method for the simultaneous estimation of frusemide 
and amiloride hydrochloride in tablet formulation is developed. The determination was carried out on a HIQ SIL, 
C18 (250×4.6 mm, 5 µm) column using a mobile phase of 50 mM phosphate buffer solution:acetonitrile (50:50 
v/v, pH 3.0). The fl ow rate was 1.0 ml/min with detection at 283 nm. The retention time for frusemide was 
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